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ABSTRACT 
 
The tylophorine analogue, DCB-3503 (1-62b, NSC-716802), has been found to exhibit 
broad spectrum activity in vitro in the National Cancer Institute’s (NCI) panel of 60 
human-derived cell lines.  Recent studies involving HepG2, a human hepatocellular 
carcinoma cell line, and two pancreatic ductal carcinoma cell lines (PANC-1 and 
HPAC), have suggested that DCB-3503 (1-62b) exerts its unique growth inhibition 
properties by modulating nuclear factor kappa B activity as well as through the 
inhibition of nuclear protein synthesis.  However, the physiologically relevant protein 
binding partner(s) of DCB-3503 (1-62b) have not been identified.  Herein, the design 
and synthesis of two biotin conjugates of DCB-3503 are described.  In both cases, 
attachment of the biotin moiety to the active core was achieved through a Cu(I)-
catalyzed 1,3-dipolar Huisgen cycloaddition (“click”) coupling reaction.  Additionally, 
3D QSAR studies were performed using comparative molecular field analysis (CoMFA) 
on a set of phenanthrolizidine alkaloids with inhibitory activities against the HepG2 cell 
line.  A satisfactory CoMFA model was obtained with LOO cross-validation q2 and non-
cross-validated r2 values of 0.567 and 0.935, respectively.  The developed model 
demonstrated promising predictive abilities as discerned by the results of the external 
test set.   
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CHAPTER 1 
INTRODUCTION 
1. INTRODUCTION 
 
1.1 Natural Products as Anti-tumor Agents 
 
 
Throughout history, the natural world has continued to furnish man with an 
effective arsenal of compounds that have served as antitumor, antibacterial, and 
antifungal agents.  It is the lush tropical rainforests and vibrant coral reefs of the planet 
that have yielded these numerous natural products.  However, passage from nature to 
the world of human therapeutics has been simpler for plants than it has been for 
invertebrates.  To date, over 60% of clinically useful antitumor agents are natural, plant–
derived products.  In fact, a milestone took place in 2006 when after several trials, the 
Food and Drug Administration (FDA) approved the drug ziconotide1 for the treatment 
of intractable severe chronic pain.  Derived from a toxin of the cone snail Conus magus,2 
ziconotide (Prialt®) became the first licensed pharmaceutical to make the transition from 
invertebrate to man.3  
More importantly though, within the sphere of cancer therapeutics, natural 
products have served as sources of lead molecules for the development of new drugs.  
Due to their immense structural diversities and high bioactivity potentials, natural 
products have continuously provided new avenues for the treatment of cancers that 
have resisted conventional antitumor therapies.  In fact there are currently 30 naturally 
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derived compounds in different phases of clinical trials targeted at several types of 
cancer.4  Of note are ixabepilone (epothilone B from Soragium cellulosum) and the 
dibenzodiazepine ECO-4601 (Micromonospora) (Figure 1.1).   
Considering the fact that over 60% of the current anticancer drugs are from 
natural sources5 or are “natural product mimics”, natural products seem poised to play 
an important role in the fight against cancer.  The cancer problem though is 
multifaceted and, accordingly, warrants the deployment of compounds with unique 
modes of action if they are to play any role in the field of oncology.  An example of such  
a compound is romidespin (Figure 1.2), which has recently emerged as a novel 
antitumor agent.  Belonging to new class of anticancer drugs known as histone  
 
 
 
 
 
 
Figure 1.1.   Naturally derived antitumor agents ixabepilone and ECO-4601 
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Figure 1.2.   Romidepsin 
 
 
deacetylase (HDAC) inhibitors,6 romidespin’s mode of action involves the induction of 
chromatin remodeling, growth inhibition apoptosis, tumor suppressor gene 
transcription and tumor suppression.7   
 
1.2 The Phenanthroindolizidine Alkaloids 
 
 
Hallucinogenic alkaloids from plants of the Convolvulaceae family (Argyreia, Ipomoea, 
Rivea, Turbina) have been known to be used for divinatory means in Mexico, 
particularly by the Aztecs.8  Several of these alkaloids were isolated by Gourley et al. 
from Ipomoea albla which, after characterization, revealed a family of heterocycles9 
(Figure 1.3).  Each member bore a bicyclic skeleton consisting of a six-membered ring 
fused to a five membered one, with nitrogen as one of the bridging atoms.  These 
compounds and their derivatives would later be known as the indolizidine alkaloids.  
Then, in 1891, Hooper noted the presence of two alkaloids10 isolated from Tylophora 
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Figure 1.3.   Simple indolizidine alkaloids from Ipomoea alba. 
 
 
indica of the plant family Asclepiadaceae.  Plants of the genus Tylophora are found 
throughout Africa, Asia, Australia and the Pacific islands; of its 50 or so species, 23 have 
been reported to possess alkaloids.11,12  Due to limitations in methods of 
characterization at the time, the structures of Hooper’s isolations were never properly 
determined.  However, Ratnagiriswaran and Venkatachalam managed to re-isolate and  
characterize them in 1935, naming them “tylophorine” (1-1) and “tylophorinine” (1-2) 
(Figure 1.4).13  Featuring conjoined phenanthrene and indolizidine moieties, tylophorine 
(1-1), tylophorinine (1-2) and all other compounds bearing this unique architecture 
would become known as the phenanthroindolizidine alkaloids.  These alkaloids were 
found to exhibit interesting cytotoxicities, and this prompted a re-investigation by 
Govindachari et al. who aside from reaffirming Ratnagiriswaran and Venkatachalam’s 
discovery,14 isolated numerous more alkaloids from T.crebiflora15,16 (Figure 1.5) and the 
genus Pergularia17,18 (Figure 1.6).   
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Figure 1.4.   Alkaloids 1-1 and 1-2 from Tylophora indica. 
 
 
 
 
Figure 1.5.   Alkaloids from T. crebiflora. 
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Figure 1.6.   Alkaloids from the genus Pergularia. 
 
 
1.3 The Phenanthroindolizidine Alkaloids and Cancer 
 
 
Following early but promising pharmacological studies as described in the 1935 
isolation by Ratnagirisvaran and Venkatachalam,13 tylophorine (1-1) and its analogues 
warranted further biological evaluation.  The 1960’s saw studies focused on the 
inhibitory properties of these alkaloids on nucleic acid and protein synthesis,19,20 as well 
as an evaluation by the National Cancer Institute (NCI) of tylophorine (1-1) in its 
antitumor screen.  Tylophorine (1-1) and its related analogues demonstrated a potent 
growth inhibitory effect (average GI50 ≈10-8 M) against all 60 human–derived cell lines 
in the screen.21  Selectivity was directed towards several refractory cell lines notably 
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melanoma, and the lymphocytic L1210 leukemia cell lines.22  
A few years later, Gellert and Rudzats reported their findings on the effect of the 
administration of tylocrebrine (1-3), a positional isomer of tylophorine (1-1), to L1210 
leukemia bearing mice.23  Encouragingly, the results of this study showed that 1-3 
caused the leukemia-bearing mice to gain a 50% increase in life span (ILS).  However, 
tylocrebrine (1-3) showed no activity against the sarcoma 180, B16 melanoma, 
adenosarcinoma 755, P1534 carcinosarcoma tumor cell lines.  Tylophorine (1-1) and 
tylophorinine (1-2) were also shown to be active against the L1210 leukemia cell line but 
with diminished ILS values of about ca. 30% and ca. 20%, respectively.  Accordingly, 
based on its superior antitumor activity, tylocrebrine (1-3) was selected as a drug 
candidate and progressed through to phase I clinical trials.  Unfortunately, tylocrebrine 
(1-3) induced negative central nervous system (CNS) effects which manifested as ataxia 
and disorientation.24  In addition to prematurely terminating clinical trials in 1966, this 
unfortunate development also disseminated any further interest in the 
phenanthroindolizidine alkaloids as antitumor agents for many years to come.    
As 1989 dawned, Bhutani and Ali isolated a set of seven additional alkaloids 
from Tylophora indica, some of which bore novel structural features.25  Of particular 
interest, was the presence of an angular methyl in the indolizidine periphery and 
varying patterns of substitution in the phenanthrene framework.  A subset of these rare 
phenanthroindolizidine alkaloids would be known as the tyloindicines A–E (Figure 
1.7).  In a follow-up study in 1991, Ali et al. isolated yet another  set of tyloindicines  
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Figure 1.7.   Tyloindicines A–I 
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(Figure 1.7, F–I) from T. indica with even more intriguing structural features.26  Of this 
set, tyloindicines F (1-15) and G (1-16) each featuring a unique tertiary hydroxy group at 
the 12a position, were screened for anti-tumor potential by the NCI and found to be 
extremely potent. Tyloindicines F (1-15, NSC-650393) and G (1-16, NSC-650394) 
displayed GI50’s in the 10-10 M range with pronounced activities against certain lung and 
melanoma cell lines,27 for which there are few effective agents.  Furthermore, of the 
33,744 compounds screened at the time, 1-15 and 1-16 were ranked as the two most 
potent antitumor agents in the 60–cell NCI screen.  The results of this screen proved to 
be instrumental in the renewed vigor toward developing the phenanthroindolizidine 
alkaloids into a new class of antitumor agents. 
 
 
1.4 Biosynthesis of Tylophorine 
 
 
Interest in the biogenesis of these phenanthroindolizidine alkaloids was first 
investigated by Herbert and co-workers28 and Bhakuni and Mangala29 utilizing an 
isotope-labeling technique.  Herbert and co-workers30 then published a report in 1978 
prompting the first biomimetic total synthesis (Figure 1.8) of tylophorine (1-1).31,32  This 
was accomplished by the condensation of 3,4-dimethoxybenzoylacetic acid (1-19) with 
1-pyrroline (1-20) affording the amino ketone 1-21.  Further condensation of the amine 
ketone 1-21 with 3,4-dimethoxyphenylacetaldehyde (1-22) occurred, and the reaction 
was then followed up with a series of NaBH4 reductions/rearrangements to yield  
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Figure 1.8.   Biosynthesis of tylophorine (1-1). 
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septicine (1-25).   A final oxidation of 1-25 ultimately furnished racemic tylophorine (1-
1).   
Since its isolation and purification, tylophorine (1-1) was well characterized33 by 
1H and 13C- NMR spectroscopy and by mass spectrometry; however its absolute three-
dimensional structure remained largely unknown.  Wang et al. were finally able to solve 
the crystal structure of tylophorine B,34 a close analogue of 1-1, in the year 2000.  The 
ORTEP (Oak Ridge Thermal Ellipsoid Plot) representation revealed that these alkaloids’ 
phenanthrene skeleton was almost planar, and that their indolizidine moieties were 
somewhat puckered.   
 
 
1.5 Total Syntheses of Tylophorine 
 
Featuring a chiral center at C-13, tylophorine is optically active. These isomers 
are shown in Figure 1.9; the 13-S-isomer [(S)-1-1] was confirmed to be dextrarotatory,35 
while its 13-R-enantiomer [(R)-1-1]) was determined to be levrorotatory.   
The impressive antitumor potential of this class of compounds mandated a total 
synthesis.  Accordingly, tylophorine (1-1) was synthesized both in racemic36-38 and 
optically active forms.35,39  Highlights of some of  these synthetic accomplishments are 
discussed in the following sections. 
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Figure 1.9.   The two enantiomers of tylophorine (1-1). 
 
 
1.5.1 Synthesis of Tylophorine (1-1) by Ihara et al. 
 
 
In 1985, Ihara et al.40 utilized an intramolecular double Michael reaction in their 
short synthesis of racemic tylophorine [(±)-1-1].  This highly effective annelation was 
accomplished by reaction of enamide ester 1-30 (derived from Wittig reaction of 1-29) 
with tert-butyldimethylsilyl trifluoromethanesulfonate (TBSOTf), followed by an 
oxidative ring closure to give the indolizidine derivative 1-32. Saponification and 
decarboxylation of 1-32 followed by the reduction of 1-33 finally afforded tylophorine 
[(±)-1-1] in 29.7% yield (Figure 1.10). 
Ihara et al. later revised their original synthetic approach by employing two 
chiral auxiliaries; (-)-phenylmenthol41-42 and (2R,4S,5R)-(–)-4-(tert-butyl-
dimethylsiloxymethyl)-5-hydroxy-2-phenyl-1,3-dioxane (BDH).42-43  This modification 
resulted in a highly enantioselective synthesis of (R)-(-)-tylophorine [(R)-1-1] and in the  
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Figure 1.10.   Synthetic approach adopted by Ihara et al.40 
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process confirmed the absolute configuration of naturally occurring tylophorine as 
being [(R)-1-1]. 
 
1.5.2 Synthesis of Tylophorine (1-1) by Nordlander and Njoroje 
 
 
In 1987, Nordlander and Njoroje’s short but enantioselective synthesis39  (Figure 
1.11) employed a Friedel–Crafts acylation as the key step and a Pictet–Spengler 
cyclomethylation as the final step.  The five-step synthesis commenced with the 
decarboxylation of 2,3,6,7-tetramethoxyphenanthrene-9-carboxylic acid (1-34) to the  
substituted phenanthrene 1-35 which was then acylated with (S)-N-(trifluoroacetyl)-
prolyl chloride (1-36) to give ketone 1-37.  Deketonization of 1-37 with Et3SiH and 
BF3Et2O afforded 1-38, which underwent deacylation in methanolic ammonia to yield 
amine 1-39. (S)-(+)-Tylophorine [(S)-1-1] was then obtained in 53% yield upon Pictet–
Spengler cyclomethylenation of amine 1-39. 
 
1.5.3 Synthesis of Tylophorine (1-1) by Buckley and Rapoport 
 
Buckley and Rapoport’s 1983 effort35 (Figure 1.12) would feature the use of (S)-
(+)-glutamic acid as a chiral educt and an intramolecular Friedel–Crafts acylation.  The 
successful implementation of these key steps would prove to be pivotal in their 
asymmetric synthesis of (S)-(+)-tylophorine [(S)-1-1].  Accordingly, 3,4-
dimethoxybenzylcyanide (1-40) was reduced to the aldehyde 1-41, which upon  
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Figure 1.11.   Nordlander and Njoroje’s concise enantiospecific synthesis.39 
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Figure 1.12.   Buckley and Rapoport’s total synthesis of (S)-(+)-tylophorine [(S)-1-1].35 
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treatment with the diisopropyl ester of (S)-(+)-glutamic acid (1-42a) yielded amine 1-43.  
Reduction of 1-43 with NaCNBH3 and cyclization with AcOH afforded 1-44, which was 
then hydrolyzed, converted into its corresponding acid chloride and then reacted with 
SnCl4 to furnish ketone 1-45.  Deketonization of 1-45, followed by reduction of 1-46 with 
LiAlH4, secured (S)-(+)-tylophorine [(S)-1-1]. 
 
 
1.5.4 Jin’s Approach 
 
 
The ten-step synthesis by Jin and co-workers44 (Figure 1.13) would employ the 
Lewis acid-catalyzed ring closure that Buckley and Rapoport used in their earlier 
synthesis.35  Additionally, Jin et al.’s total synthesis would also feature an N-alkylation 
of the heterocyclic moiety 1-49 by the halomethylphenanthrene derivative 1-48. 
 
1.6 The Phenanthroquinolizidine Alkaloid Cryptopleurine 
 
 
Cryptopleurine (1-51, Figure 1.14), is a representative phenanthroquinolizidine 
alkaloid. This highly toxic skin irritant and vesicant was isolated by Saifah et al. from 
Cissus rheifolia Planch.45  It is structurally similar to tylophorine (1-1), but in place of the 
pyrrolizidine ring, there exists a quinolizidine moiety.  An asymmetric synthesis of (S)-
(+)- cryptopleurine [(+)-1-51]  was reported by Buckley and Rapoport in their series 
 
 
  
 
18 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13.   Jin et al.’s total synthesis of (S)-(+)-tylophorine [(S)-1-1].44 
 
  
 
19 
 
  
 
devoted to amino acids as chiral educts.35  Of note, Grieco and Parker were able to effect 
an intramolecular Diels–Alder reaction using an immonium ion in their synthetic 
approach to 1-51.46  A study by Dolz et al. using the 40S, 60S, 70S and 80S ribosomal 
units of the yeast Sacchromyces cerevisiae found that low concentrations of 
cryptopleurine (1-51) resulted in the blockage of pepitidyl–tRNA translocation from the 
40S ribosomal subunit.47  On the other hand, higher concentrations of cryptopleurine (1-
51) inhibited peptide bond formation.  The latter was attributed to non-specific 
interactions of 1-51 with the 60S subunit. 
Although the phenanthroquinolizidine alkaloids have not garnered as much 
interest as their phenathroindolizidine counterparts, their equally profound 
cytotoxicities and unique modes of action may provide yet another avenue in the 
continued development of effective antitumor agents. 
 
 
 
 
 
 
 
Figure 1.14.   (S)-(+)-Cryptopleurine [(S)-1-51]    
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1.7 The Tylophorine Analogues 
 
 
1.7.1 Background 
 
 
The impressive antitumor potential of tyloindicines G (1-16) and F (1-15) as 
revealed by the NCI 60-cell screen would soon prompt efforts towards their total 
synthesis.  The indolizidine moiety of these two alkaloids is adorned with a tertiary 
hydroxy group at the 12a position and a double bond between C13 and C14.  Their 
phenanthrene skeletons, however, differ slightly; tyloindicine F (1-15) has an un-
bridged trimethoxy skeleton, while tyloindicine G (1-16) has a bridged tetramethoxy 
one.  With only two chiral centers, the seemingly simple indolizidine periphery would 
conceal the difficulty that lay in the installation of the allylic tertiary hydroxy group.  
In their synthetic efforts towards tyloindicine G (1-16), Baker and co-workers48 
elected to install the signature tertiary hydroxy during the final stages of the synthetic 
pathway (Figure 1.15) via an allylic oxidation.  This operation, however, yielded only 
minute amounts of the synthetic target, 1-16, but also afforded a sparing amount of two 
epimeric alcohols, 1-62a and 1-62b.  Separation of the two epimers resulted in the 
discovery of two new tylophorine analogues; identified as DCB-3501 (1-62a) and DCB-
3503 (1-62b).  Furthermore, the reduction of 1-60 was attempted using LiAlH4 but failed 
to furnish 1-61 instead giving rise to DCB-3500 or (S)-(+)-tylophorine [(S)-1-1], by the 
way of a double bond rearrangement.   
Although novel, this new class of tylophorine analogues bore structural features 
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that were similar to previously isolated alkaloids.  For instance, the indolizidine moiety 
of DCB-3501 (1-62a) was identical to that of pergularinine (1-7) and tylophorinicine (1-9) 
whilst DCB-3503 and tylophorinidine (1-2, Figure 1.16) shared an identical indolizidine 
periphery as well.  The more distinct structural differences arose from the substitution 
patterns on their phenanthrene skeletons.  
 
1.7.2 Biological Profile of the Tylophorine Analogues  
 
 
In 2000, Rao and Ventachalam evaluated both pergularinine (1-7) and 
tylophorinidine (1-2) in their in-vitro assessment49 of the effect of these 
phenanthrolizidine alkaloids on cell growth.  The study did unveil several new 
pharmacological properties such as anti-amoebic and anti-inflammatory effects, but it 
was the antitumor potential of these alkaloids that remained the focal point.  
Additionally, based in part on their previous work,50 Rao and Venkachalam were able 
to allude to the participation of the indolizidine moiety of these alkaloids in pocket 
binding possibly via hydrogen bonding.  As such, Rao and Venkachalam were able to 
conclude that these alkaloids possessed a “high order of potency as anticancer agents”.  
These and similar findings implicating phenanthroindolizidine alkaloids as a new class 
of antitumor agents therefore warranted further evaluation of analogues DCB-3500 [(S)-
1-1], DCB-3501 (1-62a), DCB-3502 (1-61) and DCB-3503 (1-62b) by the NCI. 
Of the evaluated congeners, DCB-3500 [NSC-717335, (S)-1-1] and DCB-3503 
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Figure 1.15.   Synthesis of tyloindicine G (1-16) by Baker et al.48 
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Figure 1.16.  Novel tylophorine analogues. 
 
 
(NSC-716802, 1-62b) exhibited impressive, broad–based potencies with an average GI50 
~10-8 M (concentration of drug that causes 50% growth inhibition) for most tumors in 
the 60–cell in vitro NCI screen of human–derived tumors.  Notably, selectivity was 
directed at several refractory cell lines including melanoma and lung tumor cell lines.  
The NCI’s COMPARE algorithm analyzes every compound’s in vitro growth pattern for 
similarity to other compounds in its class.  Results from this analysis revealed their 
activity to be unique among known antitumor compounds, suggesting that these 
compounds operate via a novel mode of action.  The results of the screen also identified 
the S-enantiomer of tylophorine [(S)-1-1] as being the more potent in the series.  
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1.8 Biological Evaluation of the Tylophorine Analogues 
 
 
In light of the results of the 60–cell NCI screen, the antitumor potential of these 
tylophorine analogues was further investigated in collaboration with Dr. Yung-Chi 
Cheng’s group (Department of Pharmacology, Yale University School of Medicine) 
against several cell lines.  Highlights of these studies will be summarized in the 
following sections. 
 
1.8.1 Hepatocellular Carcinoma (HCC) Studies 
 
 
Hepatocellular carcinoma (HCC) is a primary cancer of the liver. It is a secondary 
occurrence to either a viral heptatide infection (hepatitis B or C) or cirrhosis.  Due to its 
resistance to most chemotherapeutic agents, surgery remains the most effective cure.51  
Even so, the five year survival rate is less than 5%.  Although HCC is one of the most 
common tumors worldwide, the NCI screen does not include hepatoma cell lines, 
perhaps due to the non-endemic nature of hepatitis in the North America.  There is, 
however, a rising incidence of HCC in the United States.52  
A major obstacle to successful cancer treatment is resistance to chemotherapy. Of 
the various mechanisms employed by cancer cells to overcome conventional treatment, 
over-expression of the multidrug resistance gene (mdr) product, P-glycoprotein,53-54 is 
one of the best characterized.  Using this 170-kDa P-glycoprotein, the cancer cell is able 
to channel the drug out of the cell, thereby rendering the treatment ineffective.   
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 In a 2004 study, Cheng and co-workers investigated the antitumor potential of 
the tylophorine analogues DCB-3500 [(S)-1-1] and DCB-3503 (1-62b) against the human 
hepatocellular carcinoma cell line (Figure 1.17), HepG2, both in vitro and in vivo.55  Both 
[(S)-1-1] and 1-62b were able to markedly suppress HepG2 tumor growth and were 
concluded to be potent HepG2 inhibitors (Figure 1.18).  However, unlike conventional 
antitumor drugs, the tylophorine analogues DCB-3500 [(S)-1-1] and DCB-3503 (1-62b) 
were not found to exert their antitumor abilities by targeting DNA synthesis or by 
inducing DNA damage.  This discovery confirmed that these alkaloids operated via a 
unique mode of action that was different from other antitumor compounds.  
Intriguingly, it was also discovered that even though [(S)-1-1] was more potent than 1- 
62b in vitro, 1-62b was much more potent in vivo.  This discrepancy was attributed to a 
 
 
 
 
Figure 1.17.   Untreated HepG2 cells as viewed by an inverted phase–contrast 
microscope 
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Figure 1.18.   Morphology of HepG2 cells after treatment with DCB-3500 [(S)-1-1]. 
The HepG2 cells were checked with actin (shown as red fluorescence) and the 
liver cell differentiation marker, albumin (green fluorescence).  The HepG2 cells 
lost proliferative abilities and appeared to be well differentiated after exposure to 
DCB-3500 [(S)-1-1].  Adapted from the 2004 study by Cheng and co-workers.55  
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control 
HepG2 
DCB-3500 
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difference in pharmacokinetics between DCB-3503 (1-62b) and DCB-3500 [(S)-1-1] in 
vivo.   
 
1.8.2 DCB-3503 (1-62b), Cancer and the NF-κB Pathway 
 
 
The nuclear factor kappa B (NF-κB) complex of proteins is a set of closely related 
transcription factors that, amongst other things, regulates immune responses to 
infection and is a factor in the inflammatory response.56  In mammalian cells, it consists 
of five members (Table 1.1): Rel (also known as c-Rel), RelA (also known as p65 and NF-
κB3), RelB, NF-κB1 (also known as p50) and NF-κB2 (also known as p52).57  Since first 
being discovered by Sen and Baltimore in 1986,58 activation of the NF-κB group of 
proteins has since been found to mediate the expression of tumor promotion genes.59  
Significantly, the NF-κB groups of proteins have also been found to regulate the 
production of prostaglandins via the proinflammatory gene cyclooxygenase-2 (COX2), 
which has been shown to be overexpressed in several cancers.60-62  The link between 
cancer and inflammation was first hypothesized by the German physician, Rudolf 
Virchow, in 1863 who alleged that “chronic inflammation caused by certain irritants can 
lead to cancer”.63  This hypothesis was then validated by the work of Yamagiwa and 
Ichikawa in 1915.64  By repeatedly painting the ears of rabbits with coal tar, Yamagiwa 
and Ichikawa were able to demonstrate that the animals developed tumors as a result.   
The NF-κB transcription factors are usually sequestered in an inactive state in the 
cytoplasm by the inhibitory protein IκBα.65  Upon receipt of an appropriate signal, the  
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Table 1.1.   The names and aliases of the nuclear factor B (NF-κB) group of proteins. 
 
 
Protein Aliases 
Rel c-Rel 
RelA p65 or NF-κB3 
RelB - 
NF-κB1  p50 
NF-κB2  p52 
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enzyme IκB kinase (IKK) becomes activated and in turn, phosphorylates the IκBα 
protein, resulting in its dissociation from the NF-κB complex (Figure 1.19, shown using 
only RelA and p65).  This “activated” NF-κB complex then translocates to the nucleus 
where it binds to specific sequences of DNA (Figures 1.20 and 1.21) and upregulates the 
transcription of specific genes.  The phosphorylated IκBα protein is left in the cytoplasm 
to undergo eventual degradation by the proteasome 66 
Although the NF-κB group of proteins play an important role in the inducible  
expression of many proteins, including cytokines, acute–phase response proteins, and 
cell–adhesion molecules;67-68 incorrect regulation of this signaling pathway has been 
linked to a host of problems including viral infection, autoimmune diseases, improper 
immune development, inflammation and cancer.56  With regards to the progression of 
oncogenesis, a study by Baldwin and Mayo found that activation of NF-κB resulted in 
the promotion of cell proliferation and suppression of apoptosis in tumor cells.69  
Furthermore, aberrant NF-κB activation has been implicated as one of the contributing 
factors involved in the resistance to chemotherapy.70  Conversely, interruption of the 
NF-κB cascade has been found to limit the proliferative activities of cancer cells.71  The 
mediation by NF-κB of genes involved in the promotion of tumor growth,59 makes any 
drug that interrupts NF-κB an ideal target for development as an anticancer agent. 
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Figure 1.19.   The NF-κB pathway and the likely role that DCB-3503 (1-62b) may play in the inhibition of RelA (or p65). 
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Figure 1.20.   The crystal structure of the NF-κB p65 (RelA) homodimer in complex with a DNA target (PDB access code: 
2RAM).72 
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Figure 1.21.   The crystal structure of the NF-κB p50 homodimer in complex with a DNA target (PDB access code: 1SVC).73 
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In a 2004 study, Cheng and co-workers found that even at a concentration of 100 
nM, DCB-3503 (1-62b) exerted a 50% inhibition on NF-κB-mediated transcription in 
chemoresistant HepG2 cells.55  While this finding confirmed DCB-3503’s (1-62b) 
profound cytotoxity, it provided the definitive link between the growth inhibitory 
properties of the phenanthrolizidine alkaloids and the NF-κB group of proteins.  A 
subsequent study by Cheng and co-workers revealed that the inhibition of NF-κB 
activity was mainly due to the down-regulation of nuclear phosphorylated RelA (also 
known as p65) by DCB-3503 (1-62b).74  Intriguingly, the decrease in RelA (or p65) levels 
was presumed to arise from 1-62b’s ability to suppress IKK activity via degradation of 
the IKK subunit, IKK-α (Figure 1.19).  The IKK complex consists of catalytic kinase 
subunits, IKK-α and IKK-β; however, only IKK-α has been identified to play an 
auxiliary role in the activation of an alternative pathway.75  This unique role makes IKK-
α a prime target for therapeutic intervention by anticancer compounds such as 1-62b.76  
To date there are no potent IKK-α-specific inhibitors, but other compounds capable of 
suppressing IKK activity by targeting IKK-α are under development. Some examples 
include a quinazoline analogue (SPC-839),77 a β-carbolin analogue (PS-1145)78 and 
several others.79 
 
1.8.3 Additional Evaluations 
 
 
In addition to its antitumor properties, DCB-3503 (1-62b) has been shown to 
suppress collagen-induced arthritis80 and lupus-associated skin lesions as well.81  
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STATEMENT OF THE PROBLEM I 
1.9 STATEMENT OF THE PROBLEM I 
 
The original synthesis of DCB-3503 (1-62b) was accomplished by Baker and co-workers 
in 2003.48,82-84  Inspired, in part, by Buckley and Rapoport’s synthesis of tylophorine (1-
1),35 its synthetic blueprint was later modified by Kaczmarek, resulting in improved 
product yields.83  Even though recent biological studies have offered some insight into 
the mechanism of action of DCB-3503 (1-62b),85-86 there still exists the need to synthesize 
additional  quantities of DCB-3503 (1-62b), of sufficient purity, for the continued in vitro 
and in vivo evaluations.  In order to accomplish this, improvements (mostly technical) 
would have to be made to the synthetic approach devised by Kaczmarek, in order to 
facilitate a “scaled-up” synthesis of DCB-3503 (1-62b).  
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1.10 Synthesis and Purification of DCB-3503 (1-62b) 
 
 
The scheme for the synthesis of DCB-3503 (1-62b) employed by Kaczmarek, is 
presented in Figures 1.22 and 1.23.  The stilbene 1-27 was afforded in high yield 
commencing with the Perkin condensation of 3,4-dimethoxyphenylacetic acid and 3,4-
dimethoxybenzaldehyde.  Esterification of 1-27 using H2SO4 and MeOH furnished 1-47, 
an intermediate suitable for the Fe(III)-mediated ring closure.  Accordingly, treatment 
of 1-47 with Fe(III) chloride yielded the phenanthrene 1-52, whose formation was 
confirmed by the presence of only five characteristic, aromatic proton peaks at 8.63, 
8.41, 7.78, 7.74 and 7.24 ppm in its 1H NMR spectrum (Figure 1.24).  
Reduction of the ester present within the stilbene 1-52 with lithium aluminum 
hydride yielded the alcohol 1-53.  Conversion of 1-531-63 was then accomplished 
using phosphorous tribromide.  The resulting benzylic bromide 1-63 was immediately 
coupled to the chiral auxiliary 1-42b in the presence of K2CO3 and DMF to afford the 
aminal 1-64.  Treatment of the aminal 1-64 with MeOH–AcOH induced lactamization 
and secured the tetracylic derivative 1-65.  The 1H NMR spectrum of the intermediate 1-
65 confirms the compound’s intriguing structural features, particularly the doublet of 
doublets between 3.80–3.84 ppm and the set of multiplets between 1.90–2.54 ppm 
(Figure 1.25).  Hydrolysis of 1-65 was conducted using 2 N KOH in a system of MeOH–
1,4-dioxane to give the acid 1-50 which, upon treatment with oxalyl chloride and a 
Lewis acid, underwent intramolecular cyclization to give the pentacylic ketone 1-45. 
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Figure 1.22.   Scheme for the synthesis of DCB-3503 (1-62b). 
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Figure 1.23.   Continued scheme for the synthesis of DCB-3503 (1-62b). 
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Figure 1.24.   1H NMR spectra of the characteristic changes that take place in the 
conversion of 1-471-52. 
 
 
 
1-47        1-52 
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Figure 1.25.   1H NMR spectra of the intriguing structural features of intermediate 1-65. 
 
 
They key to securing pure samples of DCB-3503 (1-62b) suitable for biological 
  
 
  
 
evaluation is mainly dependent on the purity of intermediates 
both of these intermediates must be purified exhaustively in order to exclude any 
contaminants that may otherwise impact 
Accordingly, the pentacylic ketone 
(0.1:2 MeOH–CHCl3) and its purity confirmed by the HPLC trace shown in Figure 1.26.  
This purified ketone 1-
sec-butylborohydride (K-selectride
purification of 1-66 was also accomplished using 
MeOH–CHCl3) and its purity is illustrated by the HPLC trace shown in Figure 1.27.  
 
 
 
 
 
 
 
 
 
 
Figure 1.26.   HPLC trace
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1-45 and 1
overall product yield and/or purity.  
1-45 was purified using silica gel chromatography 
45 was then reduced by the bulky hydride, 
®), to furnish intermediate 1-66
silica gel chromatography (0.1:2 
 and chromophore (inset)  illustrating the purity of 
intermediate 1-45. 
-66.  Therefore, 
 
potassium tri-
.  Extensive 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.27.   HPLC trace
 
 
 
 
The installation of intermediate 
times between 1-45 and 1-
intermediates.  Furthermore, there is a subtle change in the chromophores of these two 
intermediates and these are illustrated by 
Reduction of the amide
hydride and this secured sufficient quantities of the target, 
reaction mixture, taken after two hours, 
hydride is presented in Figure 1.
depletion of the starting material 
at 3.9 min verifies that intermediate 
41 
 
 and chromophore (inset)  illustrating the purity of 
intermediate 1-66. 
1-66’s hydroxy is evident by the change in retention 
66, reflecting a change in polarity between the two 
the insets in Figures 1.26 and 1.27.  
 within 1-66 was accomplished using lithium aluminum 
1-62b.  A sampling
in the reduction of 1-66 with lithium aluminum 
28.  The simultaneous formation of the target 
1-66 can be observed.  The disappearance of the peak 
1-66 has been completely consumed 
 
 of the 
1-62b and 
(Figure 1.29).  
  
 
  
 
 
 
 
 
 
 
 
 
Figure 1.28.   HPLC trace
The simultaneous formation of the target 
material 1-66 can be observed.
 
 
Figure 1.29.   HPLC trace
The absence of the peak at at 3.9 min verifies that intermediate 
completely consumed. 
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 of the reaction of 1-66 with LiAlH4 taken after 2 h.
1-62b and depletion of the starting 
 
 of the reaction of 1-66 with LiAlH4 taken after 10 h.
1-66
 
 
 has been 
  
 
  
 
The formation of the target, DCB
shown in Figure 1.30.  There is a characteristic peak at m/z 392.18819 that cor
to the loss of a hydroxy group.
 
 
 
 
Figure 1.30.
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-3503 (1-62b), was also confirmed by HRDARTMS as 
 
   HRDART MS of DCB-3503 (1-62b). 
responds 
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STATEMENT OF THE PROBLEM II 
1.11 STATEMENT OF THE PROBLEM II 
 
 
Tylophorine and other phenanthrolizidine alkaloids are a group of compounds 
that have been shown to have potent growth inhibitory properties.  Recently the 
tylophorine analogue, DCB-3503 (1-62b, NSC-716802), has been found to exhibit 
antitumor activity both in vitro and in vivo against a hepatoma cell line, HepG2.55  A 
study by Cheng and co-workers suggested that DCB-3503 (1-62b) exerts its unique 
growth inhibition properties by modulating nuclear factor kappa B (NF-κB) activity 
through the suppression of IκB kinase (IKK).  However, no direct target was identified.  
The study also revealed that DCB-3503 (1-62b) interfered with cell-cycle progression by 
the down-regulation of several cell-cycle regulatory proteins including cyclin D1.  To 
date, DCB-3503’s (1-62b) target protein(s) and underlying mechanism of action remain 
largely unknown. 
Affinity-based methods employing biologically active biotin-conjugates of DCB-
3503 (1-62b) have the potential, to identify specific DCB-3503 (1-62b) binding proteins.  
Previous attempts aimed at synthesizing functional biotinylated probes of DCB-3503 (1-
62b) have been unsuccessful.  Given the structural and biological similarities between 
DCB-3503 (1-62b) and other phenanthrolizidine alkaloids, the elucidation of the cellular 
targets of DCB-3503 (1-62b) may also shed light on the biological mechanism of this 
interesting class of natural products.  
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OBJECTIVES 
The project described in this dissertation was primarily focused on the design 
and synthesis of biotinylated molecular probes incorporating all of the necessary 
features of DCB-3503 (1-62b) required for in-vitro binding and activity.  Access to these 
probes involved the development of several strategies ranging from the classical 
protective group approach to the late-stage, Cu(I)-mediated union (“click”) of  suitable 
alkyne-azide pairs: 
 
• In the first approach, several protective group strategies were utilized in the 
construction of a tethered form of 1-62b which, upon conjugation with biotin, 
would provide access to a functional biotin conjugate. 
 
• The second approach sought to synthesize a propargylated derivative of 1-62b 
for later coupling to an azide-bearing biotin moiety using the Cu(I)-catalyzed 
variant of the Huisgen 1,3-dipolar cycloaddition.   
 
• A third approach would seek to synthesize a biotin-conjugate of 1-62b bearing a 
super-long polyethylene glycol (PEG) based linker.  Access to this probe would 
involve the incorporation of functionalized PEG spacer units on both 1-62b and 
biotin for later coupling using the Cu(I)-catalyzed variant of the Huisgen 1,3-
dipolar cycloaddition. 
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Finally, using a computational model, more potent analogues of the lead compound, 
1-62b, would undergo in silico screening.  New analogues that are found to be more 
active than 1-62b would be placed in a virtual library and prioritized as future synthetic 
targets. 
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CHAPTER 2 
PROTECTIVE GROUP STRATEGIES TOWARD 
BIOCONJUGATION: A CLASSICAL APPROACH 
2. PROTECTIVE GROUP STRATEGIES TOWARD 
BIOCONJUGATION: A CLASSICAL APPROACH 
2.1 Introduction 
 
 
Molecules that are able to modulate cellular functions are often identified 
through the phenotypic changes that result from their administration to cell or 
organism-based models.  Antitumor drugs, in particular, are commonly discovered 
using this methodology.  In fact, the in vivo antitumor potential of DCB-3503 (1-62b) and 
several other tylophorine analogues was realized by the phenotypic observation of 
tumor-bearing mice after undergoing treatment with doses of DCB-3503 (1-62b)86-87 
(Figure 2.1).  Despite the fact that a large percentage of drugs in use today were 
discovered in this manner, their specific mechanisms of action of were not known until 
several years after their approval by the FDA.   
 
2.2 Target Identification 
 
 
A promising new strategy for the development of efficacious disease therapies 
relies on the discovery and validation of novel drug targets.  Of the 1,357 FDA-
approved drugs on the market today, about 50% of them target only four of the ca. 
16,000 protein families in the genome.88  Current approaches toward target 
identification employ either genomic or affinity-based proteomic methods. 
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Figure 2.1.   The phenotype-based approach to drug discovery. 
In this study, a tumor-bearing animal model is injected with a 
dose of the bioactive drug of interest and the resulting 
phenotypic changes are noted. 
 
 
 
 
2.2.1 The Genomic Approach 
 
In the genomic approach, mutants that are missing specific functions are 
engineered from genetic model organisms (e.g., S.cerevisae, C. elegans, D. melangonaster 
or mammalian cells).89  Upon exposure to the bioactive molecule of interest, only the 
mutants that demonstrate sensitivity or resistance are investigated further.  Although 
this approach is useful in the indirect determination of molecular targets, it is 
particularly suited to molecules whose targets are already known but whose cellular 
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impact is not completely understood.   
Utilizing the genomic approach to target identification, Davis et al. were able to 
successfully identify the drug target of tunicamycin90 using deletion strains of S. 
cerevisae. 
 
2.2.2 The Affinity-Based Approach 
 
Affinity based approaches, on the other hand, are based on the assumption that 
the lead compound will bind strongly (covalently or non-covalently) to its target and 
that this binding event is responsible for the observed change(s) in phenotype.  This 
approach often entails the addition of an affinity tag to the lead compound prior to its 
immobilization on resin. The resulting affinity matrix is then incubated with a lysate of 
a cell line of interest, followed by chromatographic purification.  Typically, the bound 
protein(s) is (are) separated from other cellular proteins by simple filtration, washing 
and elution.91  In most cases, the bound protein(s) can be identified by modern 
degradative mass spectrometric (MS) methods or with a combination of enzyme 
degradation and MS techniques (Figure 2.2).92  
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Figure 2.2.   The affinity-based approach to target identification. 
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2.3 Successful Target Identification Studies Employing Affinity-
Based Approaches 
 
The power of natural products as discovery tools in chemical biology was well 
demonstrated by Schreiber and co-workers in their studies of trapoxin (Figure 2.2) and  
histone deacetylases (HDACs).93-94  Since being discovered in 1964 by Allfrey et al.,95 the 
enzymatic activity of histone deacetylase remained relatively uncharacterized until 1993 
when Kijima et al. demonstrated that the natural product trapoxin96 was found to inhibit 
histone deacetylation in vivo.97  However, trapoxin, also induced phenotypic changes in 
cells in addition to its inhibition of histone deacetylation.  Although the changes in cell 
morphology were thought to arise from cell-cycle arrest, the correlation between 
histone deacetylation and cell-cycle arrest was not completely understood.   
 
 
 
 
 
Figure 2.3.   The natural product, trapoxin, which inhibits histone deacetylation. 
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To further investigate this issue, Schreiber and co-workers synthesized an 
analogue of trapoxin called K-trap93 (Figure 2.3) that was able to be covalently 
immobilized on resin.  Following incubation with a mammalian cell extract, K-trap 
revealed that one of the molecular targets of trapoxin was a protein (HD1) whose amino 
acid sequence was 60% identical to that of the yeast protein Rpd3p.94  Although the 
function of this protein was unknown at the time, the RPD3 gene had already been 
shown to be essential for the transcriptional regulation of a subset of inducible genes in 
yeast.98   
Ultimately, Schreiber and co-workers were able to clone the human ortholog of 
the yeast gene RPD3, and its recombinant protein was found to exhibit histone 
deacetylase activity.  This exclusive finding was instrumental in the identification of a 
histone  deacetylase gene.94  Additionally, the changes in cell morphology were found  
 
 
 
 
 
Figure 2.4.   Structure of the tethered trapoxin derivative, K-trap. 
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to be an indirect consequence of trapoxin’s interaction with actin filaments.  Although 
trapoxin was never developed into a drug, the work by Taunton and others established 
a precedent for the development of vorinostat99 (Zolinza®, Merck), a potent histone 
deacetylase inhibitor, which was approved by the FDA in 2006 for the treatment of 
cutaneous T-cell leukemia.  In another example, in which affinity chromatography 
played a key role, Schreiber and co-workers utilized an agarose-supported derivative of 
the immunosuppressant FK-506, which after incubation with the cellular lysate of 
bovine thymus, revealed that FK-506 bound to the protein FKBP12, a cis-trans prolyl 
isomerase.100 
 
2.4 Biotinylated Probes in Target Identification 
 
A commonly used technique in target identification is the synthesis of 
biotinylated versions of the lead compound for immobilization on avidin/streptavidin 
beads.  Biotin binds to the proteins avidin and streptavidin with dissociation constants 
of 10-15 M, making it one of the strongest non-covalent proteins known.101-102  As a 
result, streptavidin-based resins, when incubated with a biotinylated probe of interest, 
will give rise to a stable non-covalent affinity matrix.  The resulting affinity matrix can 
then be treated with a lysate of a cell line of interest to identify any target protein(s) 
(Figure 2.3).  This method is directly analogous to the affinity-based approach described 
in Section 2.2.2.   
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Figure 2.5.   The use of biotinylated probes in target identification studies. 
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2.4.1 Probing the NF-κB Pathway With Biotinylated Probes 
 
 
The sesquiterpene lactone parthenolide (Figure 2.6) is an anti-inflammatory 
agent from the medicinal herb Feverfew (Tanacetum parthenium).  It was demonstrated 
to be a potent inhibitor of the transcription factor NF-κB (see Section 1.8.2) by Bork et 
al.103-104  In a subsequent study, Hehner et al. found that parthenolide inhibited NF-κB 
activity by interfering with the phosphorylation of the IκB kinase complex; however, it 
was not known whether parthenolide directly targeted the catalytic subunits IKK-α and 
IKK-β.105  In a study aimed at identifying the specific target of parthenolide, Crews and 
co-workers synthesized a parthenolide-biotin conjugate (Figure 2.6), which upon 
incubation with lystates from human cervical carcinoma (HeLa) cells, revealed that 
parthenolide’s direct molecular target was in fact IKK-β.106  Thus, the anti-inflammatory 
properties of parthenolide were found to arise from its direct binding to IKK-β, which 
resulted in the loss of NF-κB activity. 
 In another example, Crews and co-workers synthesized a biotinylated 
isopanepoxydone derivative (Figure 2.7) in order to determine the cellular target(s) of 
isopanepoxydone, a potent NF-κB signaling inhibitor.107  After treatment of the 
biotinylated isopanepoxydone derivative with HeLa cells, a protein species ca. 50 kDa 
was confirmed to be isopanepoxydone’s target.  This 50 kDa protein, however, has not 
yet been characterized. 
 The examples described above illustrate the power of biotinylated probes in 
ascertaining the specific mechanisms by which the compounds of interest operate.  To 
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date, all that is known is DCB-3503 (1-62b) exerts its unique growth inhibition 
properties by modulating nuclear factor kappa B (NF-κB) activity.  Although this 
inhibition was suggested by Cheng and co-workers to occur through the suppression of 
IκB kinase (IKK),85 the protein/cellular targets of DCB-3503 (1-62b) remain unidentified.  
Therefore, a biotin-based affinity agent has the potential to isolate and identify the 
binding protein(s) of DCB-3503 (1-62b).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.   The structure of pathenolide and the pathenolide–biotin conjugate. 
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Figure 2.7.   The structure of isopanepoxydone and its biotin conjugate. 
 
 
 
 
2.5 Synthesis of Biotin-Based Affinity Reagents 
 
In all target identification strategies, the molecular probe plays a central role in 
identifying the molecular target(s) of a compound of interest.  In most cases, the probe 
arises from the attachment of an affinity tag such as biotin, to the bioactive compound 
using a suitable linker.  Classical approaches to the biotinylation of bioactive molecules 
often involve the formation of peptide and ester bonds.108  In a generic approach (Figure 
2.8), the molecule of interest is appended with a functional linker arm for subsequent 
coupling to a biotin moiety through the formation of either an ester or amide bond.   
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Figure 2.8.   The generic approach to classical biotinylation. 
The small molecule of interest is typically appended with a 
functional linker arm bearing either a terminal hydroxy or 
amino function. Conjugation with biotin occurs through the 
formation of either an ester or amide linkage. 
 
 
 
2.5.1 The Use of Protective Groups in the Synthesis of Biotinylated Probes 
 
Because the conjugation of a bioactive compound with biotin often takes place in 
the end stages of a synthetic strategy, protective groups are commonly utilized to 
preserve the integrity of the appropriate amine or hydroxy motif.  For example, Abrams 
and co-workers synthesized a biotinylated derivative of the plant hormone abscisic acid 
S-(+)-ABA using tert-butyldimethylsilyl (TBDMS) as their hydroxy protecting 
function.109  Towards the end of their synthesis, Abrams and co-workers first cleaved 
the silyl ether using TBAF before coupling the deprotected hydroxyl group to the biotin 
moiety (Figure 2.9).  In another example, Kobayashi and co-workers were able to 
synthesize a biotinylated derivative of neoechinulin A by using a methoxymethyl ether 
to protect the phenolic position of neoechinulin A, which would later serve as the site of 
biotinylation (Figure 2.10).110 
X
n
O
OH
O
n
esterification or 
peptide coupling 
= biotin = ether linkage = ester or amide linkage X = OH or NH2 
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Figure 2.9.   Abrams and co-workers’ protective group approach to the synthesis of a 
biotinylated derivative of abscisic acid.109 
 
 
 
 
 
 
 
 
 
Figure 2.10.   Kobayashi and co-workers’ protective group approach to the synthesis of 
a biotinylated derivative of neoechinulin A.110 
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2.6 Target Validation 
 
 
Once a molecule’s potential target protein has been identified, it has to undergo 
validation to confirm that it is indeed the relevant binding partner of the molecule in 
vivo.  Several experimental strategies exist to accomplish this,111 including gene 
expression profiling and yeast three hybrid studies.  One of the simplest validation 
strategies involves the in vitro analysis of the bioactive compound with its presumed 
target.  Using either fluorescence anisotropy, isothermal titration calorimetry or surface 
plasmon resonance, the direct binding of the affinity-purified protein to the compound 
can be experimentally observed. 
Cell-culture experiments have also been developed to assist in target validation.  
Of the cell-culture validation experiments available, the modulation of the expression 
level of the putative target protein using RNAi techniques is the most common.  Cells 
that lack the putative target protein should exhibit no changes in phenotype upon 
exposure to the compound of interest.  Conversely, cells that are overly abundant in the 
putative target protein through overexpression should diminish the potency of the 
molecule of interest. 
 
2.7 Limitations of Target Identification Strategies  
 
 
The successful target identification strategies discussed so far have demonstrated 
the ability of natural products (or their mimics) to serve as powerful discovery tools in 
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the fields of chemistry and biology.  However, the determination of the protein target(s) 
of bioactive molecules remains a significant challenge in modern drug discovery.  A 
common issue seems to be an attenuation of activity of the bioactive compound upon 
biotinylation;107,112 however, biotinylated derivatives with diminished activities have 
been successfully employed in past studies.106,113-114  Furthermore, the aqueous 
solubility of biotin conjugates can be rather poor especially if an aliphatic variant such 
as biotinyl-6-aminohexanoic is used.115-116  This induced hydrophibicity can result in the 
retention of many proteins from an extract in addition to the physiologically relevant 
target(s).  Additionally, the compound of interest also has the potential to behave 
“promiscuously” by binding to numerous targets and forming aggregates as 
demonstrated by Shoichet and co-workers.117   
Typically, in an affinity chromatography experiment, an extract is passed over 
the immobilized compound of interest, requiring extensive washing (using denaturing 
buffers) to remove non-specific binding partners.  In this case, if the molecule–protein 
interaction has a low kinetic half-life, then the likelihood exists that the target may not 
survive washing.  Therefore, the degree of affinity that a compound has for its target is 
a key determinant of the success or failure of an affinity chromatography experiment.  
Another obvious factor in all target identification strategies is the abundance of the 
target protein(s).  If the abundance of this protein is low, then it becomes exceedingly 
difficult to detect it above background noise.   
Clearly, the success of a target identification experiment depends on many 
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factors, and there are a considerable number of challenges that need to be overcome.  
However, the discovery of the targets of bioactive compounds can reveal new proteins 
and revolutionize targeted-based drug discovery efforts. 
 
2.8 Research Plan: Retrosynthetic Analysis 
 
 
A DCB-3503-biotin conjugate (2-19) suitable for the investigation of DCB-3503 (1-
62b) binding partners is presented in Figure 2.11.  As demonstrated by the 
retrosynthetic transform, the ester linkage is expected to arise from the late stage 
esterification between 2-18’s primary hydroxy and commercially available D-(+)- biotin.  
In designing the affinity agent, 2-19, the length of the carbon chain between the active 
head unit and the biotin moiety was anticipated to comprise six carbon atoms.  A linker 
of this length would ensure that any potentially unfavorable interactions between the 
functional tag (biotin) and the active head unit of 2-19 would be kept to a minimum. 
Additional retrosynthetic transformations are detailed in Figure 2.12.  
Intermediate 2-17, the protected derivative of 2-18, is presumed to arise from ketone 2-
15 by means of a selective hydride delivery procedure.  The formation of 2-15 can be 
anticipated from the intramolecular cyclization of an appropriate form of intermediate 
2-13.  Retrosynthetic cleavage at 2-13’s benzylic position identifies the chiral adduct 1-
42b and the benzylic bromide, 2-10, as being the suitable coupling partners.  It is likely 
that the bromo derivative 2-10 could be accessed from 2-5c via a series of functional 
group transformations.   
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In his attempted synthesis of a DCB-3503–biotin conjugate, Kaczmarek elected to 
attach a functional linker in the final stages of his synthetic route (Figure 2.13) using a 
free hydroxy intermeidate of DCB-3503. 83  However, this strategy was unsuccessful due 
in part, to the poor solubility of the phenolic derivative.  Therefore, to circumvent this 
issue, attachment of the six-carbon linker is expected to occur in the early stages 2-19’s 
synthesis.  Continued cleavage at the phenolic and equatorial positions of 2-5c (Figure 
2.14) reveals the commercially available building blocks as being 4-hydroxy-3-
methoxybenzaldehyde, 2-(3,4-dimethoxyphenyl)acetic acid and 6-chlorohexanol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11.   Initial retrosynthetic transforms of the molecular probe 2-19. 
esterification 
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Figure 2.12.   Retrosynthetic scheme for the construction of the subtarget, 2-18. 
deprotection asymmetric 
reduction 
intramolecular 
acylation 
N-alkylation 
bromination 
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Figure 2.13.   Kaczmarek’s attempted alkylation of a free hydroxy intermediate.83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14.   Retrosynthetic scheme of intermediate 2-5c. 
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2.9 Synthesis of the O-linked DCB-3503 Subtarget, 2-18 
 
 
2.9.1 Attachment of the Linker Arm 
 
 
Construction of the desired stilbene core, 2-2, was accomplished in two steps 
commencing with the Perkin condensation118 of 3,4-dimethoxyphenylacetic acid and 
vanillin, followed by the Fisher esterification119 of 2-1 to afford the stilbene 2-2 (Figure 
2.15).86  Based in part on Kaczmarek’s earlier work,83 early attempts focused on the 
derivation of a functional linker from the ammonolysis of γ-butyrocaprolactone to give 
6-hydroxyhexanamide.  Attachment of this linker to the stilbene core 2-2 was attempted 
using a phenolic Mitsunobu procedure,120 which, despite its ability to couple a wide 
range of phenol and alcohol substrates, proved unsuccessful (Figure 2.16).  In a revised 
approach, alkylation of the stilbene 2-2 was attempted using a sodium hydride/DMF 
system and the bromo and chloro derivatives 6-hydroxyhexanamide (Figure 2.17).  This 
approach, however, did not yield any trace of the product 2-2a. 
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Figure 2.15.   Construction of the stilbene core 2-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16.   Attempted Mitsunobu coupling to the stilbene 2-2.  
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Figure 2.17.   Derivatization of 6-hydroxyhexanamide and attempted alkylation of the 
stilbene 2-2. 
 
 
A more exotic approach employed the triflate 2-5a (Figure 2.18) and two linkers, 
2-6 and 2-7, derived from 1-bromo-6-chlorohexane and 6-chlorohexanol, respectively, 
(Figure 2.19).  It was hoped that a Stille coupling121 reaction would enable attachment of 
the linkers to the stilbene core (Figure 2.20).122  Although this approach went against the 
plan set forth in the retrosynthesis (Figure 2.12), it was interesting for one particular 
reason, the elimination of the polar phenolic ether linkage could conceivably alter the 
overall pharmacokinetics of the resulting probe.  Disappointingly, attempts to effect this 
Stille coupling123 using several palladium catalysts such as Pd(dppf)2Cl2 and 
Pd(PPh3)2Cl2 were unsuccessful.   
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Figure 2.18.  Synthesis of the Stille coupling partner 2-5a. 
 
 
 
 
 
 
Figure 2.19.  Synthesis of the Stille-compatible linker arms 2-6 and 2-7 . 
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Figure 2.20.   Mechanism of the attempted Stille coupling of the triflate 2-5a with 
partners 2-6 and 2-7. 
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Corona co-workers were able to accomplish the late-stage biotinylation of a 
phenylalanine derivative using an alkyne functionalized biotin moiety124 and this 
inspired the attempted Suzuki–Miyaura coupling125 shown in Figure 2.21.  Moreover, 
biotinylation was envisaged to occur via a similar palladium-mediated coupling during 
the end stages of the synthesis (Figure 2.22).  Unfortunately, repeated attempts at 
coupling 2-5a with a potassium alkyltrifluoroborate linker, 2-8, using PdCl2(dppf) 
failed.  After a personal discussion with Akira Suzuki, it was postulated that the 
electron-rich nature of the phenanthrene core of triflate 2-5a may be a factor in the 
attempted couplings of 2-5a and 2-8.126  This unfortunate revelation prompted a return 
to the original synthetic plan.   
 
 
 
 
 
Figure 2.21.   Attempted Suzuki–Miyaura coupling of 2-5a with a potassium 
alkyltrifluoroborate linker, 2-8. 
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Figure 2.22.   The envisaged late-stage biotinylation via a Pd-mediated coupling. 
 
 
 
Pioneering efforts by a fellow group member, Julio Gutierrez, successfully 
established K2CO3 and refluxing acetone as being the optimal conditions for the 
monoalkylation of the stilbene 2-2 with 1-bromo-6-chlorohexane (Figure 2.23) to give 2-
2c.127  Employing similar conditions, the O-linked stilbene 2-2d was afforded in good 
yield from 2-2 and 6-chlorohexanol (Figure 2.24).  It is important to note that the 
reaction required 48 h of continuous refluxing in order to furnish 2-2d in good yield.  
The addition of sodium iodide dramatically shortened reaction times, presumably 
through halide exchange (Finkelstein reaction).128 
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Figure 2.23.   Gutierrez’s successful alkylation of the stilbene 2-2.127 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.24.   Alkylation of the stilbene 2-2 using the Finklestein modification. 
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2.9.2 Protection with TBDPS 
 
With the desired O-linked stilbene 2-2d now in hand, efforts would now be 
directed toward the installation of a suitable protecting group at 2-2d’s hydroxy 
position.  Given the spate of functional group transformations needed to go from 2-
2d2-10, the appropriate protecting function would not only have to withstand all of 
these operations, but also be able to continually mask the primary hydroxyl group for 
the remainder of the synthesis.   
Silyl ethers are commonly used in organic synthesis for the protection of 
alcohols, and depending on steric bulk, are known to be stable under a wide range of 
conditions.  As such, silylation of 2-2d with tert-butyldiphenylsilyl chloride (TBDMSCl) 
yielded the silyl-protected derivative 2-2e (Figure 2.25), which was then subjected to a 
FeCl3-mediated ring closure procedure (Figure 2.26).  This mild, yet effective oxidative 
ring closure was able to yield the O-linked phenanthrene 2-5, but the Lewis acidity of 
FeCl3 also caused simultaneous cleavage of the silyl ether.  This problem was 
immediately addressed by attaching the linker to the bridged-phenanthrene 2-5 instead 
of the stilbene 2-2 (Figure 2.27). 
The ester 2-5d was then treated with a suspension of LiAlH4 in THF to effect its 
conversion to 2-9 (Figure 2.28).  Initially, this reduction resulted in the unexpected and 
unusual cleavage of the silyl ether,129-130 prompting a switch to lithium borohydride; a 
milder reducing agent (Figure 2.28).131  However, in doing so, 2-9’s yield was 
compromised considerably probably as a consequence of the acidic work-up conditions.   
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Figure 2.25.  Silylation of the O-linked stilbene derivative 2-2d with TBDMSCl. 
 
 
 
 
 
 
 
 
Figure 2.26.  Cleavage of the silyl ether by FeCl3 during the oxidative ring closure of 2-
2e. 
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Figure 2.27.  Alkylation of the bridged phenanthrene core 2-5 with 6-chlorohexanol. 
 
 
 
 
 
 
 
 
 
Figure 2.28.  Cleavage of 2-9’s silyl ether by LiAlH4 and reduction of 2-5d with LiBH4. 
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Ultimately, changes were made to the lithium aluminum hydride procedure, 
which included shortening the reaction time from the original 4 h to 2 h and keeping the 
reaction temperature at 0 °C.  These modifications then resulted in the smooth 
conversion of 2-5d2-9. 
The resulting benzylic alcohol 2-9 would first have to be converted to the bromo 
derivative 2-10 before coupling to the chiral auxiliary 1-42b can take place.  All attempts 
to effect this conversion with phosphorous tribromide (Figure 2.29) resulted in complex 
reaction mixtures with no isolatable product.  Investigations into the failure of this 
seemingly straightforward operation revealed that the silicon and oxygen atoms of 2-9 
could be complexing to the phosphorous and bromine atoms of PBr3 (Figure 2.29).132  
The inevitable decomposition of the unstable four center adduct likely resulted in 
cleavage of the Si–O bond.  
 
 
 
 
 
 
 
 
Figure 2.29.   Interaction of PBr3 with 2-9’s silyl ether. 
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With the incompatibility of 2-9 with PBr3 noted, conversion of 2-92-10 was 
attempted using other reagents but was met with little success (Figure 2.30), probably 
due to the interaction of triphenylphosphine (PPh3) with the silyl ether.133   
Conversion of 2-9 to its benzylic chloride form 2-10a was achieved using N-
chlorosuccinimide,134 but this intermediate proved to be extremely unstable, 
decomposing readily in the presence of light.35  Conversion of 2-9 into the tosylate (2-
10b),135 acetimidate (2-10c)136 and triflate (2-10d)137 forms was also not effective (Figure 
2.30).  It was postulated that the reactive nature of the 2-9’s benzylic position was 
affecting the stability of intermediates 2-10b, 2-10c and 2-10d through a probable SN1 
decomposition process.138 
At this juncture, with all attempts at converting the hydroxy group in 2-9 into a 
stable leaving group exhausted, the synthetic strategy was redesigned so that coupling 
of the chiral auxiliary 1-42b could occur via a “reductive lactamization” procedure.139  
Accordingly, 2-9 was first converted to the aldehyde 2-11 via a Swern oxidation 
protocol140 and aminated using the chiral auxiliary 1-42b.  The resulting imine 2-12 was 
then treated with sodium triacetoxyborohydride in hopes that the tandem reduction–
lactamization sequence would be able to afford 2-13 (Figure 2.20).  Discouragingly, even 
though Abdel–Magid and co-workers were able to complete a similar operation using 
benzaldehyde and methyl 4-aminobutyrateHCl,139 the attempted conversion of 2-
112-13 proved to be unsuccessful.  Other attempts at reducing the imine 2-12 using 
either Pd/C or NaBH4 also did not succeed.  The main obstacle to this conversion  
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Figure 2.30.   Failed attempts at accessing the bromo derivative 2-10. 
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Figure 2.31.   Attempted conversions of 2-9 to other derivatives. 
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Figure 2.32.   Reductive–lactamization strategies in the TBDPS-protective group approach. 
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seemed to lie with the instability of the imine 2-12 which, upon formation, was 
presumed to dissociate back to 2-11 and 1-42b.   
 
 
2.9.3 MOM Protection Route 
 
In light of the challenges presented in the TBDPS strategy, the protecting group 
was switched to a methoxymethyl (MOM) ether.  As a result, the MOM-protected 
derivative 2-5e was obtained in good yield from 2-5c using MOM-Cl and DIPEA. 
Reduction of 2-5e using LiAlH4 proved successful and furnished 2-9b without incident 
(Figure 2.33).  Unfortunately, this initially promising approach was again thwarted by 
the failed conversion of 2-9b2-10e using phosphorous tribromide (Figure 2.34).  At 
this stage, the practicality of using MOM as a protecting group for the remainder of the 
synthesis was re-examined.  Assuming that intermediate 2-9b could be advanced past 
the bromination step, the MOM group would certainly undergo cleavage in the 
upcoming acid-catalyzed lactamization, necessitating the need to re-protect the hydroxy 
motif.   
 
2.9.4 Trityl Protecting Route 
 
Although a myriad of hydroxy protecting groups are available as alternatives to 
TBDPS and MOM, it became apparent at this point in 2-18’s synthesis that a more 
resilient protecting function was needed.  More importantly, this protecting function  
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Figure 2.33.   MOM protection of 2-5c and conversion to 2-9b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.34.   Attempted conversion of 2-9b using PBr3. 
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would have to completely suppress the hydroxy group’s reactivity within the protected 
moiety.  To this end, it was envisioned that conversion of 2-5c to its triphenylmethyl 
ether form 2-5f would minimize or block interactions at the protected hydroxy’s 
oxygen.  In fact, the steric bulk of this protecting function has been utilized in 
nucleoside synthesis to intentionally block access to certain portions of the substrate.141  
As such, introduction of the trityl group was first attempted by reaction of 2-5c with 
trityl chloride (TrCl) in a mixture of DMAP, TEA and DMF (Figure 2.35).142-143 
While this method provided only tangible amounts of 2-5f, it marked a turning 
point in the synthetic strategy as 2-18 would no longer be pursued as the subtarget.  As 
 
 
 
 
 
Figure 2.35.   Protection of 2-5c using trityl chloride. 
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exemplified in the redesigned retrosynthesis (Figure 2.36), 2-34 was selected as the new 
probe and would seem to be attainable from the conjugation of 2-31 and the 
commercially available biotin–maleimide derivative, 2-33.  In contrast to the original 
probe 2-18, the new probe 2-34 was redesigned to preclude ester linkages as these could 
be subject to cleavage by nonspecific esterases144 in the ensuing affinity studies (see 
Section 3.7).   
In this revised approach, a shorter linker arm would be incorporated in the early 
stages of 2-31’s synthesis, and access to the primary hydroxyl would be blocked by 
installation of a trityl ether.  In accordance with this strategy, alkylation of the 
phenanthrene 2-5 with 1,3-dibromopropane in a refluxing mixture of acetone and 
K2CO3 afforded 2-20 in excellent yield (Figure 2.37).   
Etherification of 2-20 was accomplished using carbinol and NaH (Figure 2.37) to 
furnish the protected derivative 2-21, which was then reduced to the alcohol 2-22 using 
lithium aluminum hydride.  Intriguingly, during a routine conversion of 2-212-22, an 
additional product was isolated and was subsequently identified as 2-36 (Figure 2.38).  
The alkene 2-36 was postulated to arise from the ethoxide-induced elimination of 2-22’s 
triphenylmethoxy motif (Figure 2.38).  Generation of the ethoxide was attributable to 
the action of excess hydride on EtOAc during workup.  The 1H NMR spectrum 
confirmed that elimination of the triphenyl methoxy product had in fact taken place 
and this event had triggered the formation of the alkene 2-36.  The characteristic allylic 
peaks are highlighted in Figure 2.39.   
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Figure 2.36.   Retrosynthetic analysis of the new molecular probe 2-34. 
1,4-conjugate 
addition 
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Figure 2.37.   Etherification of 2-20 with carbinol. 
 
 
 
 
 
Figure 2.38.   Elimination of 2-22’s triphenylmethoxy motif. 
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Figure 2.39.   Intriguing structural features of intermediate 2-36 and their corresponding 
1H NMR patterns. 
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 Intermediate 2-22 was advanced to the bromo-derivative 2-23 with phosphorous 
tribromide without complication.  Bromine displacement of 2-23 (Figure 2.40) using the 
chiral auxiliary 1-42b, established access to the aminal 2-24, which upon treatment with 
0.5% acetic acid, underwent lactamization to give minute amounts of 2-25 (Figure 2.41).  
The inherent sensitivity of trityl groups to acid was hypothesized to be the main factor 
that was impacting 2-15’s yield.  Other, attempts to obtain 2-25 from 2-24 using a 
thermal cyclization procedure145 failed as did refluxing 2-24 in toluene146 (Figure 2.42).  
Selective hydrolysis of 2-24 (LiOH, dioxane–H2O),147 followed by tosylation with TsCl 
in pyridine, also did not result in the formation of 2-25 (Figure 2.42).   
 
 
 
 
 
 
Figure 2.40.   Coupling of the chiral auxiliary 1-42b to the bromo derivative 2-23. 
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Figure 2.41.   Acid catalyzed lactamization of 2-24. 
 
Then, the diester 2-24 was hydrolyzed to the diacid (LiOH, MeOH–H2O),148 
which, upon workup with acid, resulted in cleavage of the trityl group to give the 
intermediate 2-27.  With the subtarget 2-31 still a few steps away, the unprotected state 
of 2-27 would appear to present a tactical disadvantage. However, it was projected that 
the remaining conversions could be effected in the presence of 2-27’s free hydroxy 
group.  As such, the cyclization of the diacid 2-27 was completed by activation of the 
diacid using N,N’-carbonyldiimidazole149 in refluxing THF to yield the bisimidazole 
derivative, which then immediately cyclized, affording 2-28 (Figure 2.43).  The 
pentacyclic ketone 2-29 was then accessed via the intramolecular acylation of 2-28 using 
TFAA and BF3Et2O, which also resulted in “reprotection” of the free hydroxy as the 
trifluoroacetate.  Selective hydride delivery using K-Selectride®, accomplished the 
conversion of 2-292-30.  Finally, reduction of 2-30 with LiAlH4 (Figure 2.43) secured 
access to usable amounts of the subtarget 2-31.   
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Figure 2.42.   Attempted lactamization of 2-24 using non-acidic means. 
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Figure 2.43.   Scheme for the synthesis of 2-31. 
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Conjugation of 2-31 to the maleimide–biotin derivative 2-33 was anticipated to 
occur via the 1,4-conjugate addition of 2-31’s hydroxy motif with 2-33’s maleimide 
moiety.  To probe the viability of this approach, 2-31 was allowed to react with 
cyclohex-2-enone under mild conditions150 (K2CO3/acetone) giving rise to 2-32 (Figure 
2.44).  Despite the success of this model study, it was deemed that 2-31’s overall yield 
and purity were not adequate for coupling to the maleimide biotin derivative 2-33.   
 
 
 
 
 
 
 
 
 
Figure 2.44.   Model study for the 1,4-conjugate addition of 2-31 to cyclohex-2-enone. 
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2.9.5 Synthesis of the Allylated Derivative 2-44 
 
 
The unexpected formation of intermediate 2-36 during the conversion of 2-212-
22 (Figure 2.38) inspired an overhaul of the problematic, protective group-based 
approach toward the subtarget 2-31.  As demonstrated by the retrosynthetic transform 
in Figure 2.45, the use of an allylic linker would obviate the need for protective groups 
and allow the subtarget 2-31 to be accessed from 2-44 through a hydroboration or 
epoxidation procedure.  Of note, allyl ethers are stable to moderately acidic conditions 
and are commonly employed in carbohydrate research as stable protective groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.45.   Retrosynthetic transform of 2-31 leading to the allylated precursor 2-44. 
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Construction of the new subtarget 2-44 began with allylation of 2-5’s phenolic 
handle to furnish the intermediate 2-35, which then underwent smooth conversion to 
the alcohol 2-36 using lithium aluminium hydride.  Conversion of 2-36 to the bromo 
derivative, 2-37, was again accomplished with the use of phosphorous tribromide.  The 
coupling of 2-37 with the chiral auxiliary 1-42b was conducted using K2CO3 and DMF 
to yield the aminal 2-38 (Figure 2.46).  Lactamization was attempted by heating 2-38 at 
30 °C in a mixture of AcOH–MeOH but yielded only detectable amounts of 2-40.  
Attempts to secure higher yields of 2-40 using a NaH-mediated cyclization procedure151 
were also unsuccessful.  However, hydrolysis of 2-382-39 with LiOH–MeOH, 
followed by activation of the resulting diacid 2-39 with N,N’-carbonyldiimidazole,149 
provided only moderate amounts of 2-41 (Figure 2.47).  Amazingly, ample quantities of 
2-40 were finally accessed by first passing the aminal 2-38 through a plug of silica gel 
(hexanes–EtOAc) and then allowing the evaporated crude product to self-condense at 
ambient temperature for 48 h (Figure 2.48).  The formation of the intermediate 2-40 was 
confirmed by its 1H NMR spectrum which reflected a lot of its intriguing structural 
figures (Figure 2.49).  
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Figure 2.46.   Allylation of the phenanthrene core 2-5 and advancement to the aminal 2-
38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.47.   Lactamization of the diacid 2-38 using N,N’-carbonyldiimidazole. 
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Figure 2.48.   Self-condensation of the aminal 2-38 at ambient temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
98 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.49.   Intriguing structural features of intermediate 2-40 and their corresponding 
1H NMR patterns. 
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With adequate quantities of 2-40 in hand, rapid hydrolysis of its methyl ester was 
achieved using 2 N KOH to furnish the carboxylic acid intermediate 2-41 in good yield.  
The usual protocol of effecting the intramolecular Friedel–Crafts acylation via Lewis 
acid activation (BF3Et2O or SnCl4) failed in going from 2-412-42 (Figure 2.50).  It was 
later discovered that allyl ethers have the potential to interact strongly with Lewis 
acids.152  To overcome this eventuality, the intramolecular cyclization of 2-412-42 was 
accomplished by reaction of the carboxylic acid 2-41 with triflic anhydride.  The 
mechanism of this transformation is thought to involve formation of the 
trifloxycarbenium cation, which upon loss of triflic acid forms the 
trifluoromethanesulfonic carboxylic anhydride153 (Figure 2.50).  This was then 
proceeded by acylation of the phenanthrene furnishing the aryl ketone 2-42.  Reduction 
of 2-42 with K-Selectride® cleanly afforded 2-43, which upon further treatment with 
LiAlH4, was able to furnish 2-44 (Figure 2.51). 
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Figure 2.50.   Intramolecular acylation of 2-412-42 via treatment with triflic anhydride. 
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Figure 2.51.   Final stages in the synthesis of the allylated derivative 2-44. 
 
 
The attempted epoxidation of 2-44 with m-CPBA resulted in the unanticipated 
formation of 2-45, the N-oxide derivative of 2-44 (Figure 2.52).  In their synthesis of 
potent enediynes, Nicolaou et al. also noted the formation of a similar adduct and were 
able to effect its deoxygenation by refluxing in Ac2O.154  However, efforts to 
deoxygenate 2-45 in the same manner did not succeed.  Hydroboration of 2-44 also 
resulted in the over-oxygenated derivative 2-46, probably due to exposure to hydrogen 
peroxide (Figure 2.52). 
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Figure 2.52.   Formation of N-oxides of 2-44 during hydroboration and epoxidation 
 
 
2.10 Conclusions 
 
The synthetic sequences to prepare the targeted affinity probes, 2-19 and 2-34 
were based, in part, on the methodology by Buckley and Rapoport35 and Kaczmarek83 
but included several new and notable modifications.  Among the most interesting 
features of the synthetic strategy were the following: 
1. The efficient lactamization of the aminal 2-38 to give 2-40 through self-
condensation. 
2. The utilization of trifluoromethanesulfonic anhydride in the conversion of 2-
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41 to 2-42 provided a means of effecting intramolecular acylation without the 
need for a Friedel–Crafts type catalyst.  
Efforts to secure biotin-conjugated derivatives of DCB-3503 (1-62b) via protective 
group approaches proved to be unsuccessful.  Because the synthesis employed some 
harsh transformations, the protecting functions were often prematurely cleaved or 
involved in complex side reactions.   
Most significantly, the unanticipated formation of the alkene intermediate 2-36 
was instrumental in the development of a strategy that utilized no protecting functions 
(Section 2.9.5).  While only partially successful, the use of an allylic linker as a masked 
tether could be poosibly expanded upon in future syntheses by attachment of a dithiol 
linker155 instead of relying on oxidation of the alkene (Figure 2.51). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.51.   Possible attachment of a dithiol linker to 2-44 in lieu of alkene oxidation.  
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CHAPTER 3 
BIOCONJUGATION VIA CLICK CHEMISTRY: A 
NONCLASSICAL APPROACH. 
 
3. BIOCONJUGATION VIA CLICK CHEMISTRY: A 
NONCLASSICAL APPROACH 
 
3.1 Background and Significance 
 
 
Classical approaches to the synthesis of probes for the elucidation of protein 
binding targets have often relied on the formation of peptide and ester bonds.108  More 
recently, the Cu(I)-catalyzed variant of the Huisgen 1,3-dipolar cycloaddition (“click” 
chemistry) has emerged as a powerful technique for chemoselective ligation.156-158   
In a generic approach, the synthesized probe is chemically tagged with a 
propargyl marker and coupled with a biotinylated azide under standard “click” 
coupling conditions to give rise to the biotinylated probe (Figure 3.1).  The use of 
kinetically stable entities such as azides and alkynes, which in addition to being tolerant 
to a wide range of synthetic conditions,159 have allowed this particular type of click 
chemistry to have broad utility in organic synthesis.  Additionally, azides160 and 
alkynes possess a relatively narrow window of reactivity allowing them to be 
incorporated in the early stages of a synthetic strategy, providing the ability to “click” at 
any stage.  Furthermore, the relative inertness of these functional groups161 allows them 
to remain virtually “invisible” throughout the synthesis, thereby minimizing the need 
for protective groups.  Another advantage offered by this approach arises from the 
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rigidity of the 1,2,3-triazole moiety, which ensures that the two linked substances are 
not intruding into each other’s structural space.   
This highly modular approach to bioconjugation has simplified syntheses and 
allowed for the rapid and high-yielding synthesis of several molecular probes.  
 For example: 
1. Uemura and co-workers recently synthesized and evaluated biotin-labeled (-)-
ternatin,162 a potent fat-accumulation inhibitor against 3T3-L1 adipocytes.  
Biotinylation was accomplished using a strategically installed propargyl marker 
and click chemistry  (Figure 3.2) 
2. Hulme and co-workers utilized the Cu(I)-catalyzed 1,3-DCR to couple an N-
linked propargyl ansiomyic derivative to an azido functionalized biotin fragment 
affording the corresponding biotinyated probe in 73% yield (Figure 3.2).163 
 
 
3.1.1 Click Chemistry: A Background  
 
 
The exergonic fusion of 1,3-dipoles to dipolarophiles (i.e., acetylenes or alkenes) 
via the 1,3-dipolar cycloaddition reaction (1,3-DCR) to afford five-membered 
heterocycles is a ubiquitous transformation in synthetic organic chemistry.  Of the 
various five-membered heterocycles that are accessed using this reaction, the 
cycloaddition of azides and alkynes to give triazoles is arguably the most utilized.  The 
classical Huisgen 1,3-DCR between an azide and an alkyne proceeds under thermal  
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Figure 3.1.   A generic approach to biotinylation via click chemistry. 
N3
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Figure 3.2.   Biotinylation of ternatin163 and an anisomycin162 derivative via click chemistry. 
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conditions affording a mixture of 1,4- and 1,5-disubstituted 1,2,3-triazoles (Figure 3.3).  
Although the relative proportion of these regioisomers is dictated by electronic and 
steric factors, 1,4-regioselectivity can be increased by reacting an electron deficient 
acetylene with an azide that is electron rich.164-165  
In 1999, Sharpless and co-workers introduced a Cu(I)-catalyzed variant of the 
Huisgen 1,3-dipolar cycloaddition  which in addition to featuring a dramatically 
enhanced rate (up to 107 times),166 also offered improved regioselectivity.167  Recent 
thermal and kinetic studies have shown that compared to the non-catalyzed, concerted 
process, this Cu(I)-catalyzed (“click”) variant occurs via a stepwise process whose 
activation barrier is lowered by as much as 11.8 kcal mol-1.166  The proposed catalytic  
 
 
 
 
 
 
 
 
 
Figure 3.3.   The thermal and Cu(I)-catalyzed 1,3-DCR reactions. 
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cycle (Figure 3.4)166 is postulated to involve several transient Cu(I)-acetylide complexes 
that originate from complexation of the terminal alkyne to the Cu(I) metal center 
(Sonogashira coupling168) resulting in a Cu(I)–alkyne ̟-complex (A, Figure 3.4).  
Deprotonation results in the dimeric copper species (B, Figure 3.4) then complexes with 
the azido group to set up nucleophilic attack at the N-3 center of the azide by the 
acetylide C-4 affording (C, Figure 3.4).  Facile ring contraction of the metallocycle C via 
a transannular association of the N-1 lone pair with the C5–Cu ̟* orbital results in a 
copper–triazole complex (D, Figure 3.4).  Subsequent protonation of complex D results 
in dissociation of the labile copper complex securing the 1,4-disubstituted 1,2,3-triazole 
(E, Figure 3.4). 
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Figure 3.4.   Mechanism of the Cu(I)-catalyzed 1,3-DCR.166  
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3.1.2 The 1,2,3-Triazole 
 
 
1,2,3-Triazoles share similar structural and electronic features to amide bonds 
with a few exceptions; the extra atom in the triazole backbone causes a 1.1 Å increase in 
the R1–R2 distance over the amide bond (Figure 3.5).169  Also, ab initio calculations have 
revealed that triazoles possess a larger dipole character than ordinary amide bonds,170 
and this may possibly enhance their amide mimicry by increasing the hydrogen 
bonding and acceptor abilities.169  Additionally, this larger dipole may polarize the C-5 
proton of the triazole to the extent that it may function as a hydrogen-bond donor 
similar to that of the amide proton.171  Because of these properties, many 1,2,3-triazoles 
exhibit biological activities including anti-HIV activity,172-173 potent anti-histamine 
activity,174 anti-bacterial activity175 and more.176-177  Unlike their amide counterparts, 
however, these heterocycles do not share the same susceptibility to hydrolytic 
cleavage.178-179  These and other features of the 1,2,3-triazole moiety establish it as being 
more than just a rigid linking unit; its mimicry of the conventional amide bond and 
enhanced characteristics highlight its pharmacological potential. 
 
 
3.2 Retrosynthetic Analysis and Strategy 
 
 
Azides and alkynes have been noted for their tolerance to a wide range of 
synthetic conditions; however, as with all unsaturated functionalities, they are 
vulnerable under reducing conditions.  In fact, azides are often utilized in organic 
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synthesis as “masked” forms of the amino group;180 they are reliably introduced via 
nucleophilic displacement and are usually a single reduction away from the 
corresponding amine.  Likewise, upon exposure to hydride-rich reagents, alkynes are 
often reduced to their appropriate alkene or alkane forms.  Therefore, incorporation of 
either of these functionalities into a synthetic strategy employing hydride-rich reagents 
must be done so with careful planning.   
Access to the biotinylated probe 3-17 is envisioned to involve a chemoselective 
ligation procedure that gives rise to its 1,4-disubstituted 1,2,3-triazole.  Accordingly, 
initial operations of the retrosynthetic analysis logically excised both the azide 3-14 and 
the alkyne 3-9 from 3-17 as two separate fragments (Figure 3.6).  Fragment 3-14 would 
bear the azide handle as it can be prepared by a literature procedure.156  Further 
cleavage across 3-14’s amide bond reveals its building blocks as being D-(+)-biotin and 
the bifunctionalized polyethylene glycol (PEG) derivative, 3-12.   
 
 
 
 
 
 
 
 
 
Figure 3.5.   Comparison of bond distances in the 1,2,3 triazole and amide motifs. 
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Figure 3.6.   Retrosynthetic cleavage of the triazole within the affinity probe 3-17. 
[3+2] cycloaddition 
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Figure 3.6.   Retrosynthetic analysis of the azide-functionalized biotin derivative 3-14. 
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Upon initial retrosynthetic examination, 3-9 is revealed to be a propargyl 
“tagged” derivative of the previously synthesized tylophorine analogue DCB-3506;86 
thus 3-9 can potentially be accessed from the phenolic alkylation of DCB-3506 with 
propargyl bromide (Figure 3.7).  Considering that the preparation of DCB-3506 entails a 
sequence of reductions,86 this would seem like the logical approach as it would ensure 
the integrity of the propargyl tag.  While attractive, this approach has a few 
shortcomings; there are additional sites on DCB-3506 that could also undergo alkylation 
(Figure 3.8).  Even with the careful regulation of reagents, alkylation at the tertiary 
amine center could still pose a problem. 
 
 
 
 
 
 
 
Figure 3.7.   Access to 3-9 via the late-stage propargylation of the tylophorine analogue 
DCB-3506. 
 
propargylation 
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Figure 3.8.   Possible sites of propargylation on DCB-3506. 
 
 
Another avenue of possibility for introducing the propargyl tag could occur as 
shown in Figure 3.9 using an intermediate in the synthesis of DCB-3506, whose only 
viable site of alkylation is at the phenolic position.  Previous studies,83 however, have 
shown that this intermediate has poor solubility in conventional organic solvents thus 
making this approach less likely.   
With the various options surveyed and scrutinized, installation of the propargyl 
handle was envisoned to occur in the early steps of the synthetic strategy, with several 
goals in mind: 
1. By masking the naked phenolic handle, its participation during the synthesis 
would be kept to a minimum and this might limit any unfavorable 
interactions that may otherwise impact product yield. 
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2. It is postulated that the solubilities of the intermediates resulting from 
alkylation at the phenolic position maybe enhanced over their free hydroxy 
counterparts.  Phenolic compounds are generally known to have good 
solubilities in aqueous media,181 but this solubility is diminished in organic 
solvents.182 
3. Installation of the chemical tag in the infancy of the synthesis ensures that an 
intermediate can be readily “clicked” at any stage of the synthesis, in one 
step, should the need arise. 
 
 
 
 
 
 
 
 
 
Figure 3.9.   Possible propargylation  of an intermediate from DCB-3506’s synthesis. 
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The appropriate retrosynthetic transforms resulting from this approach are 
presented in Figure 3.10.  A critical feature of the synthetic strategy is the installation of 
the hydroxy function at 3-9’s benzylic position, possibly by the asymmetric reduction of 
3-7.  Early isolation and characterization studies revealed the labile nature of this 
functionality, particularly to sodium borohydride;17 therefore, its incorporation is 
reserved until the later stages of the synthesis.  Intermediate 3-7 is envisioned to arise 
from the intramolecular acylation of the saponified form of 3-5.  Intermediate 3-5 
possesses a lone stereogenic center, whose formation can be anticipated from the 
coupling of the halo form of 3-2 with an appropriate auxiliary from the chiral pool.  
Attachment of the functional chemical handle would have to occur prior the formation 
of 3-2, possibly via the alkylation of 3-1 with propargyl bromide.  Finally, disassembly 
of 3-1 exposes 3,4-dimethoxyphenyl acetic acid and vanillin as being the commercially 
available building blocks responsible for construction of the phenanthrene skeleton.  
 
3.3 Synthesis of the Propargyl Tagged Analogue 3-9 
 
 
3.3.1 Overview of the Target 
 
 
The pentacylic architecture of 3-9 consists of a planar, functionalized 
phenanthrene backbone (rings A,B,C) and the conjoined indolizidine portion (rings D, 
E) which houses the molecule’s two stereogenic centers at C-13a and C-14.  Other 
structural highlights include the hydroxy function at C-14 and several methoxy groups 
distributed throughout the phenanthrene framework. 
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Figure 3.11.   Overview of the propargyl tagged subtarget, 3-9. 
A 
B 
C D E 
14 
13a 
N
O
OCH3
OCH3
H3CO
13a
14
HO H
3-9
A
C
B
D E
  
 
 
120 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10.   Retrosynthetic analysis of the propargyl-tagged subtarget 3-9. 
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3.3.2 Synthesis of 3-9’s Phenanthrene Core 
 
 
As with most endeavors in natural product total synthesis, preliminary efforts 
towards the synthesis 3-9 begin with construction of a suitable scaffold.  Intended to set 
the foundation for construction of the indolizidine motif, the desired scaffold was 
accessed with the Perkin condensation183-184 of 3,4-dimethoxyphenyl acetic acid and 
vanillin to give the carboxylic acid 2-1 in excellent yield (Figure 3.11).  Such 
condensations have been known to invariably give a mixture of E and Z isomers with 
the Z-isomer being the minor product.35  Transformation of 2-12-2 proceeded via a 
Fisher esterification procedure in a straightforward fashion to yield the deacetylated 
stilbene derivative.  With the A and B rings of the scaffold now complete, access to ring 
C commences with the re-acetylation at the phenolic position of 2-2 to furnish the 
oxygenated stilbene 2-3 in good yield.  Oxidative ring closure is then effected using a 
facile FeCl3-mediated procedure, bridging the stilbene and affording the phenanthrene 
derivative 2-4 (Figure 3.11).185-187  The first synthesis of a phenanthrene core was 
established using an arenediazonium salt by Pschorr in 1896 as a means to conduct the 
intramolecular coupling.188  Through the years, the Pschorr reaction has become the 
standard for phenanthrene formation; however, it generally features long steps and 
only modest yields that restrict its implementation in this synthesis.  Alternatively, the 
oxidative aryl–aryl coupling could be accomplished using a transition metal oxide such 
as vanadium(V) trifluoride oxide,189 which has been known to effectively cyclize 
polymethoxy stilbenes.  While an attractive possibility, the transition metal oxide is 
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prohibitively expensive, highly toxic and often leads to numerous side products.  
Fortunately, the FeCl3 procedure is devoid of all these shortcomings and has become 
the new method of choice for oxidative ring closures leading to phenanthrene 
formation.190-191  The proposed mechanism associated with this Fe(III)-mediated ring 
closure is presented in Figure 3.12.191  The initial step in this sequence is presumed to 
involve a single-electron oxidation of the stilbene unit to generate an aryl radical cation.  
The electrophilic center is then subsequently attacked by the opposing aromatic ring 
bridging the stilbene in the process. A series of deprotonations then restores aromaticity 
to give the phenanthrene 2-4.   
In the advancement of intermediate 2-1 to intermediate  2-4, there was a sequence 
of acetylation/reacetylation steps that must be addressed.  One could theoretically go  
 
 
Figure 3.11.   Construction of the stilbene 2-1 and advancement to the phenanthrene 2-4. 
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Figure 3.12.   Mechanism for the FeCl3-mediated ring closure191 of stilbene 2-3. 
 
from 2-22-5 directly, but this proved difficult under experimental conditions as more 
molar equivalents of the catalyst are required and overall product yields poor.  This 
compromise in product yields maybe caused by the generation of a radical species 
through the reaction of the phenolic hydroxy group with the catalyst (Figure 3.12).  The 
oxygenated phenanthrene 2-4 was then subjected to a standard deacetylation procedure 
that exposed its phenolic handle and gave 2-5 in quantitative yield (Figure 3.13).  
Alkylation of 2-5 with propargyl bromide afforded the intended phenanthrene scaffold 
3-1 in good yield (Figure 3.13) and its formation was confirmed by the appearance of a 
triplet at 2.61 ppm and a doublet between 4.99–5.00 ppm in its 1H NMR spectrum 
(Figure 3.14). 
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Figure 3.12.   Generation of a radical species from the reaction of 2-2 with FeCl3. 
 
 
 
 
 
 
 
Figure 3.13.   Deacetylation of 2-4 and propargylation of the phenanthrene skeleton 2-5. 
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Figure 3.14.   1H NMR spectra of the intriguing structural features of intermediate 3-1. 
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3.3.3 Model Click Reactions Using the Phenanthrene Core 3-1 
 
 
As delineated in the initial retrosynthetic map (Figure 3.6), the main objective of 
this synthetic approach was to perform a late-stage [3+2]-cycloaddition as means of 
conjugating 3-9 with the biotin derivative 3-14.  Given the importance of this key 
merger, considerable model system exploration would have to first take place in order 
to establish the viability of this approach and to probe for optimal coupling conditions.  
The phenanthrene scaffold 3-1 made an ideal alkyne substrate for this model study 
owing to its easy preparation and modest stereochemical complexity.  Some of the azide 
coupling partners featured in the study were synthesized, and several were derived 
from other sources.192 
While a number of methods exist to generate the active catalyst for the 1,3-
DCR,193 a commonly employed technique is to reduce Cu(II) salts, such as CuSO45H2O 
in situ to form Cu(I) salts.194  Sodium ascorbate195 is typically used as the reducing agent 
in a 3- to 10-fold excess,193 but other reducing agents, including hydrazine196 and tris(2-
carboxyethyl)phosphine (TCEP),197 have also been used with reasonable success.  The 
advantages to this strategy are that it is cheap, it can be performed in water, and does 
not require deoxygenated atmosphere.198  Appropriately, the initial investigation  
entailed the reaction of azide 6-azidochlorohexanol (prepared by the SN2 displacement 
of 6-chlorohexanol with sodium azide) with 3-1 under these “standard click” conditions 
(Figure 3.15).  Disappointingly, only starting material was recovered, and there were no 
detectable amounts of the desired product 3-1a.  A survey of the literature revealed that 
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the over-reduction of Cu(II) down to Cu0 by the reducing agent was a likely cause. 
Ordinarily, this problem can be overcome by properly regulating the ratio of reducing 
agent to catalyst and/or by the inclusion of copper-stabilizing agents such as 
tris(benzyltriazolylmethyl)-amine (TBTA).199  More recently though, tris(2-
benzimidazolylmethyl)amines (Figure 3.16; 3-15) have been found to be superior 
accelerating ligands for the Cu(I)-catalyzed azide–alkyne cycloaddition reaction.200-201  
Incorporation of this catalyst into the reaction of 3-1 and the azide, 6-azidohexanol, 
finally afforded detectable amounts of 3-1a (Figure 3.17).   However the recovery of a 
high percentage of the starting material 3-1 indicated that these were not the ideal 
conditions for coupling this azide–acetylene pair.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15.   Attempted coupling of 3-1 with 6-azidohexanol using standard “click” 
conditions. 
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Figure 3.16.   Tris(2-benzimidazolylmethyl)amine (3-15). 
 
 
 
 
 
 
 
Figure 3.17.   Model study utilizing tris(2-benzimidazolylmethyl)amine. 
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Initial attempts at maximizing product yield focused on the adjustment of the 
solvent/co-solvent systems.  These were altered as shown in Figure 3.18, but failed to 
offer any dramatic improvement in product yield.  Then, as a means of probing 
functional group tolerance, the complexity of the azide partner was varied and these 
results are presented in Figure 3.19. Even with these series of successful clicks, there 
was the lingering issue of poor product yield that had to be further investigated.  
It was hypothesized that the reaction’s dependence on a copper-stabilization 
agent such as 3-15, was an indication that the generated Cu(I) was too short-lived.   
 
 
 
 
Entry Cu(II) saltb 3-15 NaAsca Solvent 
1 0.01 eq 0.0001 eq 0.1 eq 1:1 H2O:THF 
2 0.01 eq 0.0001 eq 0.1 eq 1:1 H2O:EtOH 
3 0.01 eq 0.0001 eq 0.1 eq 1:1 H2O:1,4-dioxane 
4 0.01 eq 0.0001 eq 0.1 eq 1:1 H2O:CH2Cl2 
5 0.02 eq 0.002 eq 0.1 eq 1:2 H2O:tBuOH 
6 0.02 0.001 eq 0.3 eq 1:1 H2O:CH3CN 
a Sodium ascorbate 
b Copper(II) sulfate 
 
Figure 3.18.   Attempts at optimizing the yield of 3-1a. 
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Figure 3.19.   Click reaction of 3-1 using more complex azide partners. 
 
Furthermore, due to the second-order dependence on Cu(I) concentration, product 
yields were being compromised because of this.  Therefore, other methods of generating 
the Cu(I) species had to be sought.  One such possibility is the oxidation of copper metal 
with an amine salt to generate the Cu(I) catalyst.  However, there are considerable 
disadvantages with this strategy; of particular concern are the longer reaction times and 
the slightly acidic environment that is needed to dissolve the metal, which could be 
damaging to any acidic-sensitive functional groups such as the secondary hydroxy that 
is present in 3-9. 
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With the instability of the Cu(I) oxidation state in the presence of oxygen well 
documented, the reaction conditions had to be adjusted such that they excluded 
oxygen.202  Consequently, another method was employed that utilized a copper salt 
such as CuBr, or CuI, to source the Cu(I) catalyst.193  This method was an attractive 
possibility for three reasons: 
 
1.  The direct use of Cu(I) salts would bypass the need for a reducing agent.  
2. Organic solvents could be utilized in lieu of H2O. 
3. A deoxygenated environment would ensure the stability of the Cu(I) 
oxidation state and obviate the need for a copper-stabilizing agent.   
 
Encouragingly, a preliminary implementation of this solution-phase Cu(I)-
catalyzed coupling reaction using CuI, TEA and CH3CN was able to furnish detectable 
quantities of 3-1a (Figure 3.20).  Although only partially successful, this early result 
seemed to highlight the inherent sensitivity of these types of reactions to the choice of 
base.203  In fact, if an “incompatible” base is selected, the substrate could be prone to 
numerous side reactions.204  This base-dependence is believed to revolve around the 
formation of the active copper acetylide complex (D, Figure 3.4), which is dependent on 
the deprotonation of the ̟-complex D (Figure 3.4).  Although this deprotonation occurs 
without the need for base under conditions involving water, it is disfavored under 
organic solvents; thus the need for a base.  Bases such as diisopropylethylamine 
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(DIPEA) and 2,6-lutidine were identified in the literature as being suitable choices that 
offered improved results and kept side product formation to a minimum.178-179,193  
Additionally, certain solvents such as acetonitrile, have the ability to act as “nitrogen-
type donors” thereby preventing the degradation of Cu(I) by oxidation or 
disproportionation.205  Gratifyingly, a model based on these findings was able to furnish 
the triazoles 3-1a and 3-1d in high yield (Figure 3.21).  
 
3.3.4 Construction of 3-9’s Indolizidine Moiety 
 
 
With the phenanthrene scaffold 3-1 secured and optimal “clicking” conditions 
established, efforts were now directed towards construction of the indolizidine 
periphery.  Reduction of 3-1 with lithium aluminum hydride would seem like a risky 
 
 
 
 
 
 
 
Figure 3.20.   Click reaction of 3-1 using a Cu(I) source. 
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Figure 3.21.   The click reactions of 3-1 using a Cu(I) source and DIPEA and 2,6-lutidine 
as bases. 
 
 
maneuver as lithium aluminum hydride can reduce alkynes.206-207  To safeguard against 
this possibility, the reaction had to be carried out at 0 °C in order to effect the 
conversion from 3-13-2; (see Figure 3.22) however, it was particularly pleasing to 
observe the same transformation occur at ambient temperature without incident.  
Functional group conversion of 3-2 using phosphorous tribromide (PBr3) afforded 3-3, 
which was then coupled with the glutamate diester 1-42b.  It is noteworthy to note that 
in coupling these two fragments, the order of addition of the reactants does matter.  
This may be due to the fact that the glutamate diester is used in excess and is 
introduced into the  
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Figure 3.22.   Advancement of 3-1 to the pentacyclic intermediate 3-7. 
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system as a hydrochloride salt, and this may react prematurely with the alkyne.  
Therefore, addition of the chiral auxillary 1-42b must occur first, followed by K2CO3 
and then the benzylic bromide 3-3.  The resulting crude aminal 3-4 was subjected to a 
lactamization procedure using acetic acid and methanol to give rise to 3-5.  The 1H 
NMR spectrum confirmed the formation of intermediate 3-5 and some of these 
characteristic peaks are presented in Figure 3.23.  With the construction of the E ring of 
3-9 now complete, the next set of operations focused on the construction of 3-9’s D ring.  
Accordingly, base-mediated hydrolysis of the methyl ester function within 3-5 using 2 
N KOH furnished the carboxylic acid derivative 3-6 in quantitative yield.  With the 
stage now set for the key intramolecular acylation, treatment of 3-6 with 
trifluoromethanesulfonic anhydride for 48 h induced ring closure and furnished 3-7 in 
good overall yield.  This type of intramolecular acylation has been accomplished in past 
syntheses using strong Lewis acids such as SnCl4 and AlCl3, but these approaches 
involved the mandatory formation of the acid chloride and were deemed to be too 
harsh for the alkyne present in 3-6.  On the contrary, the procedure involving 
trifluoromethanesulfonic anhydride was gentler and required no Lewis acid, relying 
instead on the formation of a mixed anhydride to effect ring closure.  Similarly, another 
mild but effective acylation procedure using TFAA and BF3Et2O was able to transform 
3-6 3-7 in good yield as well.  The pentacylic ketone 3-7 was confirmed via 1H NMR 
spectrosocopy and some of its intriguing structural features are illustrated in Figure 
3.24. 
  
 
 
136 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23.   1H NMR spectra of the intriguing structural features of intermediate 3-5. 
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Figure 3.24.   1H NMR spectra of the intriguing structural features of intermediate 3-7. 
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3.3.5 Functionalization of the Indolizidine Moiety 
 
The next planned synthetic operation was the asymmetric reduction of the 
ketone in 3-7 to install 3-9’s second stereocenter.  While there are several reagents 
capable of accomplishing such reactions, chiral oxazaborilidines are among the most 
widely utilized catalysts available.208  While an attractive possibility, these 
oxazaborilidine-mediated reductions require the generation of a chiral catalyst via 
complexation of a Lewis basic nitrogen with a borane reagent (Figure 3.25).  This 
complexation is rapid and reversible but because 3-7 possesses a similar moiety, it was 
reasoned that similar complexation may take place at this site as well (Figure 3.26), 
thereby compromising overall selectivity.  The use of a borane reagent may also 
endanger 3-7’s alkyne motif. 
 
 
 
 
 
 
 
Figure 3.25.   Complexation of the chiral oxazaborolidine with a borane reagent. 
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Figure 3.26.   The postulated complexation of the borane reagent at the indolizidine’s 
nitrogen. 
 
Interestingly, however, 3-7 possesses some subtle structural features resulting 
from the planarity of the phenanthrene backbone that are only evident in the three-
dimensional model as represented in Figure 3.27.  In fact, the C-14 ketone seems to be 
accessible from two faces, each with its own distinct spatial environment.  Access to the 
A-face seems favorable while an apical C-13 methylene unit renders the B-face highly 
inaccessible.  Therefore, by exploiting this unique conformational state of 3-7, the 
stereoselective reduction was achieved using the reagent K-Selectride® (potassium tri-
sec-butylborohydride) whose facial selectivity afforded 3-8 in good yield.  As illustrated 
in Figure 3.28, approach of this bulky hydride is only favored from the A-face, as an 
approach from the B-face is effectively blocked by the “protruding” apical C-13 
methylene unit.   
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Figure 3.27.   The two unique faces  of intermediate 3-7. 
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Figure 3.28.   Approach of the bulky hydride from face A of intermediate 3-7. 
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A similar model was adopted by Buckely and Rapoport in their synthesis of S-
tylophorine [(S)-1-1].35  Though highly effective, this synthetic operation came with 
considerable risk to the alkyne.  Initial implementations of this reduction resulted in the 
reduction of the 3-7’s alkyne to give the corresponding alkene.  It was therefore 
established that the experimental conditions had to be kept at -78 °C to safeguard 
against reduction of the alkyne by the Selectride.  The formation of intermediate 3-8 was 
verified using 1H NMR spectroscopy and some of these structural features are 
illustrated in Figure 3.29.  The triplet at 3.27 ppm corresponds to intermediate 3-8’s 
alkyne proton while the set of multiplets between 2.23 and 2.75 ppm correspond to 3-7’s 
indolizidine periphery.  The broad peak at 3.06 ppm corresponds to 3-8’s hydroxy 
moiety, confirming that the reduction of the ketone 3-7 was successful. 
A controlled reduction of 3-8 with lithium aluminum hydride in THF at -10 °C 
finally provided the propargyl-tagged analogue 3-9 (Figure 3.30).  Again, because of the 
caliber of the reducing agent, there existed the likelihood of reducing the alkyne motif.  
Therefore, as a precautionary measure, the order of addition was modified such that the 
hydride was added to substrate 3-8 at -10 °C, and experimental conditions were 
carefully maintained at 0 °C thereafter.  
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Figure 3.29.   1H NMR spectra of the intriguing structural features of intermediate 3-8. 
 
 
 
 
 
 
Figure 3.30.   Final stages in the synthesis of the propargyl tagged subtarget 3-9. 
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3.4 Synthesis of the Azide-Functionalized Biotin Derivative  3-14 
 
Originally, efforts towards a biotin substrate suitable for the [3+2]-cycloaddition 
involved the functionalization of biotin itself124 as delineated in the scheme in Figure 
3.31.  However, this approach was discontinued due its low yields and the numerous 
functional group manipulations needed to furnish 3-16.  A new method was 
subsequently sought: one that limited the number of synthetic operations on the biotin 
substrate while offering improved yields.156   
As depicted in its earlier retrosynthesis (Figure 3.6), 3-14 incorporates a 
functionalized polyethylene glycol (PEG) moiety.  PEG is a widely used biomaterial due 
to its high solubility in water and in most organic solvents.  Moreover, PEG is nontoxic, 
and more importantly, is resistant to protein adhesion.209-210  Therefore, it is anticipated 
that the inclusion of this moiety in 3-14 would help in the solubility of the target probe 
3-17. 
The synthesis of 3-14 synthesis commenced with the mesylation of commercially 
available tetraethylene glycol to furnish the dimesylate 3-10.  A standard azidization 
procedure then converted 3-10 to 3-11, which, after treatment with NaHCO3, was 
subjected to an elegant desymmetrization protocol with PPh3 and H3PO4 to give the 
amino-PEG-azide, 3-12 (Figure 3.32).211 
Coupling of the functionalized PEG unit 3-12 to D-(+)-biotin was then 
accomplished using N,N'-dicyclohexylcarbodiimide (DCC) and DIPEA (Figure 3.33).   
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Figure 3.31.   Synthesis of the biotin-azide derivative 3-16. 
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Figure 3.32.   The heterobifunctionalization of tetraethylene glycol leading up to 3-12. 
 
 
 
Figure 3.33.   Peptide coupling of 3-12 to biotin via activation as the NHS ester. 
  
 
 
147 
 
  
 
Although yields were markedly improved by first activating biotin with N- 
hydroxysuccinimide212 (Figure 3.29), a more robust coupling procedure employed the 
peptide coupling agent O-benzotriazole-N,N,N’,N’-tetramethyluronium hexafluoro-
phosphate (HBTU), which furnished 3-14 in quantitative yield (Figure 3.34).  The 1H 
NMR data matched those previously reported.156 
 
3.5 Conjugation of 3-9 with the Biotin-PEG-Azide Derivative 3-14 
 
With the synthesis of 3-9 and 3-14 now complete, the target compound 3-17 
would now appear to be attainable from the click reaction of these two subtargets. 
However, as a prerequisite to this conjugation, a final model study was set up using the 
phenanthrene core 3-1 and the biotin conjugate 3-14 (Figure 3.35).  Using conditions 
established earlier (see Section 3.3.3), 3-1e was afforded in moderate yield and its 
formation was verified by MALDI-TOF MS (Figure 3.36) and DART-ESI MS (Figure 
3.37).  The successful union of these two precursors to ultimately afford 3-1e was a very 
positive development and established a precedent for the late-stage coupling of 3-9 and 
3-14.  Indeed, upon exposure to CuI, the crucial [3+2]-cycloaddition of 3-9 and 3-14 
proceeded smoothly and secured the desired target 3-17 (Figure 3.38). 
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Figure 3.34.   Peptide coupling of 3-12 to biotin using HBTU. 
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Figure 3.35.   Model-click-study involving the phenanthrene backbone, 3-1, and the biotin-azide conjugate 3-14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.36.   MALDI-TOF spectrum of 3-1e. 
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Figure 3.37.   DART-ESI MS spectrum of a crude sample of 3-1e showing the 887.3 
[M+Cu]+ adduct. 
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Figure 3.38.   Synthesis of the target 3-17 via click chemistry 
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3.6 Purification and Characterization of the Affinity Probe 3-17  
 
Up until this point, the Cu(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of 
terminal alkynes and azides has served as powerful tool in the conjugation of 3-9 and 3-
14; however, an obvious disadvantage to this approach is the involvement of a copper 
catalyst.  The presence of copper is clearly evident from the MALDI-TOF spectrum of a 
reaction mixture of 3-17 (Figure 3.39) and the ESI spectrum of 3-1e (Figure 3.37) which 
both feature an [M+Cu]+ adduct.   
Although living systems require copper for specific processes, excessive amounts 
of this metal can be cytotoxic and affect neurological systems.  This stems from the fact 
that copper readily participates in single-electron transfer processes which can catalyze 
toxic reactions, especially the in vivo reduction of hydrogen peroxide to form hydroxy 
free radicals.213  Therefore, the biotinylated probe 3-17 must be exhaustively purified 
prior to its in vivo evaluation. 
By taking advantage of 3-17’s ready MALDI-TOF ionizability, the reaction 
between 3-9 and 3-14 can be easily monitored.  Compound 3-17 has characteristic 
fragmentation patterns, one of which is shown in Figure 3.35.  The use of other 
methods, however, such as HPLC and/or TLC is complicated due to the dominating 
presence of 2,6-lutidine.  This is best illustrated by the HPLC trace in Figure 3.40.  The 
high concentration and strong absorptive properties of 2,6-lutidine easily overwhelm all 
other components in the reaction.  This particular problem was overcome by relying on  
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Figure 3.39.   MALDI-TOF MS fragmentation of the probe 3-17.
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Figure 3.40.   HPLC trace of the reaction mixture of the conjugation of 3-9 and 3-14. 
The major peak at 4.433 min is that of 2,6-lutidine. 
 
the unique absorptive properties of each component in the reaction. Each has a 
characteristic chromophore which can be used as a unique identifier or “fingerprint” as 
shown in Figures 3.41, 3.42, and 3.43.  Using this approach allowed the principal peaks 
of the chromatogram to be easily mapped and also facilitated the monitoring of the 
reaction’s progress as shown in Figure 3.44.  Unfortunately, the similarity in retention 
times between 2,6-lutidine and 3-17 precluded preparative HPLC as a means of 
purification. 
In 2001, Sharpless and co-workers defined a set of criteria that a process must 
meet in order to be classified as a click reaction.180  One of these requirements was that 
“purification if required must be by non-chromatographic methods, such as 
crystallization or distillation.”  In order to adhere to these guidelines, initial efforts  
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Figure 3.41.   HPLC trace and chromophore (inset) of the biotin derivative 3-14 
 
 
 
 
 
 
 
 
 
 
Figure 3.42.   HPLC trace and chromophore (inset) of 2,6-lutidine. 
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Figure 3.43.   HPLC trace and chromophor
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Figure 3.44.   A chromatogram mapped with the chromophores of the 
3-17 
3-14
157 
 
reaction’s components.
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towards the purification of 3-17 relied on standard extraction and recrystallization 
procedures.  Unfortunately, these attempts were complicated by 3-17’s limited 
solubility and were unsuccessful in removing 2,6-lutidine from the reaction mixture.   
Other attempts utilized reversed phase chromatography and freeze drying from 
1,4-dioxane.  This approach seemed to remove most of the 2,6-lutidine but was plagued 
with low recovery of the sample.  Even though the use of chromatography as a means 
of purification seemed to go against Sharpless’ philosophy of click chemistry, its partial 
success inspired a return to more “traditional” purification methods.  Subsequently, 3-
17 was purified successfully using normal-phase silica gel chromatography (2:0.1 
CH2Cl2–MeOH), and this proved to be very effective in removing the 2,6-lutidine and 
residual copper as evident by the absence of the [M+Cu]+ adduct in the MALDI-TOF 
analysis (Figure 3.45).  The HPLC trace of the purified sample revealed an impurity at 
4.48 min, which was later determined to be 3-8a, a product from the click reaction of the 
unreduced amide 3-8 and the biotin unit 3-14 (Figure 3.46).  In the end, after a sequence 
of rigorous chromatographic separations, 3-17 was finally obtained with ~95% purity 
and submitted to our biological collaborator, Dr. Y.-C. Cheng at Yale University School 
of Medicine. 
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Figure 3.45.   MALDI-TOF analysis of 3-17. The [M+Cu]+ adduct is absent after 
purification. 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.46.   HPLC trace and
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3.7 Planned Affinity Studies 
 
Once synthesized, biotinylated probes such as 3-17, can be utilized in various 
target identification strategies. In a typical affinity-based approach, the biotinylated 
molecule is adhered to an avidin-functionalized resin, creating an extremely stable, 
noncovalent affinity matrix.  This matrix can then incubated with the cell lysate of 
interest and later eluted together with any bound protein.  Another approach is to first 
incubate the cell lysate with the biotinylated probe which can be retrieved using avidin-
functionalised resin together with any bound protein.  In both approaches, the 
biotinylated probes and any attached proteins may be eluted from the avidin resin by 8 
M guanidine–HCl, pH 1.5, or by boiling in a denaturing SDS-PAGE loading dye.  
Commercially available alternatives such as CaptAvidin resin (Invitrogen), allow for 
elution under gentler conditions.   
 The planned affinity study of 3-17 is illustrated in Figure 3.47.  First, streptavidin-
agarose beads will be pre-treated with a HepG2 cellular lysate in order to remove any 
non-specific binding proteins.  Compound 3-17 would then be immobilized onto a 
streptavidin–agarose resin and incubated with HepG2–cellular lysate.  Elution of any 
bound proteins would then occur using SDS loading buffer, followed by gel 
electrophoresis or trypsin digestion.  Any cellular binding partners of 3-17 would then 
be elucidated by MS/MS spectrometry or LC–MS.92 
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Figure 3.47.  Planned affinity studies of the synthesized probe 3-17. 
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3.8 Conclusions 
 
 
In conclusion, the synthesis of a biotin conjugate of DCB-3503 has been 
accomplished using “click” chemistry.  The synthesized probe 3-17 managed to 
incorporate all of the structural features of DCB-3503 (1-62b) required for in vitro 
binding and should be well suited for use in the aforementioned target identification 
study.  
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CHAPTER 4 
BIOCONJUGATION VIA PEGYLATION AND 
CLICK CHEMISTRY: A SECOND 
NONCLASSICAL APPROACH 
 
4. BIOCONJUGATION VIA PEGYLATION AND CLICK 
CHEMISTRY: A SECOND NONCLASSICAL APPROACH 
4.1 Background  and Significance 
 
 
The synthesis of biotinylated probes such as 3-17 and their subsequent use in 
affinity studies is based on the assumption that a crucial binding event between the 
molecular probe and its target may ultimately lead to the identity of the targeted 
protein(s).  Furthermore, another assumption is that the bioactivity elicited by the probe 
is a direct consequence of this binding event.  Therefore, the affinity of a molecular 
probe for its target is a critical concern, as the quality of this interaction has proven to be 
a key factor in the success of target identification experiments.93,100  Other variables such 
as probe construction, particularly linker length and composition, may also play a 
role.214  For example, in 2006 Whitesell and co-workers utilized a biotinylated derivative 
of withaferin A (Figure 4.1), identifying annexin II as being its covalently bound 
target.215  Shortly thereafter in 2007, using a biotinylated probe different from that of 
Whitesell (Figure 4.1), Mohan and co-workers reported the identification of the protein 
vimentin as a second covalent target of withaferin A.216-217  Oddly, Mohan and co-
workers were unable to detect annexin II binding even though their probe was outfitted 
with a long aliphatic linker.  In addition to demonstrating that bioactive small  
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Figure 4.1.   Whitesell’s and Mohan’s biotinylated derivatives of withaferin A. 
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molecules may have more than one binding partner, this example also illustrated the 
effect of linker arm construction in target identification experiments.   
In another study, Sato and co-workers synthesized several uniquely rigid linkers 
that were comprised of repeating polyproline units (Figure 4.2).  The “rod-like” rigidity 
of these linkers was attributed to the formation of a stable left-handed helix.  Studies 
featuring such a rigid linker ultimately led to the identification of glyoxylase 1 (GLO1), 
as a new target of indomethacin.218  
Morocho et al. reported the synthesis of several biotinylated phosphoramidites, 
some with exceptionally long tethers ranging in length from 22 to 39 atoms (Figure 
4.2).219  These “super-long tethering arms” improved capturing efficiency from 40–45%  
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Figure 4.2.   Sato and co-workers’ approaches to the biotinylation of indomethacin. 
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(Bt19AU, 22 atoms) to 90–95% (Bt34Ach, 39 atoms) as compared to the 16-atom, 
commercially available, Biotin TEG (15-atom triethylene glycol spacer), which only 
managed a capturing efficiency of 35–40%.  Aside from featuring slightly proprietary 
linking units, these tethers also comprised several polyethylene subunits (derived from 
polyethylene glycol; PEG) that were designed to improve solubility and enhance 
hydrophilicity. 
In light of these studies, it is clear that a correlation exists between linker arm 
length/composition and the molecular probe’s ability to interact with its potential 
targets.  The design of 3-17 took into account most of these considerations; by 
incorporating a long PEG linker between the active head unit and the biotin moiety.  
However, there exists the opportunity of incorporating into 3-17 a much longer PEG-
based tether, similar to the one reported by Morocho et. al.219  One way of 
accomplishing this via click chemistry is illustrated in Figure 4.4.  First, the active 
member is outfitted with an alkyne-functionalized PEG spacer, followed by conjugation 
with a biotin–PEG derivative such as 3-14 to afford a probe with a super long tether. 
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Figure 4.3.   Structures of biotinylated phosphoramidites bearing super-long linkers. 
 
 
  
 
 
169 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4.   A generic approach to the synthesis of a biotinylated probe bearing a super-long tether by employing “click” 
chemistry. 
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Aside from the biocompatibility enhancements that this modification would 
offer, there are additional benefits to this approach: 
 
1. The enhanced hydrophilic nature of this type of linker would minimize 
nonspecific binding interactions.220   
2.  The exceptional length of such a tether would keep the probe separate 
from the steric bulk of the resin, thereby minimizing unfavorable 
interactions that could otherwise block potential target protein binding.   
3. The added conformational flexibility may allow the probe to assume an 
optimal binding stance during affinity studies. 
Accordingly, a new probe 4-14, consistent with this approach is presented in 
Figure 4.5 alongside the original probe 3-17.   
In recent years, PEGylation,221 or the process of attaching polyethylene glycol 
(PEG) chains to molecules, has found considerable utility in drug delivery222 and other 
pharmaceutical applications.  This is due, in part, to PEG’s unique ability to be soluble 
in both organic and aqueous solvents.  In fact, PEG has been shown to bind 2–3 water 
molecules per ethylene oxide unit in solution studies.223-225  Additionally, PEG shows 
little toxicity, and as a result, is approved by the FDA for use as a drug delivery 
vehicle.226-227  The PEGylated probe 4-14 would not only assume many of these 
properties, but its biological activity would also be retained.228  In general, PEGylated 
molecules exhibit activity similar to that of a freely soluble molecule, due in part to 
PEG’s high mobility. 
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Figure 4.4.   Two- and three-dimensional models of the new probe 4-14 and its shorter 
variant 3-17. 
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4.2 Retrosynthetic Analysis and Strategy of the Probe 4-14 
 
 
The synthetic blueprint of the PEGylated probe 4-14 has been fashioned such that 
it closely resembles that of its non-PEGylated variant 3-17.  Similarly, 4-14 is also 
expected to arise from a similar chemoselective ligation procedure, involving a suitable 
alkyne–azide pair.  Accordingly, retrosynthetic cleavage across the triazole moiety of 4-
14 (Figure 4.5) reveals 4-9 and 3-14 as being the respective alkyne–azide coupling 
partners.  The probe 4-9 is clearly just a PEGylated variant of 3-9, while the biotin 
derivative 3-14 was utilized previously to construct the original probe 3-17. 
The synthesis of 4-9 is expected to closely mimic the somewhat linear 
construction of 3-9.  In accordance with this strategy, PEGylation or attachment of the 
bifunctionalized PEG moiety is expected to take place in the early stages of the 
synthesis.  Appropriately, the retrosynthetic transforms consistent with this strategy are 
delineated in Figure 4.6; compound 4-8 can be accessed from the asymmetric reduction 
of the pentacyclic ketone 4-7.  The Rapoport-inspired intramolecular acylation of 4-6 is 
expected to give rise to the ketone 4-7.  Formation of the carboxylic acid 4-6 is 
envisioned to take place by the alkylation of a functionalized derivative of 4-1 with a 
chiral auxillary 1-42b.  Severance of the ether linkage at 4-1’s phenolic position reveals a 
bifunctionalized derivative of tetraethylene glycol serving as the linker arm.  
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Figure 4.5.   Retrosynthesis of the PEGylated probe 4-14. 
[3+2] cycloaddition 
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Figure 4.6.   Retrosynthesis of the PEGylated alkaloid 4-9. 
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4.3 Synthesis of the PEGylated Alkaloid 4-9 
 
 
4.3.1 Construction of the PEG-based Linker Arm 
 
 
PEGylation is generally accomplished by first chemically modifying the terminal 
hydroxy groups of the native PEG moiety before attachment to the substrate.  
Conventional approaches have often involved the monofunctionalization of 
monomethoxy PEG (mPEG), converting the terminal hydroxy into either an active ester, 
tresylate or active carbonate.  While this approach is well suited to the pegylation of 
proteins, liposomes and polypeptides,  it does not facilitate the linkage of two molecular 
entities.  Recently, the need for heterobifunctional PEG derivatives has intensified and 
has resulted in the introduction of numerous functionalities as end groups.229  For 
example, Nagasaki, Kataoka and co-worker were able to synthesize a heterobifunctional 
PEG derivative comprising of aldehyde and thiol end groups.230  As forecasted by the 
retrosynthetic plan in Figure 4.6, the appropriate linker arm would have to feature an 
alkyne as one of the end groups.  The other end of this linker would have to be 
activated so that attachment to substrate 2-5 could occur under mild conditions.  An 
ether linkage, as opposed to amide or ester bond, is desired between the PEG moiety 
and the substrate, in order to ensure stability and to preserve any PEG-induced 
pharmacological changes.231-232 
 The regulation of the molar equivalents of a reagent is a strategy that is 
commonly used in the monofunctionalization of end groups.  Therefore, treatment of 
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tetraethylene glycol with one equivalent propargyl bromide in sodium hydride 
afforded the monoalkylated PEG derivative 4-10 (Figure 4.7).156  After chromatographic 
purification, 4-10 was converted to its corresponding bromo- derivative 4-12 using 
phosphorous tribromide.233  This seemingly basic transformation proved problematic at 
first, due to the in situ generation of HBr.  As illustrated by the NMR spectrum in Figure 
4.8, this generated HBr subsequently reacted with the alkyne motif as evident by the 
presence of signals at 5.45 and 5.80 ppm, which were consistent with those of allylic 
protons.  This complication was overcome by lowering the reaction temperature to -30 
°C. Alternatively 4-10 was also converted to either its tosylate (4-11) or mesylate211 (4-
13) derivatives (Figure 4.7).   
 
4.3.2 PEGylation of the Phenanthrene Core 2-5 
 
 
The phenanthrene core 2-5 was then pegylated using the bifunctionalized PEG 
derivative  4-12 under mild conditions (refluxing acetone, K2CO3) to afford 4-1 in good 
yield (Figure 4.9).  PEGylation using either the tosylate (4-11) or mesylate (4-13) variants 
of 4-10 worked best using a K2CO3 and a toluene–acetone system (Figure 4.9). 
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Figure 4.7.   Synthesis of the heterobifunctional PEG derivatives.
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Figure 4.8.   1H NMR spectrum of the action of in situ HBr on 4-12. 
 
 
 
  
 
 
179 
 
  
 
 
 
 
 
Figure 4.9.   PEGylation of the phenanthrene skeleton 2-5. 
 
 
 
 
 
4.3.3 Model Click Reaction Studies Using the PEGylated Phenathrene Core 4-1 
 
 
It was hypothesized that the change in the chemical environment of the alkyne, 
caused by insertion of the PEG-spacer, could impact its ability to successfully undergo a 
[3+2]-cycloaddition.  In hopes of disproving this hypothesis, a model click study was set 
up using the PEGylated phenanthrene core 4-1 and the derivatized biotin conjugate 3-14 
(Figure 4.10).   Gratifyingly, 4-1a was synthesized using established clicking conditions, 
and its formation was confirmed using MALDI-TOFMS analysis (Figure 4.11). 
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Figure 4.10.   Clicking the PEGylated core 2-5 to the biotin derivative 3-14. 
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Figure 4.11.   MALDI-TOFMS spectrum of 4-1a. 
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4.3.4 Construction of the Indolizidine Moiety 
 
 
With the PEGylated phenanthrene scaffold 4-1 synthesized, the construction of 
the indolizidine portion of 4-9 proceeded with the reduction of 4-1’s ester function 
using lithium aluminum hydride.  This seemingly straightforward transformation 
highlighted the risk associated with the use of hydride reagents on substrates 
possessing alkynes as evident by the formation of the unwanted alkene 4-2a (Figure 
4.12).  Unlike the similar conversion of 3-13-2, which was fashioned under ambient 
conditions, the reduction of 4-1 could only be accomplished by keeping the temperature 
at 0 °C.  Compound 3-2’s unusual resistance to over-reduction by hydride agents such 
as LiAlH4 may be attributable to electronic and steric factors.   
 
 
 
Figure 4.12.   Reduction of 4-1’s ester and alkyne functionalities by LiAlH4 at ambient 
temperature. 
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Conversion of 4-2’s hydroxy group to the corresponding bromide 4-3 using 
phosphorous tribromide also proved problematic (Figure 4.13).  The 1H NMR spectrum 
of 4-3 revealed signals at 5.55 and 5.88 ppm that were consistent with those of allylic 
protons; indicating that hydrobromination of the triple bond was taking place (Figure 
4.14).  In an attempt to counteract this undesired side reaction (caused by the in situ 
generation of HBr), pyridine was employed to act as a proton scavenger.  
Unfortunately, the extremely reactive nature of 4-3’s benzylic bromide resulted only in 
N-alkylation of pyridine (Figure 4.13; 4-3b).  Treatment of 4-3b with the chiral auxiliary 
1-42b, failed but modest amounts of 4-2 were recovered by treatment of the quaternary  
amine with 2 N KOH.  A more sterically hindered proton scavenger, 2,6-lutidine,234 was 
then employed, and this also resulted in the N-alkylation of the base.  These 
complications were ultimately overcome by employing 2,6-di-tert-butyllutidine.  Its 
extremely large steric footprint deterred nucleophilic attack at 4-3’s benzylic position 
and instead allowed it to function as an effective proton sponge (Figure 4.16).  
Intriguingly, this problem was not observed in the analogous conversion of 3-23-3, 
even with the presence of excess reagent, highlighting the unusual stability of this 
particular alkyne motif.  
Alkylation of 4-3 with the chiral auxiliary 1-42b proceeded smoothly to afford 4-
4, which then underwent lactamization using methanolic–acetic acid to furnish 4-5 in 
good yield (Figure 4.16).  Hydrolysis of 4-5’s methyl ester using 2 N KOH gave the 
resulting carboxylic acid 4-6.  The intramolecular acylation of 4-6 was then effected  
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Figure 4.13.   Complications in the conversion of 4-24-3 using PBr3. 
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Figure 4.14.   1H NMR spectrum of the bromo- derivative 4-3a. 
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Figure 4.15.   Successful conversion of 4-24-3 using a bulky proton scavenger. 
 
 
using trifluoromethanesulfonic anhydride or the TFAA/BF3Et2O system to give rise to 
the pentacyclic ketone 4-7 (Figure 4.16).  The overall yield of 4-7 was quite modest after 
this sequence of operations, an outcome which was attributed to 4-7’s enhanced 
aqueous solubility. 
 
4.3.5 Functionalization of 4-14’s Indolizidine Moiety 
 
 
 Installation of 4-9’s second stereogenic center would again exploit the unique 
conformational state of 4-7.  Therefore, treatment of 4-7 with the bulky hydride, K-
Selectride®, effected its conversion to 4-8.  As in the conversion of 3-73-8, it is 
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Figure 4.16.   Advancement of 4-3 to the pentacyclic intermediate 4-7. 
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important that reaction conditions be kept at -78 °C to avoid over-reduction to the 
alkene.  Finally, careful reduction of 4-8 with lithium aluminium hydride at -10 °C 
secured 4-9, the pegylated variant of 3-9 (Figure 4.17). 
 
4.4 Conjugation of the biotin derivative 3-14 to the-PEGylated- 
Analogue 4-9 
 
 
Although the early incorporation the alkyne-functionalized PEG-spacer was met 
with several challenges, such an approach was designed to facilitate the [3+2]-
cycloaddition of intermediates at any stage of the synthesis.  Indeed, as demonstrated 
by the model study in Figure 4.18, conjugation of the representative intermediate 4-5 
with 3-14 successfully furnished the triazole bearing compound 4-5a.  The mass 
spectrum of 4-5a (Figure 4.19) confirmed its ionizability under MALDI-TOF conditions. 
 Having now secured both of the required fragments, the pegylated alkaloid 4-9 
was immediately conjugated with the biotin derivative 3-14 through the established 
click protocol to finally afford 4-14 (Figure 4.20).  
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Figure 4.17.   Final steps in the synthesis of the PEGylated derivative 4-9. 
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Figure 4.18.   Biotinylation of the PEGylated derivative 4-5 with 3-14. 
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Figure 4.19.   MALDI-TOFMS spectrum of 4-5a. 
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Figure 4.20.   Completed synthesis of the probe 4-14 bearing a long tether. 
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4.5 Modeling Studies on Streptavidin Binding to the Biotinylated 
Probes 3-17 and 4-14 
 
 
Streptavidin is a tetrameric protein that when bound to biotin, creates one of the 
tightest, noncovalent, interactions known between a protein and a small ligand.102  The 
crystal structure of the binding site in the streptavidin-biotin complex indicates that 
specific hydrogen bonding in addition to sterics, make this binding site complementary 
to biotin.101  Furthermore, biotin seems to bind within a deep cleft inside the core of 
streptavidin, leaving a distance of only about 10 Å from the bound biotin molecule to 
the surface of the protein (Figure 4.21). 
 
 
 
Figure 4.21.   X-ray crystal structure of the streptavidin–biotin complex.   
The captured biotin fragment resides in a deep pocket, the distance 
between it and the surface of the protein is 10.007 Å (PDB code: 1STP). 
10.007 Å 
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Modeling studies were then conducted in order to examine how biotinylated 
probes 3-17 and 4-14 would sit inside the binding pocket of streptavidin during the 
subsequent affinity studies.  First, the lowest energy conformations of both probes was 
determined (Figures 4.22 and 4.23) using the MM4 force-field in SYBYL 8.0 (Tripos 
Associates).  The fit was then accomplished by superimposing ligands 3-17 and 4-14 
onto the pre-docked biotin moiety that lay inside the streptavidin–biotin complex.  The 
resulting renderings are presented in Figures 4.24, 4.25, 4.26 and 4.27.   
The length of probe 3-17’s linker was measured to be 18.525 Å before 
streptavidin capture (Figure 4.24), while the length of linker outside the streptavidin 
surface was found to be 9.015 Å after capture (Figure 4.25).  On the other hand, the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22.   Lowest energy conformation of 3-17 with a calculated energy of 42.2243 
kcal mol-1 
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Figure 4.23.   Lowest energy conformation of 4-14 with a calculated energy of 44.4817 
kcal mol-1 
 
 
 
length of the longer linker in probe 4-14 was found to be 33.027 Å before-streptavidin 
capture, and a staggering 21.365 Å of it remained outside the protein’s surface after 
capture.  Probe 4-14’s added length is expected to provide conformational flexibility. 
 
4.6 Conclusions 
 
 
The synthesis of a biotin conjugate of DCB-3503 (1-62b) bearing an exceptionally 
long, PEG-based tether has been achieved.  Modeling studies indicate that a portion 
(21.365 Å) of the synthesized probe 4-14 remains sufficiently exposed even after 
streptavidin capture, making it suitable for targeting any potentially elusive binding 
partners of DCB-3503 (1-62b).  
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Figure 4.24.   Molecular modeling of the binding between streptavidin and the biotinylated probe 3-17.   
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram) 
associated with the PDB accession code 1STP.  Compound 3-17 was minimized using the MM4 force field (SYBYL 8.0, 
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package.  Molecular graphics 
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081).  Depicted in the figure is the 
full length of 3-17’s linker arm (18.525 Å) and a snapshot of how 3-17 is oriented once placed into the streptavidin binding 
pocket. 
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Figure 4.25.   Molecular modeling of the binding between streptavidin and the biotinylated probe 3-17.   
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram) 
associated with the PDB accession code 1STP.  Compound 3-17 was minimized using the MM4 force field (SYBYL 8.0, 
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package.  Molecular graphics 
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081).  Depicted in the figure is the 
length of 3-17’s linker arm (9.015 Å) that remains outside of the binding vicinity of streptavidin. 
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Figure 4.26.   Molecular modeling of the binding between streptavidin and the biotinylated probe 4-14.   
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram) 
associated with the PDB accession code 1STP.  Compound 4-14 was minimized using the MM4 force field (SYBYL 8.0, 
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package.  Molecular graphics 
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081).  Depicted in the figure is the 
full length of 4-14’s linker arm (33.027 Å) and a snapshot of how 4-14 is oriented once fitted into the streptavidin binding 
pocket. 
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Figure 4.27.   Molecular modeling of the binding between streptavidin and the biotinylated probe 4.-14.   
This model was derived with the crystal structure of streptavidin (represented as a hydrophobicity surface diagram) 
associated with the PDB accession code 1STP.  Compound 4-14 was minimized using the MM4 force field (SYBYL 8.0, 
Tripos Associates) and then fitted into the streptavidin pocket using the UCSF Chimera package.  Molecular graphics 
images were produced using the UCSF Chimera package from the Resource for Biocomputing, Visualization, and 
Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081).  Depicted in the figure is the 
length of 4-14’s linker arm (21.365 Å) that remains outside of the binding pocket of streptavidin. 
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CHAPTER 5 
CoMFA STUDIES OF THE TYLOPHORA 
ALKALOIDS 
 
5. CoMFA STUDIES OF THE TYLOPHORA ALKALOIDS 
 
5.1 Background and Significance 
 
 
5.1.1 Introduction 
 
Since first being isolated in 1935,13 tylophorine (1) and the rest of the 
phenanthroindolizidine alkaloids have continued to be the focus of study in the field of 
cancer therapeutics.  Their pronounced cytotoxicity and unique modes of action have 
inspired renewed efforts to further their development as antitumor agents.  More 
recently, phenanthroindolizidine alkaloids have demonstrated inhibitory effects toward 
NF-κB binding-mediated transcription.55,74,86-87  The NF-κB pathway has been 
implicated as one of the avenues of resistance to chemotherapy.  Although the 
inhibitory mechanisms of these compounds are still largely unknown, these 
phenanthroindolizidine alkaloids are presumed to elicit their phenotypic responses 
through unique and specific binding events that involve their targets.  Therefore, 
optimization of the structural features associated with this binding event could result in 
an enriched affinity with the target(s) and possibly enhance potency.   
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5.1.2 Early Structure–Activity Relationship (SAR) Studies of the Tylophora 
Alkaloids 
 
In their structure–activity relationship (SAR) studies of several non-alkylating 
antitumor agents including tylophorine (1-1), Zee-Cheng and Cheng identified a 
structural feature that was common to all of them.235  Comprising of a nitrogen atom 
triangulated to two oxygens, this arrangement of atoms was postulated to play a role in 
the in vivo binding of the drug to the appropriate receptor (Figure 5.1).  In a subsequent 
SAR study focused on both the phenanthroindolizidine and phenanthroquinolizidine 
alkaloids, Zee-Cheng and Cheng235 and Gupta and co-workers236 were able to conclude 
that these alkaloids could share the same site of action because they had several 
structural features in common.  These features, presented in Figure 5.2, were thought to 
consist of two planar, oxygenated, aromatic systems and a lone pair bearing-nitrogen 
that was positioned equidistantly between them.   
Then, after evaluating the cytoxicities of seven phenanthroindolizidine alkaloids 
against several drug-resistant cell lines, Staerk and co-workers237 implied that a rigid 
phenanthrene framework was a prerequisite for cytotoxicity.  As the SAR profile of 
these potent alkaloids began to emerge, Staerk and co-workers released another study22 
in which he reflected upon the 1965 failure of tylocrebine (1-3) during Phase I clinical 
trials, due to ataxia.  Staerk and co-workers proposed that a more polar analogue of 
tylocrebrine (1-3) would be unable to pass the blood–brain barrier, thus keeping CNS 
effects to a minimum.   
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Figure 5.1.   Zee-Cheng and Cheng’s proposed triangulation of the nitrogen and oxygen 
atoms.235 
 
 
 
 
 
 
Figure 5.2.   The proposed SAR model for receptor binding by Zee-Cheng and Cheng 
and Gupta and co-workers.236  
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5.1.3 CoMFA and In Silico Screening 
 
 
Advances in modern drug discovery have resulted in a significant increase in the 
number of synthetic and naturally occurring molecules that are available for use in 
biological assays.  Traditionally, the search for lead compounds has involved the high-
throughput screening of all members in a chemical library that have been obtained 
through synthetic or isolative means.  However, the recent development of virtual 
screening methods, has extended this search to compounds whose physical existence 
has not yet being achieved through synthesis or isolation.  An obvious advantage to this 
approach is that once a lead compound is identified, its activity may be further enriched 
by making sensible modifications to its structural composition and the resulting 
derivatives stored in a virtual library.  These members can then be screened in silico to 
identify even more active members, bypassing the immediate need for synthesis and 
biological assays. 
One way of accomplishing this would be to establish a classical quantitative 
structural–activity relationship (QSAR) model, which would correlate the biological 
activities of a set of compounds with their physiochemical properties.  In their QSAR 
study on phenanthrene-based tylophorine derivatives,238 Liao and co-workers were able 
to use their computational model to predict the activities of ten theoretical tylophorine 
analogues that were derived from modifications made to the indolizidine motif.  
However, as with most conventional QSAR studies, neither the chiralities nor the three-
dimensional aspects of the compounds were considered during development of the 
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model.   
CoMFA (Comparative Molecular Field Analysis) is a 3D QSAR technique based 
on data from known active molecules.  The aim of CoMFA is to derive a correlation 
between the biological activity of a set of molecules and their three-dimensional shape, 
as well as from their electrostatic and hydrogen bonding characteristics.  
The first stage is the construction of the CoMFA model.  The biologically active 
forms are first properly aligned and their corresponding IC50’s (or EC50, LC50) entered.  
The series of conformers are then superimposed, and their surrounding molecular fields 
are calculated.  The generated QSAR is then subjected to several validation techniques 
after which the model’s predictive ability is tested.  This is typically done using the 
original compounds in the set to “back-predict”, and the results compared. If 
acceptable, the CoMFA or 3D-QSAR model can then applied to a set of analogues and 
predict their target properties.  Additionally, the relationship between 
steric/electrostatic properties and biological activity can be represented as a CoMFA 
contour map, highlighting key features about potential ligand–receptor interactions.  
These findings would allow the properties of the lead compound to be optimized and 
prioritize active compounds for synthesis or further screening.  The CoMFA approach 
has been used with great success to identify potent antineoplasmatic agents.239  
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5.2 Creation of the CoMFA Model 
 
5.2.1 CoMFA Methodology 
 
All molecular structures were modeled with the SYBYL 8.0 molecular modeling 
program (Tripos Associates, Saint Louis, MO) on a Linux PC (2 GHz Intel Xeon 
processor).  Each structure was energy minimized using the MM4 force field, and 
electrostatic charges were assigned by the Gasteiger–Hückel method.  CoMFA potential 
fields were calculated at each lattice intersection of a regularly spaced grid of 2.0 Å.  
Generation of a CoMFA model usually consists of the following steps: 
 
1. A set of molecules whose activities have been measured are superimposed onto 
each other. 
2. CoMFA interaction energies are computed for each molecule in the set. 
3. Statistical analyses, e.g., partial least squares (PLS), are conducted to correlate the 
CoMFA fields with biological activities of each molecule. 
4. The coefficients from the computations are interpreted, and the model is 
validated using a cross-validation analysis.  
5. The predictive ability of the model is tested using compounds with measured 
biological activities. 
6. The model is then applied to set of compounds whose biological activities are yet 
to be established. 
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5.2.2 Training Set Selection 
 
The biological data used for the CoMFA training set was derived from a study by 
Cheng and co-workers87 on the effect of tylophorine and several of its analogues on the 
growth of HepG2 cells (Table 5.1).  Typically, the minimum number of compounds 
needed for a CoMFA training set is 10 and these compounds should have good 
structural diversity.  The selected set consisted of 12 compounds that seemed to satisfy 
the criteria of being fairly diverse in their biological activities and molecular 
architectures (Figure 5.3).   
 
Table 5.1.   The GI50 values of a set of tylophora alkaloids on the growth inhibition of 
HepG2 cells by Cheng and co-workers.87 
 
Compound HepG2 GI50 a(nM) 
(+)-(S)-tylophorine [S-(1-1)]b 11 ± 4 
(-)-(R)-tylophorine [R-(1-1)] 33 ± 2 
(-)-antofine (5-1) 4.9 ± 0.4 
Rac-cryptopleurine (5-2) 1.5 ± 0.2 
Precursor # 1 (5-3) 1723 ± 417 
Precursor # 2 (5-4) >10,000 
(-)-Ficuseptine C (5-5) 371 ± 27 
HepG2 GI50 (µM) 
PBT # 28 (5-6) 2.3 ± 0.3 
PBT # 31 (5-7) 8.6 ± 3.6 
PBT # 32 (5-8) 5.4 ± 1.4 
PBT # 33 (5-9) 3 ± 0.7 
PBT # 34 (5-10) 3.1 ± 1.0 
a  Values are means ± SD of three experiments, with each data point done in triplicate. 
b  Published86 
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Figure 5.3.   Structures of the 12 tylophora alkaloids and PBTs used in the CoMFA 
study. 
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5.2.3 Structure Preparation and Alignment 
 
All structures from the training data set were constructed using the SYBYL 
sketcher, and their conformations were arrived at by optimization via minimization 
with the MM4 force field.  Electrostatic charges were then assigned using the Gasteiger–
Hückel method. 
Structural alignment is one of the most sensitive parameters in 3D-QSAR 
analyses.  The accuracy of the prediction of a CoMFA model and the reliability of the 
contour models strongly depend on the structural alignment of the molecules.  The 
method chosen for this study was alignment by substructure because the 
pharmacophore for this family of compounds is still unknown.  Several substructures 
were tested, ranging from a simple phenanthrene to the modified phenanthrene shown 
in Figure 5.4, which proved to be the best core structure for the alignment.  During the 
alignment process, each molecule was retrieved from the set and aligned on the 
substructure; however, compounds 5-3 and 5-4 were not able to be aligned using this 
substructure and were therefore disqualified from use in the training set.  Additionally, 
the study by Cheng and co-workers featured rac-cryptopleurine (5-2), which was tested 
in racemic form during the study, and proved to be the most potent member.  In order 
to keep 5-2 in the training set, it was assumed that both the R [(R)-5-2)] and S [(S)-5-2)] 
isomers contributed equally towards the observed biological activity.  With all these 
considerations taken into account, the alignment was performed, and these results are 
presented in Figure 5.5. 
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Figure 5.4.   The substructure utilized in the superimposition of the training set 
molecules. 
 
 
 
 
 
 
 
 
 
 
Figure 5.5.   Plot of all 11 superimposed compounds used for the 3D-QSAR analysis.  
During the alignment, all of the other molecules were superimposed onto the 
template molecule, while maintaining their molecular geometry.  Oxygen is shown 
in red, carbon in white, hydrogen in cyan and nitrogen in blue. 
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5.2.4 Preparation of the Biological Data 
 
 
The main goal of a CoMFA model is to relate structural information to biological 
data.  The experimental GI50 values for all molecules in the training set were converted 
to their corresponding negative logs (pGI50, Table 5.2). 
 
5.2.5 CoMFA Field Calculation 
 
 
After superposition of the molecules, the CoMFA field was calculated using 
default SYBYL parameters (grid spacing = 2 Å, truncation cutoff = 30 kcal/mol).  In a 
CoMFA field analysis, each compound was placed in a three-dimensional lattice and 
the steric and electrostatic fields at the various grid points of the lattice was calculated.  
Generally, depending on the dimensions of this box, a few to several thousand points 
were generated.  The results of this analysis are displayed in Table 5.3 and range from 
136 to 176 for this training set. 
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Table 5.2.   The pGI50 of tylophora alkaloids and PBTs on the growth inhibition of 
HepG2 cells. 
 
Compound HepG2 pGI50  
(+)-(S)-tylophorine [(S)-1-1)] 7.96 
(-)-(R)-tylophorine [(R)-1-1)] 7.48 
(-)-antofine (5-1) 8.31 
(R)-cryptopleurine [(R)-5-2)]) 8.82 
(S)-cryptopleurine [(S)-5-2)] 8.82 
Precursor # 1 (5-3) 5.76 
Precursor # 2 (5-4) 5.00 
(-)-Ficuseptine C (5-5) 6.43 
PBT # 28 (5-6) 5.64 
PBT # 31 (5-7) 5.07 
PBT # 32 (5-8) 5.27 
PBT # 33 (5-9) 5.52 
PBT # 34 (5-10) 5.51 
 
 
 
 
Table 5.3.   Results from the CoMFA field analysis. 
 
Compound 
HepG2 pGI50  
(experimental) CoMFA Field 
(+)-(S)-tylophorine [(S)-1-1)] 7.96 176 
(-)-(R)-tylophorine [(R)-1-1)] 7.48 174 
(-)-antofine (5-1) 8.31 160 
(R)-cryptopleurine [(R)-5-2)]) 8.82 158 
(S)-cryptopleurine [(S)-5-2)]) 8.82 158 
(-)-Ficuseptine C (5-5) 6.43 136 
PBT # 28 (5-6) 5.64 152 
PBT # 31 (5-7) 5.07 142 
PBT # 32 (5-8) 5.27 144 
PBT # 33 (5-9) 5.52 152 
PBT # 34 (5-10) 5.51 152 
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5.2.6 Derivation and Validation of the CoMFA Model 
 
 
 
The field matrix resulting from the CoMFA field calculation was then analyzed 
by the Partial Least Squares (PLS) method to give r2 and q2 values (Table 5.4).  PLS, the 
statistical method used in deriving the 3D-QSAR models, is an extension of multiple 
regression analysis in which the original variables are replaced by a small set of their 
linear combinations.240  The r2 value is the Pearson correlation coefficient, which is the 
correlation between the calculated activities and the observed cytotoxic activities; it is 
an indication of the quality of the data fit rather than the quality of prediction.  The q2 is 
the predicted value based on a leave-one-out (LOO) cross-validation method.241  In the 
LOO cross validation method, one compound is excluded from the training set, and a 
PLS model is derived from the remaining compounds.  This model is used to predict the 
biological activity value of the compound that was not included in the model.  This 
procedure is repeated after exclusion of another compound until all compounds have 
been excluded once.  
For this study, the r2 was found to be 0.935 and q2 was 0.567 with the optimum 
number of components set to 3.  Generally, the q2 is expected to be lower than r2, and 
values greater than 0.5 indicate good predictive power.  The CoMFA model was then 
checked by predicting the activities of the compounds in the training set, and the values 
were compared to the experimental data (Table 5.5 and Figure 5.6). 
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Table 5.4.   Results from the LOO cross validation method. 
 
 
  CoMFA 
q2 0.567 
r2 0.935 
No. of Compounds 11 
Steric 0.511 
Electrostatic 0.489 
Optimum No. of Components 3.0 
Grid spacing (Å) 2.0 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.5.   CoMFA predictions for compounds in the training set. 
 
 
 
Compound 
HepG2 pGI50  
(experimental) CoMFA Field 
HepG2 pGI50  
(predicted) Residual 
(+)-(S)-tylophorine [(S)-1-1)] 7.96 176 7.81 0.15 
(-)-(R)-tylophorine [(R)-1-1)] 7.48 174 7.578 0.10 
(-)-antofine (5-1) 8.31 160 8.385 0.08 
(R)-cryptopleurine [(R)-5-2)]) 8.82 158 8.842 0.02 
(S)-cryptopleurine [(S)-5-2)]) 8.82 158 8.842 0.02 
(-)-Ficuseptine C (5-5) 6.43 136 6.438 0.01 
PBT # 28 (5-6) 5.64 152 5.653 0.01 
PBT # 31 (5-7) 5.07 142 5.205 0.14 
PBT # 32 (5-8) 5.27 144 5.328 0.06 
PBT # 33 (5-9) 5.52 152 5.317 0.21 
PBT # 34 (5-10) 5.51 152 5.499 0.01 
  
 
 
  
 
 
Figure 5.6.   Plot of the experimental pGI
 
 
 
5.2.7 Generation of the CoMFA Contour Map
 
 
The contour plot representations of the CoMFA results for the tylophora 
alkaloids are presented in Figures 5.
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Figure 5.6.   CoMFA contour map using compound (R)-5-2 as the reference structure. 
 
 
 
 
 
Figure 5.7.   CoMFA contour map using compound (R)-5-2 as the reference structure. 
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5.3 Screening New Analogues Using CoMFA 
 
One of the goals of in silico screening is to optimize the properties of a lead 
compound which in this case is DCB-3503 (1-62b).  The CoMFA contour maps (Figure 
5.6 and Figure 5.7) revealed that the addition of electron-withdrawing groups to the 
“southern” ring of DCB-3503 (1-62b) would most likely enhance its biological activity.  
Accordingly, modifications were made to 1-62b’s southern ring to incorporate F, Cl, Br, 
CF3 (Table 5.6, compounds 4–15) as the electron-withdrawing groups in place of the C-6 
and C-7 methoxy motifs.  Compounds 1-62b and (S)-1-1 have already been synthesized 
and evaluated both in vivo and in vitro against the HepG2 cell line,86 and these were 
included in the set to test the predictive powers of the model.  As illustrated in Table 5.7 
and Figure 5.9, the CoMFA model was able to accurately predict the biological activities 
of 1-62b and (S)-1-1.   
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Table 5.6.   Biological activities for 20 tylophorine derivatives as predicted by the 
CoMFA model. 
 
 
 
 
Compound No. R n pGI50 
5-11 R1 = R2 = R3 = R4 = OCH3, R5 = OH 1 7.615 
5-12 R1 = R2 = R3 = R4 = OCH3, R5 = H 1 7.801 
5-13 R1 = R2 = R3 = R4 = OCH3, R5 = NH2 1 7.87 
5-14 R1 = R2 = R3 = OCH3, R4 = F, R5 = OH 1 8.183 
5-15 R1 = R2 = R4 = OCH3, R3 = F, R5 = OH 1 8.185 
5-16 R1 = R2 = OCH3, R3 = R4 = F, R5 = OH 1 8.066 
5-17 R1 = R2 = R3 = OCH3, R4 = Cl, R5 = OH 1 8.241 
5-18 R1 = R2 = R4 = OCH3, R3 = Cl, R5 = OH 1 8.15 
5-19 R1 = R2 = OCH3, R3 = R4 = Cl, R5 = OH 1 8.093 
5-20 R1 = R2 = R3 = OCH3, R4 = Br, R5 = OH 1 8.256 
5-21 R1 = R2 = R4 = OCH3, R3 = Br, R5 = OH 1 8.117 
5-22 R1 = R2 = OCH3, R3 = R4 = Br, R5 = OH 1 8.067 
5-23 R1 = R2 = R3 = OCH3, R4 = CF3, R5 = OH 1 7.866 
5-24 R1 = R2 = R4 = OCH3, R3 = CF3, R5 = OH 1 7.91 
5-25 R1 = R2 = OCH3, R3 = R4 = CF3, R5 = OH 1 7.542 
5-26 R1 = Triazb, R2 = R3 = R4 = OCH3, R5 = OH 1 8.309 
5-27 R1 = (3-hydroxypropyl)O- R2 = R3 = R4 = OCH3, R5 = OH 1 7.952 
5-28 R1 = C5H11O, R2 = R3 = R4 = OCH3, R5 = OH 1 7.623 
5-29 R1 = PEGc, R2 = R3 = R4 = OCH3, R5 = OH 1 7.319 
5-30 R1 = HC≡C-O, R2 = R3 = R4 = OCH3, R5 = OH 1 7.86 
a Published86 
b Triaz =     
 
c PEG =  
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Table 5.7.   Comparison of the experimental and predicted pGI50 values for DCB-3500 
[(S)-1-1] or 5-12) and DCB-3503 (1-62b or 5-11) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9.   Plot of experimental versus predicted pGI50s for DCB-3500 [(S)-1-1] or 5-12) 
and DCB-3503 (1-62b or 5-11) 
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(experimental) 
HepG2 pGI50  
(predicted) Residual 
DCB-3503 (1-62b or 5-11) 35 ± 5 7.46 7.62 0.16 
DCB-3500 [(S)-1-1] or 5-
12) 11 ± 4 7.96 7.80 0.16 
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5.4 Discussion 
 
 
Compound 5-13 was derived from DCB-3503 (1-62b) by replacing the C-14 
hydroxy group with an amino group.  The remainder of Table 5.6’s entries (compounds 
5-26 to 5-30), feature modification at the C-3 position: replacing the methoxy group with 
triazole (5-26), PEG (5-29), propyl hydroxy (5-27) and propargyl (5-30) motifs.  In all, 
eighteen new analogues of DCB-3503 (1-62b) were screened in silico using CoMFA, and 
these results are presented in Table 5.6 and Figure 5.10.  Compound 5-26, bearing the 
triazole, is predicted to have the greatest potency followed by compounds 5-20 and 5-
17, which feature Br and Cl groups at the C-6 position, respectively.  In fact, the general 
trend observed with the CoMFA model is that, addition of an electron-withdrawing 
substituent at the C-6 position seems to enhance potency more than a similar 
modification at the C-7 position.  Furthermore, modifications at both the C-6 and C-7 
positions (compounds 5-16, 5-19 and 5-22) results in an increase in the predicted 
activity, but these values are still lower than their monosubstituted counterparts.  
Compound 5-16 is of specific interest because it was specifically designed to be more 
polar than DCB-3503 (1-62b).  This was done in direct response to Staerk’s postulation22 
that penetration of the blood–brain barrier by these alkaloids could be reduced with the 
use of more polar analogs.  Sharma et al. reported the synthesis of several analogues242 
of septicine, one of which demonstrated elevated cytotoxity due to the addition of two 
fluorine substituents in place of the methoxy groups on the “southern” ring (Figure 
5.11). 
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Interestingly, compound 5-25, bearing two CF3 groups at both the C-6 and C-7 
positions, was projected to have a slightly lower potency than DCB-3503 (1-62b).  This 
reduction in activity may be attributed to the diminished electron-withdrawing effect of 
the CF3 group at these positions, an assumption that is supported by the fact that all 
compounds bearing aryl halogens showed superior activity than their CF3-bearing 
counterparts. 
 
5.5 Conclusions 
 
 
3D QSAR studies were performed using CoMFA on a set of phenanthrolizidine 
alkaloids with inhibitory activity against the HepG2 cell line.  A satisfactory CoMFA 
model was obtained with LOO cross-validation q2 and non-cross-validated r2 values of 
0.567 and 0.935, respectively.  The developed model demonstrated promising predictive 
abilities as discerned by the results of external test set.  Additionally, the CoMFA 
contour plots derived from the 3D-QSAR study revealed that modification(s) to the 
southern portion of the phenanthrene framework under the blue contour region greatly 
altered biological activity.  Furthermore, it was found that addition of an electron-
withdrawing substituent at the C-6 position of the phenanthrene seemed to enhance 
potency more than a similar modification at the phenanthrene’s C-7 position.  As such, 
the CoMFA model provides a guide for the design of analogues of DCB-3503 (1-62b) 
with greater inhibitory powers.  Several of these compounds that are predicted to be of 
enhanced potency relative to DCB-3503 (1-62b) are under synthesis. 
  
 
 
  
 
 
 
 
Figure 5.10.   Bar graph representation of predicted pGI
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Figure 5.11.   Sharma’s difluoro-substituted septicine analogue. 
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EXPERIMENTAL 
6. Experimental 
1H (300 MHz) and 13C (75 MHz) and NMR spectra were recorded at 25 ºC with a 
Varian Mercury 300. Chemical shifts are given in δ-units (ppm) relative to an internal 
standard of TMS for 1H, and relative to the signal for CDCl3 or pyridine-d5 for 1H and 
13C unless otherwise stated.  Apparent first-order multiplicities are indicated by s, 
singlet; d, doublet; dd, doublet of doublets; t, triplet; dt, doublet of triplets; q, quartet; 
m, multiplet.  Analytical TLC was performed on  Silica Gel 60 F254 (0.2-mm aluminum-
backed plates, E. Merck) by detection with 254 nm UV light and then spray–heat 
development using a p-anisaldehyde–sulfuric acid reagent.  Column chromatography 
was run by using silica gel, 63–200 mesh.  High-resolution DART mass spectra were 
obtained on a JEOL AccuTOF-DART workstation with an ESI source. MALDI-TOF 
mass spectra were obtained on a Voyager-DE PRO BioSpectrometry Workstation. All 
solvents were dried and distilled by standard methods unless otherwise stated. 
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(E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (1-27).  
In a 1 L round-bottomed flask was added 3,4-dimethoxyphenylacetic acid  (19.7 g, 100 
mmol) and 3,4-dimethoxybenzaldehyde (16.69 g, 100.0 mmol) in acetic anhydride (55.0 
mL, 583 mmol) to give a yellow suspension.  TEA (35.0 mL, 249 mmol) was added and 
the reaction mixture was stirred at 100 ºC.  After 24 h the darkened mixture was cooled 
to room temperature, followed by the slow addition of 50 mL of H2O.  The reaction 
mixture was then poured into aqueous K2CO3 (75.0 g in 250 mL of water) and refluxed 
until the dissolution of all solids.  After cooling to room temperature, the solution was 
extracted with ether (3 x 50 mL) and carefully acidified with 2 N hydrochloric acid to 
produce a yellow precipitate.  The isolated solid was then recrystallized from MeOH to 
give 1-27 (26 g, 76 mmol, 75% yield) as a beige solid.  . 1H NMR (300 MHz, CDCl3) δ 7.74 
(s, 1H), 6.86 (d, J = 8.2, 1H), 6.75 (d, J = 1.9, 1H), 6.78 (d, J = 1.9, 1H), 6.75 (d, J = 1.9, 1H), 
6.65 (d, J = 8.4, 1H), 6.47 (d, J = 2.0, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.73 (s, 3H), 3.74 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 55.96, 56.07, 110.58, 111.62, 112.56, 113.03, 122.34, 
125.50, 127.53, 128.92, 138.05, 138.40, 148.27, 148.73, 149.42, 150.08, 168.81, 189.56.  The 
NMR data matched those reported in the literature.55  HRDARTMS: Calcd for C19H20O6 
m/z 344.12599; [M + H]+ m/z 345.13454 (calcd 345.13381). 
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Preparation of (E)-Methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-
47).  
To a solution of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid  (1-27, 10.05 g, 29.20 mmol) 
in 500 mL of dry MeOH was added concd H2SO4 (10 mL), and the solution was stirred 
at 65 ºC for 12 h.  The reaction mixture was then concentrated using a rotary evaporator, 
and the resulting slurry was then filtered.  After being  washed several times with ice 
cold MeOH, the filtrate was then  purified by column chromatography (1:2 hexane–
EtOAc) to give (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester 1-47 
(9.70 g, 27.1 mmol, 93% yield) as a pale-yellow solid. 1H NMR (300 MHz, CDCl3) δ 7.73 
(s, 1H), 6.88 (d, J = 8.2, 1H), 6.79 (d, J = 1.9, 1H), 6.77 (d, J = 1.9, 1H), 6.74 (d, J = 1.9, 1H), 
6.68 (d, J = 8.4, 1H), 6.49 (d, J = 2.0, 1H), 3.86 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.76 (s, 
3H), 3.45 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 52.53, 55.95, 56.09, 110.59, 111.61, 112.57, 
113.00, 122.36, 125.48, 127.56, 128.90, 138.03, 138.40, 148.29, 148.71, 149.40, 150.09, 168.80, 
189.54.  The NMR data matched those reported in the literature.55  HRDARTMS: Calcd 
for C20H22O6 m/z 358.14164; [M + H]+ m/z 359.14299 (calcd 345.14946). 
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Preparation of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52).  
(E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47, 4.75 g, 13.3 
mmol) was dissolved in 200 mL of dry CH2Cl2 and stirred over an ice bath for 15 min. A 
solution of FeCl3 (12.9 g, 80.0 mmol) in 100 mL EtOAc was then added dropwise, and 
stirring was continued. After 3 h, 150 mL of H2O was added, and the reaction mixture 
was stirred for an additional 2 h. The mixture was poured from the reaction vessel into 
a separatory funnel and the phases separated. The organic phase was then dried over 
Na2SO4 and filtered.  The solvent was removed by rotary evaporation, and the crude 
product was purified by column chromatography (0.2:2 hexane–EtOAc) to give  methyl 
2,3,6,7-tetramethoxyphenanthrene-9-carboxylate  (1-52, 4.35 g, 12.19 mmol, 92% yield). 
1H NMR (300 MHz, CDCl3) δ 8.63 (s, 1H), 8.41 (s, 1H), 7.78 (s, 1H), 7.74 (s, 1H), 7.25 (s, 
1H), 4.13 (s, 3H), 4.12 (s, 3H), 4.07 (s, 3H), 4.02 (s, 3H), 4.00 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 52.27, 56.06, 56.28, 100.20, 102.81, 107.00, 109.44, 116.16, 130.61, 138.04, 149.22, 
165.17, 182.43, 192.72.  The NMR data matched those reported in the literature.55  
HRDARTMS: Calcd for C20H20O6 m/z 356.12599; [M+H]+ m/z 357.13381 (calcd 
357.12550). 
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Preparation of (2,3,6,7-tetramethoxyphenanthren-9-yl)-methanol (1-53). 
To a suspension of lithium aluminum hydride (1.44 g, 37.9 mmol) in 50 mL of THF at 0 
ºC under a nitrogen atmosphere, was added dropwise, a solution of methyl 2,3,6,7-
tetramethoxyphenanthrene-9-carboxylate (1-52,  4.50 g, 12.6 mmol) in 200 mL of dry 
THF. The solution was stirred at room temperature for an additional 4 h, then brought 
back to 0 ºC, at which point 50 mL of EtOAc was added dropwise, followed by careful 
addition of sodium sulfate decahydrate (10.0 g, 31.0 mmol). After stirring for 5 h, the 
solution was filtered, and the solvent was removed by rotary evaporation. The product 
was purified by column chromatography (0.2:2 hexane–EtOAc) to give 1-53 (4.02 g, 12.3 
mmol, 97% yield). 1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 7.66 (s, 1H), 7.48 (s, 1H), 
7.46 (s, 1H), 7.09 (s, 1H), 5.04 (s, 2H), 4.08 (s, 3H), 4.07 (s, 3H), 4.01 (s, 3H), 3.95 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 56.09, 64.87, 102.81, 103.29, 104.92, 108.47, 124.14, 
124.75,125.14, 125.97, 132.20, 137.78, 138.12,147.61, 149.14.  The NMR data matched those 
reported in the literature.55  HRDARTMS: Calcd for C19H20O5 m/z 328.13107; [M]- m/z 
328.13154 (calcd 328.13107). 
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Preparation of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63).  
A stirred solution of 2,3,6,7-tetramethoxyphenanthren-9-yl-methanol (1-53, 5.20 g, 15.8 
mmol) in 346 mL of freshly distilled CHCl3 was cooled to 0 ºC.  After stirring for 15 min, 
a solution of phosphorous tribromide (4.29 g, 15.84 mmol) in 60 mL CHCl3 was added 
dropwise. The reaction mixture was then stirred for an additional 2 h at room 
temperature and then poured over ice, and the two layers separated. The organic phase 
was dried over MgSO4, filtered and rotary evaporated to give  9-(bromomethyl)-2,3,6,7-
tetramethoxyphenanthrene (1-63, 6.07 g, 15.5 mmol, 98% yield) as a yellow solid that 
was then placed under vacuum for 1 h and used without further purification. 
1H NMR (300 MHz, CDCl3) δ 7.80 (s, 1H), 7.72 (s, 1H), 7.64 (s, 1H), 7.50 (s, 1H), 7.15 (s, 
1H), 4.96 (s, 2H), 4.10 (d, J = 2.0, 6H), 4.08 (s, 3H), 4.00 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 33.98, 56.18, 102.89, 103.52, 105.10, 108.56, 124.24, 125.45, 125.81, 126.56, 127.34, 
128.93, 149.46.  The NMR data matched those reported in the literature.55  HRDARTMS: 
Calcd for C19H19BrO4 m/z 390.04667; [M] m/z 390.03819 (calcd 390.04667). 
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Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b).  
 
To a stirred solution of L-(+)-glutamic acid (6.00 g, 40.8 mmol) in 300 mL of methanol at 
-10 ºC was added slowly thionyl chloride (40 mL, 548 mmol). Stirring was continued at 
30 ºC for an additional 6 h after which time the solvent was removed by rotary 
evaporation, and the residue was concentrated in vacuo to give 1-42b (8.42 g, 40.0 mmol, 
98% yield) as a white crystalline solid. 1H NMR (300 MHz, pyridine) δ 4.86 (t, J = 6.5, 
1H), 3.70 (s, 3H), 3.50 (s, 3H), 3.12 – 2.90 (m, 2H), 2.84 – 2.62 (m, 2H). 13C NMR (75 MHz, 
pyridine) δ 26.65, 30.48, 53.11, 171.14, 172.99.  The NMR data matched those reported in 
the literature.55  HRDARTMS: Calcd for [C7H14NO4]+ m/z 176.09173; [M]+- m/z 176.0905 
(calcd 176.09173). 
 
 
 
Preparation of (S)-dimethyl 2-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methylamino)pentanedioate (1-64).  
To a  stirred solution of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63, 4.80 
g, 12.3 mmol) in 420 mL of DMF was added 1-42b (12.98 g, 61.30 mmol), and stirring 
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was continued for 15 min.  K2CO3 (8.48 g, 61.3 mmol) was added, and the reaction 
mixture was allowed to stir at 70 ºC overnight.  The solution was then rotary 
evaporated, and the resulting crude product was partitioned between CHCl3 and H2O.  
The organic layer was then dried over MgSO4 and concentrated in vacuo to afford the 
crude of 1-64 as a dark-yellow oil that was used without further purification.55  
HRDARTMS: Calcd for C26H31NO8 m/z 485.20497; [M+H]+ m/z 486.21025 (calcd 
486.21279). 
 
 
 
 
Preparation of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (1-65).  
The crude diester, 9 (4.80 g, 9.89 mmol), was dissolved in 80 mL of MeOH and 35 mL of 
HOAc and stirred for 3 h at 45 ºC. The mixture was then cooled to room temperature, 
concentrated in vacuo, and the residue was chromatographed over silica gel (0.2:2 
hexanes–EtOAc) to afford (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (1-65, 3.90 g, 8.60 mmol, 87% yield) as a white 
solid. 1H NMR (300 MHz, CDCl3) δ 7.75 (s, 1H), 7.72 (s, 1H), 7.57 (s, 1H), 7.36 (s, 1H), 
7.13 (s, 1H), 5.45 (d, J = 14.5, 1H), 4.37 (d, J = 14.5, 1H), 4.08 (s, 6H), 4.00 (s, 5H), 3.82 (dd, 
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J = 9.1, 3.2, 1H), 3.54 (s, 3H), 2.64 – 2.49 (m, 1H), 2.36 (ddd, J = 16.9, 9.5, 3.8, 1H), 2.17 – 
1.89 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 22.88, 29.95,  44.90, 52.41, 56.08, 56.22, 56.47, 
102.79,103.17, 105.38, 108.31, 124.92, 125.67, 127.03, 138.26, 149.01, 149.16, 149.27, 149.70, 
172.42, 174.78.  The NMR data matched those reported in the literature.55  HRDARTMS: 
Calcd for C25H27NO7 m/z 453.17875; [M+H]+ m/z 454.16560 (calcd 454.18658). 
 
 
 
 
 
Preparation of (S)-5-Oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylic acid (1-50). 
To the alkylated pyroglutamate ester 1-65 (2.60 g, 5.73 mmol) in 1,4-dioxane (60 mL) 
was added 2 N KOH (30 mL) and MeOH (48 mL). After vigorous stirring for 12 h, the 
solution was cooled (4 ºC), acidified to pH 3 with 2 N HCl, and chilled overnight. The 
resulting solid was then filtered, and the filter cake was rinsed with 10 mL of ice-cold 
water to afford (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-
2-carboxylic acid (1-50, 2.44 g, 5.56 mmol, 97% yield) as a white solid. 1H NMR (300 
MHz, pyridine) δ 8.34 (s, 1H), 8.29 (s, 1H), 8.17 (s, 1H), 7.85 (s, 1H), 7.38 (s, 1H), 6.05 (d, J 
= 14.4, 1H), 4.81 (d, J = 14.5, 1H), 4.27 (dd, J = 8.4, 3.9, 1H), 4.14 (s, 3H), 4.02 (s, 6H), 3.85 
  
 
 
232 
 
  
 
(s, 3H), 2.74 (d, J = 16.8, 1H), 2.50 (s, 1H), 2.25 – 2.11 (m, 2H). 13C NMR (75 MHz, 
pyridine) δ 23.75, 30.68, 45.30, 56.04, 56.44, 59.70, 104.62, 105.16,106.64, 109.54, 125.92, 
126.05, 126.20, 126.85, 127.63, 128.78, 138.32, 175.30, 175.49.  The NMR data matched 
those reported in the literature.55  HRDARTMS: Calcd for C24H25NO7 m/z 439.16310; 
[M+H]+ m/z 440.16535 (calcd 440.17093). 
 
 
 
Preparation of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (1-45).  
Method A: Trifluoromethanesulfonic anhydride (0.877 mL, 5.19 mmol) was added to a 
well-stirred suspension of 1-65 (1.90 g, 4.32 mmol) in CH2Cl2 (130 mL) at -30 ºC.  The 
reaction mixture was allowed to reach room temperature slowly and was stirred for an 
additional 48 h. The solvent was then evaporated, and the resulting residue passed was 
through a plug of silica gel. The collected crude was then concentrated and added to a 
stirred mixture of CH2Cl2 (75 mL) and 2 g of K2CO3 in water (50 mL) for 4 h. The 
organic phase was then evaporated affording a dark oil, which was then 
chromatographed over silica gel (0.1:2 MeOH–CHCl3) to give 1-45 (0.98 g, 2.34 mmol, 
54% yield), which was recrystallized from acetone affording a bright yellow-solid.  
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Method B: Trifluoroacetic anhydride (2.41 mL, 17.3 mmol) was added to a well stirred 
suspension of the carboxylic acid 1-50 (1.90 g, 4.32 mmol) in CH2Cl2 (130 mL). The 
mixture was stirred at room temperature for 15 min, and boron trifluoride diethyl 
etherate (1.06 mL, 8.65 mmol)  was added. The mixture was stirred at room temperature 
for 24 h, then the solvents were evaporated. To the resulting residue was added a 
mixture of CH2Cl2 (100 mL) and 4 g of K2CO3 in water (50 mL) for 4 h. The organic 
phase was dried, then evaporated affording 1-45 (1.17 g, 2.77 mmol, 64% yield) as a 
bright-yellow solid.  1H NMR (300 MHz, CDCl3) δ 9.01 (s, 1H), 7.64 (d, J = 6.1, 2H), 7.13 
(s, 1H), 5.57 (d, J = 18.0, 1H), 4.50 (d, J = 21.1, 11.2, 1H), 4.32 (t, J = 5.8, 1H), 4.11 (s, 3H), 
4.07 (s, 3H), 4.05 (s, 3H), 4.02 (s, 3H), 2.58 – 2.47 (m, 4H). 13C NMR (75 MHz, CDCl3) δ 
23.59, 30.97, 41.04, 55.98, 56.19, 58.57, 65.85, 102.83, 103.06, 103.18, 104.55, 122.81,123.94, 
124.52, 124.95, 127.06, 137.50, 138.30, 155.64, 206.49, 220.10.  The NMR data matched 
those reported in the literature.55  HRDARTMS: Calcd for C24H23NO6 m/z 421.15254; 
[M+H]+ m/z 422.16064 (calcd 422.16036). 
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Preparation of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66).  
To a solution of 1-45 (0.8 g, 1.898 mmol) in THF (25 mL) was added lithium tri-sec-
butylborohydride (2.088 mL, 2.088 mmol) in THF at -30 ºC under N2.  After stirring at -
30 ºC for 10 min and 3 h at room temperature, a mixture of i-PrOH (3 mL) and H2O (3 
mL) was added, and the mixture was stirred at 0 ºC in the presence of silica gel (200 mg) 
for 0.5 h.  The mixture was filtered through a Celite pad, and the filtrate was evaporated 
in vacuo.  The residue was purified by flash column chromatography ( 0.1:2 MeOH–
CHCl3) to afford 1-66 (0.72 g, 1.7 mmol, 89% yield). 1H NMR (300 MHz, CDCl3) δ 7.68 
(s, 1H), 7.62 (s, 1H), 7.58 (s, 1H), 6.61 (s, 1H), 5.07 (s, 1H), 4.99 (d, J = 17.6, 1H), 4.26 (d, J 
= 17.8, 1H), 4.09 (s, 3H), 4.06 (s, 6H), 3.85 (d, J = 8.3, 1H), 3.65 (s, 3H), 3.08 (s, 1H), 2.73 – 
2.45 (m, 3H), 2.31–2.20 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 19.36, 30.97, 41.04, 56.19, 
58.57,65.85, 102.83, 103.06, 103.18, 104.55, 124.52, 137.50, 138.22, 148.86, 149.14, 149.28, 
149.38, 165.22.  The NMR data matched those reported in the literature.55  HRDARTMS: 
Calcd for C24H25NO6 m/z 423.16819; [M+H]+ m/z 424.17545 (calcd 422.17601). 
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Preparation of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (1-62b).  
To a suspension of lithium aluminum hydride (0.323 g, 8.50 mmol) in 50 mL of THF at 0 
ºC under a nitrogen atmosphere, was added dropwise a solution of 1-66 (0.40 g, 0.95 
mmol) in 80 mL of dry THF.  The solution was stirred at room temperature for an 
additional 4 h, then brought back to 0 ºC, at which point 30 mL of EtOAc was added 
dropwise, followed by careful addition of 7 g of sodium sulfate decahydrate.  After 
stirring for 5 h, the solution was filtered, and the solvent was removed by rotary 
evaporation.  The product was purified by column chromatography (0.1:2 MeOH–
CHCl3) to give 1-62b (0.31 g, 0.75 mmol, 79% yield). 1H NMR (300 MHz, CDCl3) δ 7.28 
(s, 1H), 7.19 (s, 1H), 7.13 (s, 1H), 6.75 (s, 1H), 4.99 (d, J = 14.0, 1H), 3.98 (s, 6H), 3.94 (s, 
3H), 3.91 (s, 3H), 3.29–3.21 (m, 1H), 3.21–3.09 (m, 1H), 3.03–2.93 (m, 1H), 2.38–2.29 (m, 
2H), 2.13–1.98 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 25.82, 32.27, 55.23, 56.03, 56.11, 
56.24, 56.32, 62.62, 65.40, 68.19, 103.01, 103.43, 104.98, 108.39, 124.65, 125.15, 125.68, 
126.09, 148.96, 149.04, 149.18, 149.47.  The NMR data matched those reported in the 
literature.55  HRDARTMS: Calcd for C24H27NO5 m/z 409.18892; [M+H]+ m/z 410.19678 
(calcd 410.19675). 
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Preparation of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic 
acid (2-1) 
In a 1-L round-bottomed flask was added 2-(3,4-dimethoxyphenyl)acetic acid (19.7 g, 
100 mmol) and vanillin (15.28 g, 100.0 mmol) in Ac2O (55.0 mL, 583 mmol) to give a 
yellow suspension.  TEA (35.0 mL, 249 mmol) was added, and the reaction mixture was 
stirred at 100 °C.  After 24 h the darkened mixture was cooled to room temperature, 
followed by the slow addition of 50 mL of H2O.  The reaction mixture was then poured 
into aqueous K2CO3 (75.0 g in 250 mL water) and refluxed until all solids dissolved.  
After cooling to room temperature, the solution was extracted with ether (3 x 50 mL) 
and carefully acidified with 2 N hydrochloric acid to produce a yellow precipitate.  The 
isolated solid was then recrystallized from MeOH to give (E)-3-(4-acetoxy-3-
methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1, 28 g, 75 mmol, 74.9% yield) 
as a beige solid.  1H NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 6.87 (dd, J = 8.2, 1.2, 2H), 
6.82–6.73 (m, 3H), 6.63 (d, J = 1.5, 1H), 3.85 (s, 3H), 3.77 (s, 3H), 3.45 (s, 3H), 2.34–2.22 (m, 
3H).  13C NMR (75 MHz, CDCl3) δ 20.73, 55.46, 56.04, 111.61, 112.87, 114.0, 122.32, 
127.96, 131.79, 133.35, 140.64, 141.07, 148.91, 149.37, 150.60, 168.93, 172.86.  The NMR 
data matched those reported in the literature.86  HRDARTMS: Calcd for C20H20O7 m/z 
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372.12090; [M+H]+ m/z 373.13023 (calcd 373.12873). 
 
 
Preparation of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-
methoxyphenyl)acrylate (2-2) 
To a solution of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid  
(9.58 g, 25.7 mmol) in 480 mL of dry MeOH was added concd H2SO4 (9.75 mL), and the 
solution stirred at 65 °C for 12 h.  The reaction mixture was then concentrated using a 
rotary evaporator, and the resulting slurry was then filtered.  After being  washed 
several times with ice-cold MeOH, the filtrate was then  purified by column 
chromatography (1:2 hexane–EtOAc) to give (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-
hydroxy-3-methoxyphenyl)acrylate (2-2, 7.88 g, 22.9 mmol, 89% yield)  as a pale-yellow 
solid.  1H NMR (300 MHz, CDCl3) δ 7.72 (s, 1H), 6.91 (d, 1H), 6.81–6.76 (m, 1H), 6.76–
6.72 (m, 3H), 6.46 (s, J = 9.8, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.76 (s, 3H), 3.46 (s, J = 3.7, 
3H).  13C NMR (75 MHz, CDCl3) δ 52.50, 55.50, 56.10, 111.65, 112.22, 113.07, 114.32, 
122.38, 126.20, 127.12, 128.98, 137.48, 140.77, 146.05, 147.06, 147.59, 148.71, 149.43, 168.83.  
The NMR data matched those reported in the literature.86  HRDARTMS: Calcd for 
C19H20O6 m/z 344.12599; [M+H]+ m/z 345.13656 (calcd 345.13381). 
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Preparation of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-
dimethoxyphenyl)acrylate (2-3). 
(E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate (2-2, 4.56 
g, 13.2 mmol) was added to TEA (23.0 mL, 164 mmol) and acetic anhydride (45 mL, 477 
mmol), and the mixture was stirred at ambient temperature for 4 h.  The solution was 
rotary evaporated.  The crude product was purified by column chromatography (2:1 
hexane–EtOAc) to give (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-
dimethoxyphenyl)acrylate  (2-3, 4.86 g, 12.6 mmol, 95% yield) as a yellowish-orange 
powder.  1H NMR (300 MHz, CDCl3) δ 7.73 (s, 1H), 6.90–6.82 (m, 2H), 6.79–6.69 (m, 3H), 
6.59 (s, 1H), 3.86 (s, 3H), 3.78 (s, 6H), 3.42 (s, 3H), 2.24 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ 52.50, 55.50, 56.10, 111.65, 112.22, 113.07, 114.32, 122.38, 126.20, 127.12, 128.98, 137.64, 
138.42, 146.05, 147.06, 147.59, 148.71, 149.43, 168.83.  The NMR data matched those 
reported in the literature.86  HRDARTMS: Calcd for C21H22O7 m/z 386.13655; [M+H]+ m/z 
387.14021 (calcd 387.14438). 
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Preparation of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4) 
(E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate  (2-3, 4.30 
g, 11.1 mmol) was dissolved in 200 mL of dry CH2Cl2 and stirred over an ice bath for 15 
min.  A solution of FeCl3 (12.9 g, 80.0 mmol) in 100 mL EtOAc was then added dropwise 
and stirring was continued.  After 3 h, 150 mL of H2O was added and the reaction 
mixture was stirred for an additional 2 h.  The mixture was poured from the reaction 
vessel into a separatory funnel, and the phases were separated.  The organic phase was 
then dried over Na2SO4 and filtered.  The solvent was removed by rotary evaporation, 
and the crude product was purified by column chromatography (1:2 hexane–EtOAc) to 
give methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4, 3.76 g, 9.79 
mmol, 88% yield)  1H NMR (300 MHz, CDCl3) δ 8.49 (s, 1H), 8.28 (s, 1H), 8.05 (s, 1H), 
7.64 (s, 1H), 7.25 (s, 1H), 4.05 (s, 6H), 4.00 (s, 3H), 3.94 (s, 3H), 2.41 (s, 3H).  13C NMR (75 
MHz, CDCl3) δ 20.94, 52.31, 55.94, 56.12, 102.78, 106.72, 110.27, 116.27, 123.60, 124.38, 
125.49, 126.38, 128.58, 129.96, 141.90, 149.24, 149.29, 150.05, 168.09, 169.30.  The NMR 
data matched those reported in the literature.86  HRDARTMS: Calcd for C21H20O7 m/z 
384.12090; [M+H]+ m/z 385.13106 (calcd 385.12873). 
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Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5). 
To a solution of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4, 8.60 
g, 22.4 mmol) in 410 mL of dry MeOH was added concd H2SO4 (9 mL) and the solution 
stirred at 65 °C for 12 h.  The reaction mixture was then concentrated using a rotary 
evaporator, and the resulting slurry was then filtered.  After being  washed several 
times with ice cold MeOH, the filtrate was air dried to give methyl 3-hydroxy-2,6,7-
trimethoxyphenanthrene-9-carboxylate  (2-5, 6.28 g, 18.4 mmol, 82% yield) and used 
without further purification.  1H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H), 8.33 (s, 1H), 7.89 
(s, 1H), 7.74 (s, 1H), 7.17 (s, 1H), 4.05 (s, 3H), 4.04 (s, 4H), 3.99 (s, 3H), 3.98 (s, 3H).  13C 
NMR (75 MHz, CDCl3) δ 52.16, 55.92, 55.98, 56.11, 102.98, 106.13, 106.76, 108.75, 121.92, 
124.13, 124.32, 125.23, 127.98, 130.67, 146.75, 147.91, 149.00, 149.34, 168.42.  HRDARTMS: 
Calcd for C19H18O6 m/z 342.11034; [M + H]+ m/z 343.12142 (calcd 343.11816). 
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Methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1) 
Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate  (2-5, 5.45 g, 15.92 
mmol) was dissolved in 60 mL of DMF and placed under a nitrogen atmosphere.  Then, 
to the stirred solution at 0 °C, was added NaH (60% in oil, 0.84 g, 35.0 mmol) ,followed 
by propargyl bromide (2.84 g, 19.1 mmol, 80% in toluene).  Stirring was allowed to 
continue overnight, after which time the reaction mixture was quenched with MeOH, 
diluted with CH2Cl2 (25 mL) and washed with satd NaHCO3.  The resulting organic 
layer was then separated, dried over MgSO4 and concentrated under vaccum.  The 
dark-yellow crude product was then chromatographed over silica gel (1:2 hexane–
EtOAc) to afford methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-
carboxylate (3-1, 5.45 g, 14.3 mmol, 90% yield) as a yellow solid.  1H NMR (300 MHz, 
CDCl3) δ 8.60 (s, 1H), 8.37 (s, 1H), 7.99 (s, 1H), 7.77 (s, 1H), 7.24 (d, J = 1.5, 1H), 4.99 (d, J 
= 2.3, 2H), 4.09 (s, 3H), 4.05 (s, 3H), 4.00 (d, J = 2.2, 6H), 2.61 (t, J = 2.6, 1H).  13C NMR (75 
MHz, CDCl3) δ 52.20, 55.91, 55.98, 56.07, 57.17, 76.73, 78.23, 102.71, 105.84, 106.87, 109.66, 
122.71, 124.15, 125.32, 125.33, 130.33, 137.73, 137.86, 137.99, 148.97, 149.18, 149.37, 149.39, 
168.31.  HRDARTMS: Calcd for C22H20O6 m/z 380.12599; [M + H]+ m/z 381.13126 (calcd 
381.13381). 
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(2,6,7-Trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2) 
To a suspension of lithium aluminum hydride (1.44 g, 37.9 mmol) in 50 mL of THF at 0 
°C under a nitrogen atmosphere, was added dropwise, a solution of methyl 2,6,7-
trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1, 6.10 g, 16.04 mmol) in 
235 mL of dry THF.  The solution was stirred at room temperature for an additional 1 h, 
then brought back to 0 °C, at which point 50 mL of EtOAc was added dropwise, 
followed by careful addition of sodium sulfate decahydrate (10.00 g, 31.04 mmol).  After 
stirring for 5 h, the solution was filtered, and the solvent was removed by rotary 
evaporation.  The product was purified by column chromatography (0.2:2 hexane–
EtOAc) to give (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2, 
5.09 g, 14.43 mmol, 90% yield).  1H NMR (300 MHz, CDCl3) δ 7.89 (s, 1H), 7.71 (s, 1H), 
7.42 (s, 1H), 7.41 (s, 1H), 7.03 (s, 1H), 5.00 (s, 3H), 4.91 (d, J = 2.3, 2H), 4.06 (s, 3H), 3.98 (s, 
3H), 3.89 (s, 3H), 2.59 (t, J = 2.3, 1H).  13C NMR (75 MHz, CDCl3) δ 55.94, 56.06, 57.36, 
64.69, 76.45, 78.58, 103.24, 104.81, 106.55, 108.76, 123.76, 124.34, 126.79, 132.72, 135.68, 
147.01, 148.80, 149.13, 149.22.  HRDARTMS: Calcd for C21H20O5 m/z 352.13107; [M + H]+ 
m/z 353.13911 (calcd 353.13890). 
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9-(Bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3) 
A stirred solution of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol  
(3-2, 3.20 g, 9.08 mmol)  in 270 mL of freshly distilled CHCl3 was cooled to 0 °C.  After 
stirring for 15 min, a solution of phosphorous tribromide (2.70 g, 9.99 mmol) in 38 mL of 
CHCl3 was added dropwise.  The reaction mixture was then stirred for an additional 2 h 
at room temperature, then poured over ice, and the two layers separated.  The organic 
phase was dried over MgSO4, filtered and rotary evaporated to give 9-(bromomethyl)-
2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3, 3.51 g, 8.45 mmol, 93% yield) as 
a yellow solid that was then placed under vacuum for 1 h and used without further 
purification.  1H NMR (300 MHz, CDCl3) δ 7.99 (s, 1H), 7.81 (s, 1H), 7.62 (s, 1H), 7.48 (s, 
1H), 7.17 (s, 1H), 4.97 (d, J = 2.3, 2H), 4.94 (s, 2H), 4.10 (s, 3H), 4.07 (s, 3H), 3.99 (s, 3H), 
2.59 (t, J = 2.3, 1H).  13C NMR (75 MHz, CDCl3) δ 33.81, 56.12, 56.17, 56.20, 57.40, 76.58, 
78.44, 103.53, 105.08, 106.70, 108.92, 124.15, 125.18, 125.53, 126.67, 129.54, 137.51, 138.02, 
147.70, 148.94, 149.56, 149.59.  HRDARTMS: Calcd for C21H19BrO4 m/z 414.04667; [M + 
H]+ m/z 415.02252 (calcd 415.05450). 
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(S)-Dimethyl 2-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9 yl)methylamino) 
pentanedioate (3-4). 
To a stirred solution of 9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-
ynyloxy)phenanthrene  (4.90 g, 11.8 mmol) in 420 mL DMF was added K2CO3 (8.48 g, 
61.3 mmol)  and stirring continued for 15 min.  1-42b (13.0 g, 61.3 mmol) was then 
added, and the reaction mixture allowed to stir at 70 °C overnight.  The solution was 
then rotary evaporated, and the resulting crude product was partitioned between 
CHCl3 and H2O.  The organic layer was then dried over MgSO4 and concentrated in 
vacuo to afford the crude of 3-4 as a dark-yellow oil that was used without further 
purification.  HRDARTMS: Calcd for C28H31NO8 m/z 509.20497; [M + H]+ m/z 510.21248 
(calcd 510.21279). 
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(S)-Methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (3-5) 
The crude diester, (S)-dimethyl 2-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9 
yl)methylamino)pentanedioate  (3-4, 5.10 g, 10.0 mmol), was dissolved in 70 mL of 
MeOH and 35 mL of HOAc and stirred for 3 h at 45 °C.  The mixture was then cooled to 
room temperature, concentrated in vacuo, and the residue was chromatographed over 
silica gel (0.2:2 hexanes–EtOAc) to afford (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-
2-ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (3-5, 3.97 g, 8.31 mmol, 
83% yield) as a white solid.  1H NMR (300 MHz, CDCl3) δ 8.02 (s, 1H), 7.80 (s, 1H), 7.59 
(s, 1H), 7.38 (s, 1H), 7.17 (s, 1H), 5.50 (d, J = 14.5, 1H), 4.97 (d, J = 2.3, 2H), 4.37 (d, J = 
14.6, 1H), 4.09 (s, 3H), 4.01 (s, 3H), 4.00 (s, 3H), 3.82 (dd, J = 9.1, 3.2, 1H), 3.57 (d, J = 1.7, 
3H), 2.64–2.51 (m, 2H), 2.37 (ddd, J = 16.9, 9.4, 3.9, 1H), 2.17–2.04 (m, 1H), 2.04–1.91 (m, 
1H).  13C NMR (75 MHz, CDCl3) δ 22.95, 30.00, 44.94, 52.49, 56.11, 56.14, 56.56, 58.68, 
76.53, 78.51, 103.27, 105.42, 106.75, 108.75, 124.77, 124.90, 125.17, 126.62, 126.96, 127.87, 
147.39, 149.29, 149.45, 149.52, 172.46, 174.82.  HRDARTMS: Calcd for C27H27NO7 m/z 
477.17875; [M + H]+ m/z 478.18873 (calcd 478.18658). 
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(S)-5-Oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylic acid (3-6). 
To the alkylated pyroglutamate ester, (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-
ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (3-5, 2.60 g, 5.44 mmol) in 
dioxane (60 mL) was added 2 N KOH (30 mL) and MeOH (48 mL).  After vigorous 
stirring for 12 h, the solution was cooled (4 °C), acidified to pH 3 with 2 N HCl and 
chilled overnight.  The resulting solid was then filtered, and the filter cake was rinsed 
with 10 mL of ice-cold water to afford (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-
ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylic acid (3-6, 2.45 g, 5.28 mmol, 
97% yield as a white solid.  1H NMR (300 MHz, pyridine) δ 8.59 (s, 1H), 8.32 (s, 1H), 8.18 
(s, 1H), 7.85 (s, 1H), 7.39 (s, 1H), 6.05 (d, J = 14.4, 1H), 5.24 (d, J = 2.3, 2H), 4.83 (d, J = 
13.6, 1H), 4.29 (dd, J = 8.0, 4.4, 1H), 4.13 (s, 3H), 3.96 (s, 3H), 3.83 (s, 3H), 3.67 (t, J = 2.3, 
1H), 2.83–2.67 (m, 1H), 2.49 (ddd, J = 16.4, 8.4, 4.7, 1H), 2.27–2.13 (m, 2H).  13C NMR (75 
MHz, pyridine) δ 23.76, 30.65, 45.28, 56.06, 56.23, 56.55, 57.98, 59.71, 78.11, 86.13, 105.08, 
106.70, 108.00, 109.89, 125.69, 126.26, 127.48, 127.68, 129.41, 148.58, 175.32, 175.51.  
HRDARTMS: Calcd for C26H25NO7 m/z 463.16310; [M+H]+ m/z 464.17009 (calcd 
464.17093). 
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(S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (3-7). 
Method A:  Trifluoromethanesulfonic anhydride (0.350 mL, 2.071 mmol) was added to 
a well stirred suspension of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-
ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylic acid  (3-6, 0.80 g, 1.73 mmol) 
in CH2Cl2 (80 mL) at -30 °C.  The reaction mixture was allowed to reach room 
temperature slowly and stirred 48 h. The solvent was then evaporated and the resulting 
residue was passed through a plug of silica gel. The crude product was then 
concentrated and added to a stirred mixture of CH2Cl2 (55 mL) and 2 g K2CO3 in water 
(35 mL) for 4 h. The organic phase was then evaporated affording a dark oil that was 
then chromatographed over silica (0.1:2 MeOH–CHCl3) to give (S)-2,6,7-trimethoxy-3-
(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-
dione  (3-7, 0.415 g, 0.932 mmol, 54% yield).  
Method B: Trifluoroacetic anhydride (1.320 mL, 9.49 mmol) was added to a well-stirred 
suspension of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylic acid (3-6, 1.10 g, 2.37 mmol) in CH2Cl2 (130 mL). The 
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mixture was stirred at room temperature for 15 min, and boron trifluoride diethyl 
etherate (0.584 mL, 4.75 mmol) was added. The mixture was stirred at room 
temperature for 24 h, after which time the solvents were evaporated.  To the resulting 
residue was added a mixture of CH2Cl2 (100 mL) and 4 g of K2CO3 in water (50 mL) for 
4 h. The organic phase was dried, then evaporated, affording (S)-2,6,7-trimethoxy-3-
(prop-2-ynyloxy)-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-
dione (3-7, 0.65 g, 1.45 mmol, 61% yield).  1H NMR (300 MHz, CDCl3) δ 9.09 (s, 1H), 8.05 
(s, 1H), 7.78 (s, 1H), 7.26 (s, 1H), 5.71 (d, J = 18.1, 1H), 4.98 (d, J = 2.4, 2H), 4.67 (d, J = 
18.1, 1H), 4.39 (s, 1H), 4.13 (s, 3H), 4.06 (s, 9H), 2.60 (d, J = 2.3, 1H), 2.58–2.52 (m, 4H).  
13C NMR (75 MHz, CDCl3) δ 20.95, 30.25, 40.89, 56.05, 56.13, 56.32, 61.17, 76.68, 78.48, 
103.10, 104.20, 106.36, 108.20, 121.66, 121.84, 124.40, 128.21, 137.68, 138.04, 146.83, 149.42, 
150.38, 152.08, 174.17, 195.73.  HRDARTMS: Calcd for C26H23NO6 m/z 445.15254; [M + 
H]+ m/z 446.16409 (calcd 446.16036). 
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(13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8). 
To a solution of  (S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione  (3-7, 0.30 g, 0.67 
mmol) in THF (25 mL) was added lithium tri-sec-butylborohydride (0.808 mL, 0.808 
mmol) in THF at -78 °C under N2.  After stirring at -78 °C for 3.5 h, a mixture of i-PrOH 
(3 mL) and H2O (3 mL) was added, followed by silica gel (200 mg).  The mixture was 
then brought to 0 °C and stirred for 30 min.  After stirring, the mixture was filtered 
through a Celite pad, and the filtrate was evaporated in vacuo.  The residue was purified 
by flash column chromatography (0.1:2 MeOH–CHCl3) to afford (13aS,14S)-14-hydroxy-
2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinolin-11(9H)-one  (3-8, 0.244 g, 0.545 mmol, 81% yield).  1H NMR (300 MHz, 
CDCl3) δ 8.00 (s, 1H), 7.67 (s, 1H), 7.61 (s, 1H), 6.71 (s, 1H), 5.07–5.00 (m, 1H), 4.98 (d, J = 
2.3, 2H), 4.30 (d, J = 17.5, 1H), 4.05 (t, J = 7.7, 6H), 3.86 (d, J = 8.9, 1H), 3.79 (s, 1H), 3.71 (s, 
3H), 3.06 (s, 1H), 2.70 (dd, J = 13.9, 8.0, 1H), 2.63 (t, J = 2.3, 1H), 2.60–2.44 (m, 3H), 2.25 
(dt, J = 14.8, 9.6, 1H).  13C NMR (75 MHz, CDCl3) δ 14.32, 19.25, 22.83, 30.93, 31.76, 40.99, 
47.85, 55.84, 55.97, 56.18, 57.37, 65.78, 76.58, 78.55, 93.62, 101.36, 102.11, 102.93, 105.02, 
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106.97, 122.26, 123.69, 124.09, 124.32,  129.88, 136.30, 137.50, 138.15, 138.38, 146.66, 146.73, 
148.72, 148.72, 148.77, 149.37, 149.64, 175.44, 175.47.  HRDARTMS: Calcd for C26H25NO6 
m/z 447.16819; [M + H]+ m/z 448.17798 (calcd 448.17601). 
 
 
 
 
(13aS,14S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (3-9) 
A suspension of lithium aluminum hydride (0.153 g, 4.02 mmol) in 50 mL of THF  was 
added, over 10 min, dropwise to a solution of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy-
3-(prop-2-ynyloxy)-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-
one (3-8, 0.2 g, 0.447 mmol) in 80 mL of dry THF at -10 °C under a nitrogen atmosphere.  
After addition, the reaction mixture was stirred for an additional 4 h at 0 ºC, at which 
point 10 mL of EtOAc was added dropwise, followed by careful addition of 2 g of 
sodium sulfate decahydrate.  After stirring for an additional 5 h, the solution was 
filtered, and the solvent was removed by rotary evaporation.  The product was purified 
by column chromatography (0.1:2 MeOH–CHCl3) to give (13aS,14S)-2,6,7-trimethoxy-3-
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(prop-2-ynyloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-
ol (3-9, 0.138 g, 0.317 mmol, 71% yield).  HRDARTMS: Calcd for C26H27NO5 m/z 
344.12599; [M + H]+ m/z 434.19722 (calcd 434.19675). 
 
 
 
 
Preparation of 1-Azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11) 
To 40 mL of  dry THF under N2 was added tetraethylene glycol (5 g, 25.7 mmol) (dried 
by addition and rotary evaporation of 15 mL of toluene).  Methanesulfonyl chloride 
(4.01 mL, 51.5 mmol) was then added by syringe, and the solution was  stirred in an ice 
bath as  TEA (7.24 mL, 51.5 mmol) in 10 mL of THF was added dropwise over 27 min.  
The ice bath was removed after 1 h of stirring, and the mixture stirred for an additional 
3.5 h with occasional swirling.  The yellow-white precipitate was dissolved by addition 
of H2O (24.4 mL), and the resulting two phases were chilled on a cold water bath.  
NaHCO3 (2.5 g, to pH 8) was added followed by NaN3 (3.35 g, 51.5 mmol), and stirring 
was commenced.  Then, THF was removed by distillation, and the solution was 
refluxed for 24 h at a temperature of 80 °C.  The aqueous layer was extracted five times 
with 20 mL aliquots of Et2O, with each layer of Et2O back-extracted with the same 20-
mL aliquot of satd NaCl.  The organic layers were then combined, dried over MgSO4 
and filtered.  Concentration of the organic layers by rotary evaporation yielded 5.38 g 
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(83%) of 3-11 as an oil.  1H NMR (300 MHz, CDCl3) δ 3.63 – 3.59 (m, 12H), 3.32 (t, J = 5.0, 
4H).  13C NMR (75 MHz, CDCl3) δ 42.12, 49.74, 61.33, 69.62, 69.90, 70.98, 71.91.  The 
NMR data matched those reported in the literature.211  HRDARTMS: Calcd for 
C8H16N6O3 m/z 244.12839; [M+H]+ m/z 245.13518 (calcd 245.13621). 
 
 
 
 
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12) 
Aqueous H3PO4 (40 mL of 0.65 M) was added to the diazide 3-11 (3.75 g, 15.4 mmol) and 
the solution was brought to stirring while PPh3 (3.99 g, 15.2 mmol) in 30 mL of Et2O was 
added dropwise over 45 min.  The addition funnel was rinsed with 4 mL of ether, and 
the solution was placed under N2 and stirred for 24 h.  The aqueous layer was separated 
and washed with 3 x 10 mL of Et2O, and 3.2 g of KOH was added.  The mixture was 
cooled to 4 °C after removal of traces of ether by evaporation.  After 16 h, the PPh3 was 
removed by filtration followed by the addition of 9.2 g of KOH (to 4 M).  The aqueous 
solution was then extracted 16 times with 7.5-mL aliquots of CH2Cl2, which were then 
dried over MgSO4, filtered and concentrated in vacuo  to furnish 2.55 g (76%) of 3-12 as 
an amber oil. 1H NMR (300 MHz, CDCl3) δ 3.55 – 3.51 (m, 8H), 3.43–3.33 (m, 2H), 3.30–
3.22 (m, 2H), 2.73 (t, J = 4.7, 2H), 1.95 (s, 2H).  13C NMR (75 MHz, CDCl3) δ 41.36, 42.52, 
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60.85, 69.72, 69.95, 70.02, 70.30, 70.34, 71.00, 72.55, 72.89.  The NMR data matched those 
reported in the literature.211  HRDARTMS: Calcd for C8H18N4O3 m/z 218.13789; [M+H]+ 
m/z 219.14449 (calcd 219.14572). 
 
 
 
 
Preparation of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14) 
Method A : TEA (0.102 mL, 0.724 mmol) was added to a solution of  3-12 (0.123 g, 0.561 
mmol) in DMF (4 mL).  After the solution was stirred for 30 min under N2, a solution of 
N-hydroxsuccinimidobiotin (3-13, 0.23 g, 0.67 mmol) was added.  The reaction mixture 
was stirred for 12 h at room temperature and then concentrated in vacuo to give a 
yellowish residue.  Purification by silica gel column chromatography using 4:1 acetone–
hexane  afforded 0.17 g (67%) of 3-14. 
Method B: A mixture of D-(+)-biotin (0.2 g, 0.819 mmol), and 3-12 (0.36 g, 1.64 mmol), 
O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (622 mg, 
0.82 mmol), and N,N-diisopropylethylamine (0.143 mL, 0.819 mmol) in DMF (10 mL) 
was stirred at room temperature for 2 h.  The reaction mixture was concentrated in 
vacuo, and the residue was purified by flash column chromatography (10:1 CHCl3–
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MeOH) to give the amide 3-14 (0.306 g, 84%).  1H NMR (300 MHz, CDCl3) δ 7.79 (d, J = 
8.0, 1H), 7.60 (d, J = 8.2, 1H), 7.38 – 7.25 (m, 1H), 6.82 (t, J = 5.4, 1H), 6.59 (s, 1H), 4.46 
(dd, J = 7.5, 4.8, 1H), 4.30–4.20 (m, 1H), 3.59 (dd, J = 9.8, 3.0, 14H), 3.49 (d, J = 5.0, 2H), 
3.36 (dd, J = 10.8, 5.0, 5H), 3.08 (d, J = 4.6, 1H), 2.87–2.80 (m, 1H), 2.17 (t, J = 7.4, 2H), 
1.71–1.51 (m, 5H), 1.37 (dd, J = 14.7, 7.4, 3H).  13C NMR (75 MHz, CDCl3) δ 25.82, 28.15, 
28.31, 35.99, 39.51, 45.09, 50.82, 55.69, 60.63, 62.12, 69.38, 69.77, 70.04, 70.11, 70.28, 70.58, 
100.22, 100.35, 100.52, 111.15, 117.69, 126.30, 126.93, 127.61, 162.52, 164.48, 169.70, 174.41.  
The NMR data matched those reported in the literature.156  HRDARTMS: Calcd for 
C18H32N6O5S m/z 444.21549; [M+H]+ m/z 445.23002 (calcd 445.22331). 
 
 
 
Methyl 2,6,7-trimethoxy-3-((1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-
yl)methoxy)phenanthrene-9-carboxylate (3-1e) 
In a 25-mL round-bottomed flask under an N2 atmosphere was added methyl 2,6,7-
trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1, 0.10 g, 0.26 mmol) , N-
(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-
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thieno[3,4-d]imidazol-4-yl)pentanamide (3-14, 0.117 g, 0.263 mmol), N,N-
diisopropylethylamine (0.184 mL, 1.05 mmol) and 2,6-lutidine (0.122 mL, 1.052 mmol) 
in CH3CN (5 mL).  The reaction mixture was stirred for 5 min, after which time 
copper(I) iodide (5.01 mg, 0.026 mmol) was added, and stirring was continued for an 
additional 12 h.  The reaction mixture was then evaporated in vacuo and 
chromatographed over silica gel (0.2:2 MeOH–CH2Cl2) to afford methyl 2,6,7-
trimethoxy-3-((1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)methoxy)phenanthrene-9-
carboxylate (3-1e) as a yellowish solid.  MALDI-TOFMS: Calcd for C40H52N6O11S m/z 
824.3415; [M + Na]+ m/z 847.3280 (calcd 847.3313). 
 
 
 
N-(2-(2-(2-(2-(4-(((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)methyl)-1H-1,2,3-triazol-1-
yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (3-17) 
In a 25-mL round-bottomed flask under an N2 atmosphere, was added (13aS,14S)-2,6,7-
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trimethoxy-3-(prop-2-ynyloxy)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinolin-14-ol (3-9, 0.08 g, 0.19 mmol), N-(2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (3-14, 0.082 g, 0.185 mmol), N,N-diisopropylethylamine 
(0.129 mL, 0.738 mmol) and 2,6-lutidine (0.086 mL, 0.738 mmol) in CH3CN (5 mL).  The 
reaction mixture was stirred for 5 min. after which time copper(I) iodide (3.51 mg, 0.018 
mmol) was added, and stirring was continued for an additional 12 h.  The reaction 
mixture was then evaporated in vacuo and chromatographed over silica gel (0.2:2 
MeOH–CH2Cl2) to afford N-(2-(2-(2-(2-(4-(((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-
9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)methyl)-1H-
1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (3-17) as a yellowish solid.  MALDI-TOFMS: 
Calcd for C191H212O36 m/z 877.4044; [M + Na]+ m/z 900.4102 (calcd 900.3942).   
 
 
 
 
 
Preparation of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10) 
To a solution of  tetraethylene glycol (6.0 g, 31 mmol) in 60 mL of THF was added 
sodium hydride (60% in mineral oil, 0.781 g, 34.0 mmol) at 0 °C with frequent venting.  
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After stirring for 15 min, 1.1 equiv of propargyl bromide (4.04 g, 34.0 mmol, 5.04 mL) 
was added slowly, and the mixture was stirred at 0 °C for 2 h and then at 23 °C for an 
additional 2 h.  The reaction mixture was passed through a silica gel column and eluted 
with EtOAc to give the purified product, 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10, 4.66 
g, 20.08 mmol, 65% yield) as a clear oil.  1H NMR (300 MHz, CDCl3) δ 4.07–4.02 (m, 2H), 
3.55–3.49 (m, 15H), 3.45–3.40 (m, 2H), 3.03 (s, 1H), 2.36 (t, J = 2.4, 1H). 13C NMR (75 
MHz, CDCl3) δ 58.13, 61.34, 68.84, 70.14, 70.28, 72.38, 74.59, 79.46.  The NMR data 
matched those reported in the literature.156  HRDARTMS: Calcd for C11H20O5 m/z 
232.13107; [M+H]+ m/z 233.14011 (calcd 233.13890). 
 
 
 
1-Bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12) 
3,6,9,12-Tetraoxapentadec-14-yn-1-ol (4-10, 1.3 g, 5.60 mmol) was dissolved in 40 mL of 
freshly distilled CHCl3 and the reaction mixture cooled to -30 °C.  After stirring for 15 
min, a solution of PBr3 (1.818 g, 6.72 mmol) in 50 mL CHCl3 was added dropwise.  The 
reaction mixture was then stirred for an additional 4 h at 0 °C and then poured over ice, 
and the two layers separated.  The organic phase was dried over MgSO4, filtered and 
rotary evaporated to give 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12, 1.32 g, 4.48 
mmol, 80% yield). 1H NMR (300 MHz, CDCl3) δ 4.07 (s, 2H), 3.59 (s, 2H), 3.56–3.52 (m, 
12H), 2.35 (dt, J = 8.3, 4.5, 1H). 13C NMR (75 MHz, CDCl3) δ 29.48, 30.32, 58.17, 68.87, 
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69.44, 70.38, 74.59, 79.49, 117.38, 117.53, 129.29, 137.55.  HRDARTMS: Calcd for 
C8H16Br2O3 m/z 294.04667; [M + H]+ m/z 295.06781 (calcd 295.05450). 
 
 
 
Methyl 3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-
carboxylate (4-1) 
Methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5, 2.1 g, 6.13 mmol) 
was dissolved in 300 mL of acetone and heated to reflux.  Then, to the stirred solution 
was added 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12, 1.992 g, 6.75 mmol) and 
stirring continued overnight.  The reaction mixture was then filtered and the filtrate 
evaporated in vacuo to give an oily residue.  The yellowish-brown crude product was 
then purified by flash column chromatography (2:0.2 EtOAc–hexanes) to afford methyl 
3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate 
(4-1, 2.63 g, 4.72 mmol, 77% yield) as an amber oil.  13C NMR (75 MHz, CDCl3) δ 16.62, 
16.69, 25.08, 25.14, 47.57, 52.14, 55.95, 62.92, 68.72, 74.70, 100.28, 100.31, 100.45, 106.88, 
109.60, 122.32, 124.90, 127.15, 130.45, 137.28, 144.08, 146.53, 149.13, 149.32, 150.66, 168.36. 
HRDARTMS: Calcd for C30H36O10 m/z 556.23085; [M] m/z 556.23236 (calcd 556.23085). 
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(3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-
yl)methanol (4-2) 
To a suspension of lithium aluminium hydride (0.232 g, 6.11 mmol)  in 50 mL of THF at 
0 ºC under a nitrogen atmosphere, was added dropwise a solution of methyl 3-(3,6,9,12-
tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (4-1, 1.70 g, 
3.05 mmol) in 150 mL of dry THF.  The solution was stirred at room temperature for an 
additional 4 h, then brought back to 0 ºC, at which point 50 mL of EtOAc was added 
dropwise, followed by the careful addition of sodium sulfate decahydrate (10 g, 31.04 
mmol).  After stirring for 5 h, the solution was filtered, and the solvent was removed by 
rotary evaporation.  The product was purified by column chromatography (0.2:2 
hexane–EtOAc) to give (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methanol (4-2, 1.356 g, 2.57 mmol, 84% yield). 1H NMR 
(300 MHz, pyridine) δ 8.42 (s, 1H), 8.39 (s, 1H), 8.12 (s, 1H), 7.98 (s, 1H), 7.49 (s, 1H), 5.55 
(s, 2H), 4.49 – 4.44 (m, 2H), 4.29 (d, J = 2.4, 2H), 4.05 (s, 3H), 3.94 (d, J = 7.3, 6H), 3.88 (s, 
3H), 3.72 (dt, J = 4.1, 3.2, 4H), 3.67 – 3.61 (m, 8H), 3.39 (t, J = 2.4, 1H). 13C NMR (75 MHz, 
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CDCl3) δ 55.80, 56.00, 56.12, 58.48, 69.17, 74.72, 79.75, 100.14, 100.44, 103.20, 104.85, 
105.27, 108.61, 123.80, 124.45, 124.58, 126.27, 132.29, 137.64, 137.81, 148.47, 148.66, 148.99, 
149.14.  HRDARTMS: Calcd for C29H36O9 m/z 528.23593; [M] m/z 528.23555 (calcd 
528.23593). 
 
 
 
1-(9-(Bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12-tetraoxapentadec-
14-yne (4-3) 
A stirred solution of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methanol (4-2, 1.45 g, 2.74 mmol)  and 2,6-di-tert-
butylpyridine (0.131 g, 0.686 mmol) in 180 mL of freshly distilled CHCl3 was cooled to 0 
°C.  After stirring for 15 min, a solution of PBr3 (0.89 g, 3.29 mmol) in 30 mL CHCl3 was 
added dropwise.  The reaction mixture was then stirred for an additional 2 h at room 
temperature, and then poured over ice and the two layers separated.  The organic phase 
was dried over MgSO4, filtered and rotary evaporated to give 1-(9-(bromomethyl)-2,6,7-
trimethoxyphenanthren-3-yloxy)-3,6,9,12-tetraoxapentadec-14-yne (4-3, 1.51 g, 2.55 
mmol, 93% yield) as a yellow solid which was then placed under vacuum for 1 h and 
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used without further purification.  1H NMR (300 MHz, CDCl3) δ 7.82 (s, 1H), 7.77 (s, 
1H), 7.61 (s, 1H), 7.47 (s, 1H), 7.13 (s, 1H), 4.94 (s, 2H), 4.39 (t, J = 5.1, 2H), 4.15 (d, J = 2.3, 
1H), 4.13 – 4.11 (m, 1H), 4.09 (s, 3H), 4.08 (d, J = 1.4, 1H), 4.06 (s, 3H), 3.71 – 3.67 (m, 2H), 
3.64 – 3.57 (m, 9H), 2.39 (t, J = 2.4, 1H). 13C NMR (75 MHz, CDCl3) δ 34.00, 56.12, 56.21, 
56.36, 58.61, 68.97, 71.14, 74.78, 75.33, 100.51, 103.59, 105.11, 105.62, 108.89, 117.76, 124.15, 
125.44, 125.53, 126.52, 137.44, 137.55, 147.65, 148.90, 149.39, 149.53, 149.67.  HRDARTMS: 
Calcd for C29H35BrO8  m/z 590.15153; [M] m/z 591.15454 (calcd 591.15936). 
 
 
 
(S)-dimethyl 2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4). 
To a stirred solution of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-
3,6,9,12-tetraoxapentadec-14-yne (4-3, 0.90 g, 1.52 mmol) in 420 mL of DMF was added 
K2CO3 (8.48 g, 61.3 mmol)  and stirring was continued for 15 min. (S)-1,5-dimethoxy-
1,5-dioxopentan-2-aminium chloride (1-42b, 1.28 g, 6.09 mmol)  was then added, and 
the reaction mixture was allowed to stir at 70 °C overnight.  The solution was then 
rotary evaporated, and the resulting crude product was partitioned between CHCl3 and 
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H2O.  The organic layer was then dried over MgSO4 and concentrated in vacuo to afford 
the crude of (S)-dimethyl 2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4, 0.939 g, 1.369 mmol, 90% 
yield) as a dark-yellow oil that was used without further purification.  HRDARTMS: 
Calcd for C36H47NO12  m/z 685.30983; [M] m/z 686.24476 (calcd 686.31765). 
 
 
 
(S)-Methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-
9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5)  
The crude diester, (S)-dimethyl 2-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methylamino)pentanedioate (4-4, 2.2 g, 3.2 mmol), was 
dissolved in 70 mL of MeOH and 35 mL of AcOH and stirred for 3 h at 45 °C.  The 
mixture was then cooled to room temperature, concentrated in vacuo, and the residue 
chromatographed over silica gel (0.1:2 hexanes-EtOAc) to afford (S)-methyl 1-((3-
(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-
oxopyrrolidine-2-carboxylate (4-5, 1.72 g, 2.63 mmol, 82% yield) as a yellowish-white 
solid. 1H NMR (300 MHz, CDCl3) δ 7.81 (s, 1H), 7.73 (s, 1H), 7.53 (s, 1H), 7.33 (s, 1H), 
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7.11 (s, 1H), 5.43 (d, J = 14.5, 1H), 4.38 (d, J = 3.6, 1H), 4.36 (d, J = 4.7, 2H), 4.31 (s, 1H), 
4.19 (dd, J = 8.3, 4.9, 1H), 4.13 – 4.11 (m, 2H), 4.06 (s, 3H), 3.97 (s, 6H), 3.95 (s, 3H), 3.80 
(dd, J = 9.1, 3.1, 2H), 3.76 – 3.71 (m, 3H), 3.69 (d, J = 5.0, 3H), 3.68 – 3.64 (m, 3H), 3.61 (d, J 
= 7.1, 13H), 3.53 (s, 3H), 2.61 – 2.45 (m, 2H), 2.35 – 2.27 (m, 2H), 2.19 – 2.03 (m, 2H), 1.98 
– 1.90 (m, 1H).  13C NMR (75 MHz, CDCl3) δ 22.95, 30.00, 44.94, 52.49, 56.11, 56.14, 56.56, 
58.68, 76.53, 78.51, 79.85, 103.27, 105.42, 106.75, 108.75, 124.77, 124.90, 125.17, 126.62, 
126.96, 127.87, 147.39, 149.29, 149.45, 149.52, 172.46, 174.82.  HRDARTMS: Calcd for 
C35H43NO11  m/z 653.28361; [M] m/z 654.28097 (calcd 654.29144). 
 
 
 
 
(S)-1-((3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-
yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6) 
To the alkylated pyroglutamate ester, (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-
ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-
5, 1.1 g, 1.683 mmol)  in dioxane (40 mL) was added 2 N KOH (24 mL) and MeOH (28 
mL).  After vigorous stirring for 12 h, the solution was cooled (4 °C), acidified to pH 3 
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with 2 N HCl and chilled overnight.  The resulting solid was then filtered, and the filter 
cake was rinsed with 10 mL of ice-cold water to afford (S)-1-((3-(3,6,9,12-
tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-
oxopyrrolidine-2-carboxylic acid (4-6, 1.023 g, 1.599 mmol, 95% yield)  as a white solid.  
HRDARTMS: Calcd for C34H41NO11 m/z 639.26796; [M+H]+ m/z 640.27554 (calcd 
640.27579). 
 
 
 
 
 
(S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-7). 
Method A:  Trifluoromethanesulfonic anhydride (0.211 mL, 1.251 mmol) was added to 
a well stirred suspension of (S)-1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6, 0.8 g, 
1.251 mmol) in CH2Cl2 (60 mL) at -30 °C.  The reaction mixture was allowed to reach 
room temperature slowly, and it was stirred for 48 h. The solvent was then evaporated, 
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and the resulting residue passed through a plug of silica gel.  The crude product was 
then concentrated and added to a stirred mixture of CH2Cl2 (45 mL) and 1.5 g of K2CO3 
in water (25 mL) for 4 h. The organic phase was then evaporated affording a dark oil, 
which was then chromatographed over silica (0.1:2 MeOH–CHCl3) to give (S)-3-
(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-7, 0.350 g, 0.563 
mmol, 45% yield).  
Method B:  Trifluoroacetic anhydride (0.21 mL, 1.50 mmol) was added to a well stirred 
suspension of (S)-1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylic acid (4-6, 0.8 g, 
1.251 mmol) in CH2Cl2 (60 mL).  The mixture was stirred at room temperature for 15 
min and BF3Et2O (0.154 mL, 1.251 mmol) was added.  The mixture was stirred at room 
temperature for 24 h, after which time the solvents were evaporated.  To the resulting 
residue was added a mixture of CH2Cl2 (50 mL) and 2 g of K2CO3 in water (40 mL) for 4 
h.  The organic phase was dried then evaporated to afford (S)-3-(3,6,9,12-
tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (4-7, 0.350 g, 0.563 mmol, 45% yield).  HRDARTMS: 
Calcd for C34H39NO10  m/z 621.25740; [M+H]+ m/z 622.25343 (calcd 622.26522). 
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(13aS,14S)-3-(3,6,9,12-Tetraoxapentadec-14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy-
12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8). 
To a solution of (S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (4-8, 0.40 g, 0.64 
mmol) in THF (25 mL) was added lithium tri-sec-butylborohydride (0.165 mL, 0.772 
mmol)  in THF at -78 °C under N2.  After stirring at -78 °C for 3.5 h, a mixture of i-PrOH 
(3 mL) and H2O (3 mL) was added followed by silica gel (200 mg).  The mixture was 
then brought to 0 °C and stirred for 30 min.  After stirring, the mixture was filtered 
through a Celite pad, and the filtrate was evaporated in vacuo.  The residue was purified 
by flash column chromatography (0.1:2 MeOH–CHCl3) to afford (13aS,14S)-3-(3,6,9,12-
tetraoxapentadec-14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8, 0.273 g, 0.438 mmol, 
68% yield).  MALDI-TOFMS: Calcd for C34H41NO10 m/z 623.2731; [M + H]+ m/z 624.2837 
(calcd 624.2809). 
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(13aS,14S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-9). 
A suspension of lithium aluminium hydride (0.012 g, 0.321 mmol) in 25 mL of THF  was 
added, over 10 min, dropwise to a solution of (13aS,14S)-3-(3,6,9,12-tetraoxapentadec-
14-ynyloxy)-14-hydroxy-2,6,7-trimethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (4-8, 0.1 g, 0.160 mmol) in 
20 mL of dry THF at -10 °C under a nitrogen atmosphere.  After addition, the reaction 
mixture was stirred for an additional 4 h at 0 ºC, at which point 8 mL of EtOAc was 
added dropwise, followed by careful addition of 1 g of Na2SO410H2O.  After stirring 
for an additional 5 h, the solution was filtered and the solvent was removed by rotary 
evaporation.  The product was purified by column chromatography (0.1:2 MeOH-
CHCl3) to give (13aS,14S)-3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-
9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-9, 0.064 g, 
0.104 mmol, 65% yield).  MALDI-TOFMS: Calcd for C34H43NO9 m/z 609.29378; [M-H]- 
m/z 608.3265 (calcd 608.28596). 
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Methyl 2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)-
2,5,8,11-tetraoxatridecan-13-yloxy)phenanthrene-9-carboxylate (4-1a) 
In a 25-mL round-bottomed flask under an N2 atmosphere, was added methyl 3-
(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthrene-9-carboxylate (4-
1, 0.10 g, 0.18 mmol), N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14, 0.080 g, 0.180 mmol), 
2,6-lutidine (0.084 mL, 0.719 mmol) and N,N-diisopropylethylamine (0.126 mL, 0.719 
mmol) in CH3CN (5 mL).  The reaction mixture was stirred for 5 min. after which 
copper(I) iodide (3.42 mg, 0.018 mmol) was added and stirring continued for an 
additional 12 h.  The reaction mixture was then evaporated in vacuo and 
chromatographed over silica gel (0.2:2 MeOH–CH2Cl2) to afford methyl 2,6,7-
trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-
4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-
yloxy)phenanthrene-9-carboxylate (4-1a) as a yellowish solid.  MALDI-TOFMS: Calcd 
for C48H68N6O15S m/z 1000.4463; [M + Na]+ m/z 1023.4335 (calcd 1023.4361). 
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(S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-triazol-4-yl)-
2,5,8,11-tetraoxatridecan-13-yloxy)phenanthren-9-yl)methyl)pyrrolidine-2-carboxylate 
(4-5a). 
In a 25 mL round-bottomed flask under an N2 atmosphere, was added (S)-methyl 1-((3-
(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-
oxopyrrolidine-2-carboxylate (4-5, 0.11 g, 0.18 mmol), N-(2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (3-14, 0.080 g, 0.180 mmol), N,N-diisopropylethylamine 
(0.126 mL, 0.722 mmol) and 2,6-lutidine (0.084 mL, 0.722 mmol) in CH3CN (3.5 mL).  
The reaction mixture was stirred for 5 min. after which copper(I) iodide (3.44 mg, 0.018 
mmol) was added, and stirring continued for an additional 12 h.  The reaction mixture 
was then evaporated in vacuo and chromatographed over silica gel (0.2:2 MeOH–
CH2Cl2) to afford (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(1-(1-(13-oxo-17-((3aS,4S,6aR)-
2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-1H-1,2,3-
triazol-4-yl)-2,5,8,11-tetraoxatridecan-13-yloxy)phenanthren-9-yl)methyl)pyrrolidine-2-
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carboxylate (4-5a) as a yellowish solid.  MALDI-TOFMS: Calcd for C191H212O36 m/z 
1097.4991; [M + Na]+ m/z 1120.4710 (calcd 1120.4889). 
 
 
 
N-(2-(2-(2-(2-(4-(13-((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)-2,5,8,11-tetraoxatridecyl)-
1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanamide (4-14) 
In a 25-mL round-bottomed flask under an N2 atmosphere, was added (13aS,14S)-3-
(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (4-19, 0.09 g, 0.15 mmol), N-(2-(2-
(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-
d]imidazol-4-yl)pentanamide (3-14, 0.07 g, 0.15 mmol), N,N-diisopropylethylamine 
(0.103 mL, 0.590 mmol) and 2,6-lutidine (0.07 mL, 0.6 mmol) in CH3CN (3.5 mL).  The 
reaction mixture was stirred for 5 min after which time copper(I) iodide (2.81 mg, 0.02 
mmol) was added, and stirring was continued for an additional 12 h.  The reaction 
mixture was then evaporated in vacuo and chromatographed over silica gel (0.2:2 
MeOH–CH2Cl2) to afford N-(2-(2-(2-(2-(4-(13-((13aS,14S)-14-hydroxy-2,6,7-trimethoxy-
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9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)-2,5,8,11-
tetraoxatridecyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-
oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (4-1a) as a yellowish solid.  
MALDI-TOFMS: Calcd for C52H75N7O14S m/z 1053.5093; [M-H]- m/z 1052.5172 (calcd 
1052.5015).
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2. Appendix 
APPENDIX 
1H and 13C NMR for selected compounds 
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 1H NMR spectrum (300 MHz, CDCl3) of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47) 
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 13C NMR (75 MHz, CDCl3) spectrum of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylic acid methyl ester (1-47). 
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 1H NMR spectrum (300 MHz, CDCl3) of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52). 
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 13C NMR (75 MHz, CDCl3) spectrum of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (1-52) 
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 1H NMR spectrum (300 MHz, CDCl3) of (2,3,6,7-tetramethoxyphenanthren-9-yl)methanol (1-53) 
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 13C NMR (75 MHz, CDCl3) spectrum of (2,3,6,7-tetramethoxyphenanthren-9-yl)methanol (1-53) 
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1H NMR spectrum (300 MHz, CDCl3) of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63) 
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13C NMR (75 MHz, CDCl3) spectrum of 9-(bromomethyl)-2,3,6,7-tetramethoxyphenanthrene (1-63) 
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 1H NMR spectrum (300 MHz, C5D5N) of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b) 
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13C NMR (75 MHz, C5D5N) spectrum of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (1-42b) 
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1H NMR spectrum (300 MHz, CDCl3) of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (1-65) 
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13C NMR (75 MHz, C5D5N) spectrum of (S)-methyl 5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (1-65). 
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1H NMR spectrum (300 MHz, C5D5N) of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-
2-carboxylic acid (1-50). 
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13C NMR (75 MHz, C5D5N) of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-2-
carboxylic acid (1-50) 
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1H NMR spectrum (300 MHz, CDCl3) of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinoline-11,14(9H,12H)-dione (1-45). 
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13C NMR (75 MHz, CDCl3) of (S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-
11,14(9H,12H)-dione (1-45). 
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1H NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66) 
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13C NMR (75 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (1-66) 
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1H NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-
hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (1-62b) 
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13C NMR (75 MHz, CDCl3) of (13aS,14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-
b]isoquinolin-14-ol (1-62b) 
 
  
 
 
304 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1H NMR spectrum (300 MHz, CDCl3) of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1) 
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13C NMR (75 MHz, CDCl3) spectrum of (E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylic acid (2-1) 
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1H NMR spectrum (300 MHz, CDCl3) of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate 
(2-2) 
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13C NMR (75 MHz, CDCl3) spectrum of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)acrylate 
(2-2) 
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1H NMR spectrum (300 MHz, CDCl3) of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate 
(2-3) 
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13C NMR (75 MHz, CDCl3) spectrum of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylate 
(2-3) 
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1H NMR spectrum (300 MHz, CDCl3) of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4) 
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13C NMR (75 MHz, CDCl3) spectrum of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-4) 
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1H NMR spectrum (300 MHz, CDCl3) of methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5). 
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13C NMR (75 MHz, CDCl3) spectrum of methyl 3-hydroxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (2-5) 
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1H NMR spectrum (300 MHz, CDCl3) of methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1) 
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13C NMR (75 MHz, CDCl3) spectrum of methyl 2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene-9-carboxylate (3-1)
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1H NMR spectrum (300 MHz, CDCl3) of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2) 
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13C NMR (75 MHz, CDCl3) spectrum of (2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methanol (3-2) 
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1H NMR spectrum (300 MHz, CDCl3) of 9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3) 
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13C NMR (75 MHz, CDCl3) spectrum of 9-(bromomethyl)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthrene (3-3) 
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1H NMR spectrum (300 MHz, CDCl3) of (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (3-5). 
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13C NMR (75 MHz, CDCl3) spectrum of (S)-methyl 5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylate (3-5). 
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1H NMR spectrum (300 MHz, C5D5N) of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-
yl)methyl)pyrrolidine-2-carboxylic acid (3-6). 
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13C NMR (75 MHz, C5D5N) of (S)-5-oxo-1-((2,6,7-trimethoxy-3-(prop-2-ynyloxy)phenanthren-9-yl)methyl)pyrrolidine-
2-carboxylic acid (3-6) 
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1H NMR spectrum (300 MHz, CDCl3) of (S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (3-7) 
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13C NMR (75 MHz, CDCl3) spectrum of (S)-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-13,13a-
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (3-7) 
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1H NMR spectrum (300 MHz, CDCl3) of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8) 
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13C NMR (75 MHz, CDCl3) spectrum of (13aS,14S)-14-hydroxy-2,6,7-trimethoxy-3-(prop-2-ynyloxy)-12,13,13a,14-
tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (3-8)
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1H NMR spectrum (300 MHz, CDCl3) of 1-azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11) 
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13C NMR (75 MHz, CDCl3) spectrum of 1-azido-2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethane (3-11) 
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1H NMR spectrum (300 MHz, CDCl3) of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12) 
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13C NMR (75 MHz, CDCl3) spectrum of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethanamine (3-12) 
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1H NMR spectrum (300 MHz, CDCl3) of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14). 
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13C NMR (75 MHz, CDCl3) spectrum of N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-5-((3aS,4S,6aR)-2-oxohexahydro-
1H-thieno[3,4-d]imidazol-4-yl)pentanamide (3-14)
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1H NMR spectrum (300 MHz, CDCl3) of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10) 
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13C NMR (75 MHz, CDCl3) spectrum of 3,6,9,12-tetraoxapentadec-14-yn-1-ol (4-10) 
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1H NMR spectrum (300 MHz, CDCl3) of 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12) 
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13C NMR (75 MHz, CDCl3) spectrum of 1-bromo-3,6,9,12-tetraoxapentadec-14-yne (4-12) 
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1H NMR spectrum (300 MHz, CDCl3) of methyl 3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthrene-9-carboxylate (4-1) 
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13C NMR (75 MHz, CDCl3) spectrum of methyl 3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthrene-9-carboxylate (4-1) 
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1H NMR spectrum (300 MHz, C5D5N) of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-
yl)methanol (4-2) 
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13C NMR (75 MHz, CDCl3) spectrum of (3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-trimethoxyphenanthren-9-
yl)methanol (4-2) 
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1H NMR spectrum (300 MHz, CDCl3) of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12-
tetraoxapentadec-14-yne (4-3) 
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13C NMR (75 MHz, CDCl3) spectrum of 1-(9-(bromomethyl)-2,6,7-trimethoxyphenanthren-3-yloxy)-3,6,9,12-
tetraoxapentadec-14-yne (4-3) 
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1H NMR spectrum (300 MHz, CDCl3) of (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5) 
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13C NMR (75 MHz, CDCl3) spectrum of (S)-methyl 1-((3-(3,6,9,12-tetraoxapentadec-14-ynyloxy)-2,6,7-
trimethoxyphenanthren-9-yl)methyl)-5-oxopyrrolidine-2-carboxylate (4-5) 
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